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Abstract 
The present dissertation entitled, “Design of Multifunctional Magnetic 
Nanostructures for Targeted Delivery of Anticancer Drugs” is an embodiment of the 
investigations aimed at developing multifunctional magnetic nanoparticles intended 
for administration of some leading anticancer drugs and simultaneous monitoring of 
the treatment by imaging techniques. The possible diagnostic and therapeutic 
applications of these multifunctional nanosystems have been explored in vitro. The 
thesis has been divided into seven chapters. 
Monodispersed amine functionalized MFe2O4 (M= Co, Mn, Ni) spherical 
nanoassemblies of size 35-50 nm have been prepared following simple solvochemical 
approach. The synthesis was accomplished by refluxing metal chloride precursors in 
ethylene glycol in presence of sodium acetate and ethanolamine. Due to large surface 
area, high density of amine groups and good aqueous dispersion stability these 
ferrites may serve as potential materials in biomedical application. Further, CoFe2O4 
made by this method was conjugated to anticancer drug methotrexate or 
doxorubincin, marker molecule folic acid and a fluorescent marker molecule 
rhodamine isothiocyanate to develop a multifunctional nanoparticle. These drug 
loaded particles shows combined advantages of superparamagnetism, receptor 
mediated endocytosis and pH sensitive drug release behavior. Magnetic mesoporous 
amorphous calcium phosphate nanoparticles with a size of 62 nm and abundant –
COOH groups on the surface have been prepared by a simple method. The presence 
of high surface area and large number of carboxylate groups, facilitate the 
incorporation of platinum pharmacophore cis-diaquadiamine platinum (II), folic acid 
and rhodamine isothiocyanate within its porous network. The cytotoxicity and 
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internalization efficiency of these nanocarriers have been evaluated on folate receptor 
overexpressed HeLa cells. These drug loaded nanoagents exhibit elevated 
cytotoxicity and induce apoptosis in HeLa cells. Furthermore development of 
theranostic mesoporous hollow silica nanospheres having therapeutic and diagnostic 
functions has been established. The internal space of the hollow spheres was utilised 
to clutch the hydrophobic anticancer drug pemetrexed and superparamagnetic 
CoFe2O4 nanoparticles while the external surface was chemically modified to grasp 
the platinum pharmacophore CDDP [cis-diaquadiamino platinum (II)], the marker 
molecule folic acid and the fluorescent dye RITC. Magnetic hollow spheres loaded 
with multiple therapeutic cargoes as well as magnetic resonance imaging (MRI) 
contrast agent exhibit enhanced cytotoxicity as compared to individual drugs. Simple 
inexpensive magnetic mesoporous carbon-based multimodal theranostic nanoagent 
best owed with magnetic targeting, T2 contrast behavior, fluorescence imaging, high 
loading and controlled release of the anticancer drug doxorubicin has been developed. 
Due to surface modification with carboxylic acid groups the nanoparticles are highly 
stable in aqueous buffer. The dual optical and magnetic properties of the mesoporous 
spheres may be utilized in advanced imaging technologies to track the curative 
responses. The transverse relaxivity value (r2) of the drug absorbed particles was 
found to be 380.25 mM
-1
S
-1
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1.1. Preface    
The application of nanoparticles in biomedical field continues to be a growing 
field. The unique properties of nanoparticles based systems have been proven to be 
advantageous over pure molecular therapeutics as well as diagnostics.1-3 The major 
applications of nanomaterials in the biomedical field can be mainly divided into 
imaging and therapy. Most of the clinically used imaging and therapeutic modalities 
are small molecules, such as the gadolinium complexes used as T1 magnetic 
resonance imaging (MRI) contrast agents and anticancer chemical drugs. The 
limitations of these small molecules are their very short blood circulation time and 
nonspecific biodistribution, which causes many unwanted side effects.4 
Nanostructured materials can be employed to overcome these limitations. For 
example, the blood circulation times can be increased significantly by the size control 
and surface modification. More recently, the combinations of various nanostructured 
materials with different properties have been explored which are capable to offer 
synergetic multifunctional nanomedical platforms, which make it possible to achieve 
simultaneous diagnosis and therapy.5 Particularly, the synthesis of multifunctional 
magnetic nanoparticles is a highly active area of current research located at the 
interface between material science, biotechnology and medicine.6-8 By virtue of their 
unique physical properties magnetic nanostructures have been revealed as potential 
agents in drug delivery, magnetic resonance imaging and hyperthermia. Moreover, 
the conjugation of targeting moieties on the surface of these multifunctional 
nanomaterials gives them specific targeted imaging and therapeutic properties. The 
unique characteristics of such multifunctional nanoparticles based systems lead to 
strategic advantages over pure molecular diagnostics as well as therapeutics.  
However, the new intricacies owing to the integration of multiple 
functionalities must be explored to make the nanoparticle based applications a viable 
option to clinics. The successful development of multifunctional nanoparticles with 
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appropriate surface functionalization with regards to their therapeutic application is a 
contemporary challenge in this field. Our present investigation in this area deals with 
the development of multifunctional nanoparticles for simultaneous drug delivery, 
fluorescence imaging and magnetic resonance imaging by incorporating cobalt ferrite 
as the magnetic component in carrier matrix. In subsequent sections a brief overview 
on the characteristic properties of nanoparticles which make them advantageous for a 
wide range of biomedical applications, types of nanomaterials used in medical 
diagnosis as well as therapy and recent progresses in designing multifunctional 
magnetic nanoparticles for medical applications will be reviewed as it is relevant to 
our work.   
1.2. Physical properties of nanomaterials    
High surface to volume ratio  
One of the most valuable properties of nanomaterials which makes them 
technologically important is their huge surface-to-volume ratio. In contrast to the 
extremely small surface to volume ratio of bulk materials and maximum for 
molecules, nanomaterials exhibit intermediate values which can effectively be 
controlled by tuning the size of the material. Novel properties of the nanomaterials 
arise from the large fraction of atoms which reside on the surface of the particle (e.g. 
for particle size of 100, 10 and 5 nm it corresponds to about 1-3 %, 15-30 %, and 30-
60 % respectively) and from finite number of atoms in each crystalline core. Surface 
atoms have reduced coordination to the crystal backbone and more prone to react 
with the surroundings. Such high surface area and surface reactivity is very important 
for optimizing drug payloads and functionalization of the drug carrier. In addition, 
solid surface of the nanomaterials eliminates some of the folding and unfolding 
molecular arrangement taking place in biological as well as molecular systems thus 
provides high degree of control while designing physical chemistry to take place in 
the biological system.  
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Controlled shape and size  
The function of nanoparticles in the biological system directly depends on the 
shape and size of nanoparticles. Applying different synthesis technique, a variety of 
nanostructures with numerous shapes and sizes can be prepared. Utilizing suitable 
growth upon different crystallographic facets and noble templates, a variety of shapes 
can be generated which include nanorods, nanoshells9,10, nanoplates11,12, 
nanoprisms13, nanocubes14-17, nanocages18-21, and even nanostars.22,23 Nanoparticles 
function in vivo, directly depends upon the shape of the particles. Many groups have 
already explored how cellular uptake is affected by the shape of nanoparticles.24-26 
Again, accumulation of NPs in the body depends upon the size of these 
nanostructures. Smaller the size of nanoparticles, quickly it can pass through the 
body's defense system and hence shows higher uptake. It has been already shown that 
larger size nanoparticles accumulate in areas of leaky vasculature by well-known 
phenomenon of the enhanced permeability and retention (EPR) effect.27-29 Bawendi, 
Jain, and Fukamura has done some influential work and reported that nanoparticles 
with a hydrodynamic diameter smaller than 5.5 nm can effectively clear the renal 
system, offering a unique opportunity for balancing efficacy with minimal toxicity.30 
Furthermore, how cellular responses in vivo was affected by shape of nanoparticles 
was reported by Chan et.al in 2010.31 Such investigations provide information 
regarding function of biological system at the nanoscale using the same material, and 
thus offering a crucial control for optimizing nonmedical platforms.  
Optical properties  
The optical properties of nanoparticles also play a vital role to optimize NP 
based technologies such as solar cells,32-36 sensors,37-42 catalysts,43-49 and imaging 
agents.50-54 For in vivo applications, the window in which light can penetrate tissue is 
relatively narrow. Optical inorganic nanomaterials can be mainly divided into two 
classes; semiconductor and metallic nanostructures. In both cases, the physical 
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confinement of the material in quantum-regime induces specific optical properties. 
For semiconductor materials, this ‘‘quantum effect’’ can be described by treating 
electronic excitation as a particle in a three dimensional box.55 Thus a physical change 
in NP characteristics directly changes its electronic structure, enable in highly 
selective rational designs. The resulting change in absorption also corresponds to a 
shift in its photoluminescence (PL), allowing for effective ‘‘tuning’’ for a desired 
application. The strong absorption of light observed in case of metallic nanostructures 
due to an entirely different phenomenon known as the surface plasmon resonance 
(SPR).56 For metal nanoparticle conduction electrons at the surface collectively 
oscillate with a corresponding excitation of a resonant wavelength of light. According 
to Mie theory, with an increase in NP size, the amount of light scattering due to the 
NP increases and variations in shape (nanorods, nanocubes, nanocages, nanoplates, 
etc.) lead to unique scattering properties.57 The scattering is coupled to the unique 
SPR phenomenon of metallic nanostructures, resulting in a dramatic enhancement 
that can be used for biomedical imaging applications.  
Magnetic Properties  
  When the size of a ferromagnetic particle is reduced below a threshold value, 
magneto-crystalline anisotropy (EA) becomes comparable with thermal activation 
energy kBT, where kB is the Boltzmann constant. The anisotropy energy barrier is so 
small that thermal activation energy and/or an external magnetic field can easily 
move the magnetic moments from easy axis. Consequently the collective behaviour 
of the magnetic nanoparticle is same as that of paramagnetic atoms. Although the 
magnetic order still exists in the nanoparticles each particle behaves like a 
paramagnetic atom but with giant magnetic moment. Such behavior is known as 
superparamagnetism. This unique property of super paramagnetism makes magnetic 
nanoparticle a suitable material in several in vivo and in vitro applications such as 
drug delivery, hyperthermia, magnetic resonance imaging etc.58,59  
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Ease of surface functionalization  
Nanomaterials show various interesting and unexpected properties due to the 
surface of the materials dominating the properties of the bulk materials. The 
percentage of atoms at the surface of a material becomes significant as the size of that 
material approaches to nanoregime. Due to high surface to volume ratio and large 
fraction of atoms present on the surface, the surface functionalization in case of 
nanomaterials is easy than their bulk counterparts. The ligand molecules attached to 
the nanoparticles surface prevent the aggregation of the nanoparticles and also control 
the growth of the nanoparticles. The surface of the nanoparticles can be 
functionalized by using some attractive interaction such as chemisorption, 
electrostatic attraction or hydrophobic interaction.  
1.3. Nanomaterials used in medicine  
Liposomes  
Liposomes are phospholipids within the size range from 50-100 nm. These are 
amphiphilic in nature having bilayer membrane structure similar to that of biological 
membranes and an internal aqueous phase. Depending upon their size and number of 
layers liposomes are classified into three types such as multi-, oligo-, or unilamellar. 
Their amphiphilic nature enables liposomes to transport hydrophilic drugs entrapped 
within their aqueous interior and hydrophobic drugs dissolved in the membrane. 
Liposomes show excellent circulation, penetration and diffusion properties due to 
their physicochemical characteristics.60 Moreover to increase the solubility of 
hydrophobic anticancer drugs, liposomal drug carriers have extensively studied from 
1970s.61,62 In 1995, a liposome-encapsulated doxorubicin formulation was the first 
liposome system permitted by the US Food and Drug Administration (FDA) for 
clinical human use and it was fully approved in 2005.63 Till now the therapy using 
liposomal drug carriers has revealed potent activity against a broad range of human 
cancers. Even though liposomes have been succeeded in many clinical applications 
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but still its applications are limited due to poor storage stability, rapid clearance from 
the bloodstream, nonspecific uptake by the mononuclear phagocytic system and rapid 
drug release profiles in vivo.64 Again the limited volume of the lipid bilayer makes 
the delivery of hydrophobic drug slightly inefficient.  
Polymer micelles and nanoparticles  
Polymer based drug delivery system was developed to reduce the inherent 
instability and degradation limitations related to liposomal drugcarrier65. Polymeric 
systems possess a series of superior activities as compared to liposomes and 
surfactant micelles. Those are 1) as pharmaceutical carrier shaving high drug loading 
capability, 2) prolonged circulation time stemming from higher stability in vivo, and 
3) slower rates of dissociation that allow retention of loaded materials for a longer 
period of time66-68. In addition to this, polymeric drug carrier has ability to provide 
either controlled release or triggered release of the therapeuticmolecule.69, 70 Among 
all polymers, amphiphilic polymers are of great importance because in selective 
solvents, amphiphilic diblock and triblock copolymers undergo self-associate to form 
micelles when the polymer concentration is at/above the critical micelle concentration 
(CMC). The self-assembly of amphiphiles in aqueous solution offers the formation of 
nanometer-sized particles with hydrophobic core/hydrophilic shell-type structures. 
The core regions serve as reservoirs for hydrophobic drugs, whereas the outer 
hydrophilic shell provides stability to the carrier in the physiological environment.71-
72 Depending upon the different synthetic condition, the drug can be chemically, 
electrostatically, or physically entrapped in situ during particle formation, or 
covalently bound to the polymer assemblies.  
Dendrimers  
Dendrimers are highly branched polymeric architecture shaving a central core, 
an internal region and numerous terminal groups that determine dendrimer 
  
Chapter 1                                                                                                                                       Review  
7  
  
characteristics. Dendrimer shows versatility in drug delivery and high functionality 
whose properties resemble with biomolecules. Again these structures have ability to 
conjugate the high molecular weight hydrophilic/hydrophobic entities either by 
physical or chemical bonding. Moreover, chemical modifications by large number of 
surface terminal groups facilitate synthetic vector for drug and imaging diagnosis-
agent.73 The accurate control over the distribution of drugs is highly valuable to 
eliminate the typical drawbacks of traditional medicine. Hence the dendrimer based 
drug delivery system should be designed to target the definite site. In recent years, 
improved pharmacokinetics, biodistribution and controlled release of the drug to the 
specific targeted site has been achieved with polymer-baseddrugdelivery.74 Due to 
their excellent water solubility,75 biocompatibilty,76 polyvalency77 and precise 
molecular weight, dendrimers have received considerable attention in biological 
applications.78 These features make them an ideal carrier for drug delivery and 
targeting applications.  
Carbon nanotubes  
Carbon nanotubes belong to the family of fullerenes and are formed of coaxial 
graphite sheets (<100 nm) rolled up into cylinders. These structures can be obtained 
either as single- (one graphite sheet) or multiwalled nanotubes (several concentric 
graphite sheets). Due to their small mass and size, Carbon nanotubes (CNTs) exhibits 
exciting structural, mechanical and electronic properties. These are mostly thermal 
stable and acting as good heat and electrical conductor. CNTs have been successfully 
applied in biomedical field due to their high surface area that is proficient of 
adsorbing or conjugating with an extensive variety of therapeutic and diagnostic 
agents (drugs, genes, vaccines, antibodies, biosensors, etc.). They have been first 
proven to be excellent vehicles for drug delivery directly into cells and keeping the 
drug intact without metabolism during transport in thebody.79-82 Furthermore, CNTs 
have been extensively performed not only for drug and gene therapies but also for 
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tissue regeneration, biosensor diagnosis, enantiomer separation of chiral drugs, 
extraction and analysis of drugs and pollutants.  
Quantum dots  
Quantum dots are colloidal fluorescent semiconductor nanocrystals (2–10 
nm). The central core of quantum dots consists of combinations of elements from 
groups II–VI of the periodic system (CdSe, CdTe, CdS, PbSe, ZnS and ZnSe) or III–
V (GaAs, GaN, In Pand InAs), which are ‘over coated’ with a layer of ZnS. Quantum 
dots are photostable. They show size- and composition-tuneable emission spectra and 
high quantum yield. They are resistant to photobleaching and show exceptional 
resistance to photo and chemical degradation. All these characteristics make quantum 
dots excellent contrast agents for imaging and labels for bioassays.83  
Gold nanoparticles  
Gold nanoparticles are metallic nanoparticles having size less than 50 nm. 
They can be prepared with different geometries, such as nanospheres, nanoshells, 
nanorods or nanocages. They are mostly inert in the biological environment and 
shows a number of suitable physical properties for several biomedical applications 
such as hyperthermia for tumor destruction or radiotherapy for cancer, photodynamic 
therapy, computed tomography imaging and as drug carriers to tumors.84 Gold 
nanoparticles are excellent labels for biosensors because they can be detected by 
numerous techniques, such optic absorption, fluorescence and electric conductivity.85 
Current advances in synthetic chemistry makes accessible for the preparation of gold 
nanoparticles with excellent physicochemical and optical properties, which are 
necessary for specific clinical or biological applications. Due to numerous method 
available for the surface modification of gold nanoparticles for conjugating different 
ligands, drug molecules and targeting moieties, AuNPs can be used in broad range of 
applications. AuNPs are biologically inert and shows much less toxicity but it shows 
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relatively low rate of clearance from circulation and tissues can lead to serious health 
problems, hence specific targeting of diseased cells and tissues must be achieved 
before AuNPs use for biological applications.  
Magnetic nanoparticles  
Recently, the synthesis of superparamagnetic nanoparticles has been 
intensively developed due to their wide applications in  magnetic resonance imaging 
(MRI),86 virus detection,87 magnetic cell separation,88enzyme catalysis, targeting 
chemotherapy,89 and radiotherapy.90  More specifically Superparamagnetic iron oxide 
nanoparticles with appropriate surface chemistry can be used for numerous in vivo 
applications, such as MRI contrast enhancement, tissue repair, immunoassay, 
detoxification of biological fluids hyperthermia, drug delivery, and cell separation. 
All of these biomedical applications require that the nanoparticles have high 
magnetization values, a size smaller than 100 nm, and a narrow particle size 
distribution. These applications also need appropriate surface coating of the magnetic 
particles, which has to be nontoxic and biocompatible and must also allow for a 
targetable delivery with particle localization in a specific area. The surface of 
magnetic nanoparticles need to be coated to avoid the formation of aggregates and 
offer different functional groups (amines or carboxylic acid) for bioconjugation to 
anticancer drugs and/or targeted ligands. Large number of surface coating have been 
used including lipids,91-92 liposomes,93-94  proteins, 95-97 polymers,98-100  and 
dextran.101 Furthermore, magnetic nanoparticles are widely used in hyperthermia 
treatment to destroy cancer cells. When an external alternating magnetic field (AMF) 
applied to the magnetic nanoparticles (MNP), it produced energy in the form of heat 
in radio frequency region. Such an effect can be exploited to use MNPs as mediators 
in magnetic hyperthermia.  
Although nanoparticles have lots of advantages because of the unique 
properties they have, there are many clinical, toxicological and regulatory aspects 
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which are the matters of concern too. The comparison of performances of different 
drug conjugated nanoparticles has been provided in table 1.1. The biocompatibility of 
nanomaterials is of utmost importance because of the effect of the nanomaterials in 
the body ranging from cytotoxicity to hypersensitivity. Certain nanomaterials have 
been associated with oxidative stress,102,103 undesirable inflammatory responses, and 
genotoxicity. Critical evaluation is necessary of whether benefit outweighs the 
adverse effect. It is quite essential to introduce cost effective, better and safer 
nanobiomaterials.  
Table 1.1 
 
 
 
 
 
 
1.4. Multifunctional nanoparticles  
The dimension of nanoparticles is in the same range as antibodies, membrane 
receptors, nucleic acids and proteins. These biomimetic features, together with their 
high surface to volume ratio and the possibility of modulating their properties, make 
nanoparticles powerful tools for imaging, diagnosis and therapy.104-105 Thus, 
nanoparticles offer significant improvements in performance compared with existing 
technologies. As we know that nanoparticles used as a powerful tool in 
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nanomedicine, still some application remain challenging, such as in vivo real-time 
monitoring of cellular events, specific targeting to the action site or efficient drug 
delivery inside the target cell. In this circumstance, to surmount this difficulty, the 
design of multifunctional nanoparticles would be essential.  
Multifunctional nanoparticles could significantly improve already existing 
nanoparticle characteristics. It combines different functionalities in a single platform. 
For example, a core particle could be linked to a specific targeting function that 
recognizes the unique surfacing natures of their target cells. Simultaneously, the same 
particle can be modified with an imaging agent to monitor the drug transport process, 
a function to evaluate the therapeutic efficacy of a drug. Whereas mono functional 
nanoparticles provide a single function, e.g. a liposome can transport drugs but does 
not have the inherent property to distinguish between healthy and unhealthy cells or 
tissues. Combination of diverse range of functionalities into a single core require 
different steps, such as the deposition of metal layers onto a supporting nanoparticle 
core, modifying the biocompatible linked to stabilize the nanoparticles etc.106-108 
 Furthermore, these different properties of multifunctional nanoparticles have 
to be coordinated so that they operate in an organized way and indeed provide the 
desired functionalities (Fig. 1.1). Early efforts toward multifunctional nanoparticles 
for integrated drug delivery and imaging focused on combining polymeric drug 
carriers with organic fluorescent dyes for particle visualization. Fluorescent drug 
particles were prepared by binding water-soluble fluorophores to the surfaces of 
preformed polymer nanoparticles or by chemically tethering fluorescent dye to the 
hydrophobic terminus of an amphiphilic block copolymer and then permitting the 
polymer to selfassemble.109-110 Organic dyes and fluorophores, however, require 
direct visualization and so are generally practical only for in vitro applications.111 
Particles having a metallic core that adds contrast to images acquired by MRI or CT, 
for example, are more suitable for in vivo biomedical applications.112-113 However, as 
synthesized, inorganic nanoparticles are incompatible with biological environments.  
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Fig. 1.1 Schematic representation of multifunctional nanoparticle for drug delivery and 
theranostic application. 
Owing to surface hydrophobicity or toxicity limitations. Consequently, several 
coating strategies have been developed to enhance their biocompatibility, improve 
their aqueous stability and provide chemical handles for further reactions with 
biomolecules.114 Modification methods have included the adsorption of small-
molecule ligands or stabilizers on the colloid surfaces,115 layer-by-layer deposition of 
polyelectrolyte chains,116 surface initiated polymerization of high-density polymer 
brushes,117 or block copolymer deposition on colloid surfaces.118 By extension, 
ligands (optionally together with drugs) can be covalently attached to the coating 
material.119-120 For example, multifunctional super paramagnetic nanoparticles 
bearing covalently-bound drugs and targeting ligands have been reported for selective 
drug delivery to regional lymph nodes and for imaging of prostate cancers .121  
The major applications of multifunctional nanoparticles in the biomedical 
field can mainly divided into imaging and therapy.  
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Multimodal imaging  
Nowadays, Most of the imaging techniques such as MRI, PET and CT are 
vital in the diagnosis of various diseases. Each modality has its own merits and 
disadvantages, and also a single imaging technique does not possess all the required 
capabilities for complete imaging. Thus, multimodal imaging methods are quickly 
becoming important tools in the field of biomedical research. Multimodal contrast 
agents could help in improving the diagnosis and treatment of diseases in their 
earliest stages by providing far more inclusive data to clinicians.  
Most commonly, magnetic nanoparticles act as a core platform for the 
addition of other functional imaging moieties. For example, MRI-optical dual-mode 
probes composed of a fluorescent dye-doped silica core surrounded by magnetic 
nanoparticles can macroscopically detect neuroblastoma cancer cells using MRI 
along with subcellular information through fluorescence imaging.122 Magnetic 
nanoparticles can also be coupled with radionuclides to construct MRI-PET dual 
modal probes.123 Such probes can accurately detect cancerous cells in lymph nodes, 
which are critical for assessing cancer metastasis. Systems using magnetic 
nanoparticles modified with fluorescent probes and biomolecules can also monitor 
gene expression and other markers in therapeutic cell studies. Each component of 
such multimodal probes complements the other modalities, and their synergistic 
materials properties can ultimately provide more accurate information both in vitro 
and in vivo.124  
Magnetic Resonance Imaging (MRI)  
Magnetic resonance imaging is a powerful tool for the diagnosis of disease 
and the study of biological processes such as cancer metastasis and inflammation. 
Super paramagnetic iron oxide nanoparticles, in particular, are effective contrast 
agents that provide high sensitivity in MRI.125-126 First introduced in the mid-1980s, 
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they are typically composed of iron oxide based cores (magnetite, maghemite, or 
other insoluble ferrites) in the size range 5 – 10 nm coated with water-soluble 
stabilizing layers. In the presence of a magnetic field, these magnetic domains possess 
large magnetic moments that produce localized disturbances in magnetic field 
homogeneity. Owing to these magnetic disturbances, there exists a large susceptibility 
difference between the iron oxide crystals and nearby protons, which causes rapid 
dephasing of spins and a resultant decrease in transverse and translational relaxation 
times. The shortening of the transverse relaxation time, specifically, results in a 
darkening of the image relative to unaffected areas, corresponding to a ‘negative’ 
contrast enhancement. Compared with micrometer-sized magnetic particles and 
chelates of paramagnetic ions such as gadolinium diethylenetriaminopentaacetic acid 
(Gd-DTPA), super paramagnetic iron oxide nanoparticles are much more efficient as 
relaxation promoters, and their effect on the relativities of water is measurable even at 
nanomolar concentrations.127 Commercial examples of super paramagnetic MRI 
contrast agents include Lumiren, silicon-coated iron oxide particles with a diameter of 
~300 nm, Endorem and Ferixex I.V, liver-specific, dextran coated iron oxide particles 
of ~ 150 nm diameter, and Sinerm, a blood pool contrast agent.  
Targeted drug delivery  
Targeted drug delivery is a method of delivering medication at the desired 
target in therapeutic concentration at the same time restricting its access to normal 
cellular lining. Insuﬃcient target selectivity of drugs can cause unwanted side eﬀects 
and reduce therapeutic eﬃcacy. Thus the targeted or site-specific delivery of drugs is 
very attractive goal because this provides one of the most potential ways to improve 
the therapeutic index of the drugs with minimal peripheral toxicity.  Passive targeting 
through the well-studied enhanced permeability and retention (EPR) eﬀect is not 
universal for all types of tumor cells, and a lack of cell speciﬁc interactions might 
decrease therapeutic eﬃcacy and induce multiple drug resistance.128 In contrast, 
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active targeting through covalent attachment of targeting molecules such as folic 
acid,129 hyaluronic acid,130 aptamer,131 antibody,132 etc. to the nanoparticle surface 
could promote the site-specific delivery of therapeutics. Yang and coworkers studied 
the use of multifunctional nanoparticles for simultaneous in vivo imaging and 
delivery of therapeutic products for cancer treatment.133 These authors developed a 
multifunctional nanosystem combining magnetic nanocrystals (for MRI), with 
therapeutic antibodies (for specific delivery) and the chemotherapeutic drug 
doxorubicin (for synergistic therapy). In a similar approach, Farokhzad and 
coworkers developed biocompatible nanoparticles for the specific delivery of 
docetaxel to localised tumors. Targeted delivery was achieved on this occasion using 
aptamers that recognized a prostate specific membrane antigen.134 The 
chemotherapeutic drug is stored and protected in the nanocarrier until it reaches the 
tumor site. The drug is thus harmless to healthy tissues during its circulation in the 
body and provided in high concentrations at the desired location.  
Hyperthermia   
Hyperthermia is a type of medical treatment in which the body tissue is 
exposed to slightly higher temperature to damage cancer to damage and kill cancer 
cells or to make cancer cell more sensitive to the effect of radiation and certain 
anticancer drugs. This technique can be controlled carefully because at high 
temperature they can also injure or kill normal cells and tissues. Hence the use of 
hyperthermia treatment for cancer is a real challenge, as it was hard to maintain the 
right temperature in the right area while limiting the effects on other parts of the 
body. A wide range of heat sources and treatments for hyperthermia are being 
developed for clinical applications. There are three main types of hyperthermia: local 
hyperthermia, regional hyperthermia and whole-body hyperthermia. The 
hyperthermia technique is chosen depending on the location, the depth and the stage 
of malignancy. In whole-body hyperthermia, the entire body is heated up. This 
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method is preferred in the case deep-seated and propagated metastases. The heating 
can be achieved through hot water baths, thermal chambers or infrared radiators. 
Local hyperthermia is selected used to treat localized tumors either superficially or 
inaccessible body cavities. It is the less invasive technique. Local hyperthermia 
systems are based on applicators or antennas emitting mostly microwaves, 
ultrasounds or radio waves. Recently, a new technology has been developed for local 
hyperthermia using MNPs as mediators of heat. This technique is called Magnetic 
Fluid Hyperthermia (MFH). MFH consists of a colloidal suspension of MNPs that is 
injected into the tumor where the MNPs will be internalized by the cancer cells.135 
Applying an external alternative magnetic field (AMF) will cause the NPs to heat and 
kill the cancer cells because when a magnetic nanoparticle is placed inside an 
alternating magnetic field, it will spin back and forth generating significant heat in the 
radio frequency region.  
The first clinical trial was conducted in 2003 on 14 patients’ suffering from 
glioblastoma multiform.136 The promising results lead to a phase II study involving 66 
patients with glioblastoma multiform. Results showed that hyperthermia therapy 
using MNPs can be applied safely and is effective for the treatment of cancer, but also 
that the overall survival following diagnosis of first tumor recurrence is longer 
compared to conventional therapies.137 MFH possesses numerous advantages over 
traditional techniques. First of all, the injection of MNPs is less invasive and can be 
potentially injected and concentrated anywhere in the body, allowing the treatment of 
all kinds of tumors with limited side effects. Moreover, once the MNPs have been 
internalized by the cancer cells, they can remain inside the cells even after creation of 
daughter cells.138 In fact, 50% of the amount of MNPs present in parent cells end up 
in the daughter cells, meaning that a subsequent hyper thermic treatment can be 
applied without large reinjection of MNPs. Magnetic targeting can be used to drive 
the MNPs toward the targeted cancer regions. The MNPs can also be functionalized 
with a recognition moiety (i.e. antibodies, proteins) to increase the selectivity to 
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malignant cells, therefore increasing the internalization of the MNPs in the cancer 
cells.139 The potential of MFH as a treatment for cancer is clear, but can even be 
improved by designing MNPs with multiple therapeutic functions, i.e. hyperthermia 
and drug delivery. Indeed, drug delivery utilizing NPs also has numerous advantages 
over traditional chemotherapy. The major drawback of chemotherapy being the non-
specificity of the drugs, healthy organs and cells may also be strongly damaged 
during the therapy. With NPs, the possibility of targeting specific locations in the 
body allows the reduction of the chemotherapeutic dose to reach the concentrations 
needed in the tumors for an e ective therapy. Besides, the concentration of drugs at 
non-targeted sites is reduced therefore minimizing undesirable side e ects.140 Taking 
advantage of the synergistic effect of the combined thermo-chemotherapy, MNP-
based therapeutic agents for hyperthermia and controlled drug delivery are  promising 
candidates in the treatment of cancer.  
1.5. Major challenges in designing multifunctional nanoparticles  
Control design of multifunctional nanodevice is an active area of research. Due to 
their enormous application in various disciplines such as potential applications in 
responsive sensors and acting as nanovehicles with targeting capabilities carrying 
drugs, DNA, imaging agents, etc.141-147 Now accumulating multiple functionalities 
onto the surface of pre-existing nanoparticles is a challenging task because this 
process involves chronological chemical processing of nanoparticles. At first drug 
encapsulated nanoparticles are formed, followed by surface modification with 
different ligands to provide other functionalities such as targeting, responsiveness to 
stimuli, etc.148 Due to this sequential conjugation/modification, there is a chance of 
the potential loss of one or more existing functionality (imparted in previous steps) 
due to the chemical processing steps involved in adding a new functionality. Hence it 
is a real challenge, to choose such a core nanoparticles that can be easily scale-up and 
reproduce their surface properties with well-defined characteristics. 
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Choosing an appropriate magnetic component  
For pharmaceutical and biomedical purposes (Fig. 1.2), magnetic platforms 
should possess very small size and narrow size distribution together with high 
magnetization  
 
 
 
 
 
 
 
 
 
Fig. 1.2 Various applications of magnetic nanoparticles in designing multifunctional 
nanoparticles.   
values. Additionally, these nanoparticles (NPs) must combine high magnetic 
susceptibility for an optimum magnetic enrichment and loss of magnetization. Size 
and shape are the key features that govern the physical properties. For instance, 
magnetization measurements have demonstrated that the saturation magnetization of 
iron oxide particles decreased with a decrease in size.149 The importance of choosing 
an appropriate magnetic component in designing multifunctional NPs as it serves as a 
targeting agent under external magnetic field, hyperthermia therapy and magnetic 
resonance imaging. The size strongly influences the magnetic moment of the particles 
and their subsequent response to the magnetic fields. However, MNPs at the very low 
size range can exhibit superparamagnetism, which determines greater magnetization 
capabilities compared to paramagnetic materials. Interestingly, particle size has also 
been described to control the signal (i.e., transverse relaxation T2/T1) in MRI of iron 
oxides which can have consequences concerning the quality of the diagnosis.150,151 
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Choosing an appropriate ligand   
An appropriate ligand contributes selectivity to the multifunctional NPs for 
targeting various cancer cell lines. Active targeting is one of great benefit for the 
application of magnetic nanoparticles in the diagnosis and treatment of cancer, in 
which magnetic nanoparticles are further functionalized with a suitable targeting 
ligand that possess a high affinity towards the receptor present on the surface of 
cancer cell. The key factor here is that expression levels of receptors in the cancer cell 
is 100–300 times higher than those observed in healthy tissues. Recently broad range 
of ligands has been used for targeted nanocarrier and belongs to the families of small 
molecules, carbohydrates, peptides, proteins or antibodies. Monoclonal antibodies 
(mAbs) were first used targeting agent for the accurate delivery of magnetic 
nanoparticles. 152-153 Up to the present day, It was recognized as one of the most very 
well-liked targeting molecules, due to their exceptionally high  affinity towards tumor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3 Mechanism for folate receptor mediated endocytosis pathway. 
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cell. However, major drawbacks of this ligand are their comparatively large size and 
inherent immunogenicity, which hinders a sufficient circulation and diffusion through 
biologicalbarriers.154 Thus, most encouraging ligand molecule that is used for targeted 
therapy should be small in size, readily available, inexpensive, easy to handle, to be 
chemically modified and to be characterized. Another popular technique developed to 
conjugate small molecule for the targeted specific delivery. Folic acid is the most 
investigated targeting ligand in this respect because this vitamin can be found on the 
surface of various human cancer cell, such as breast, ovarian, lung, renal, and colon 
cancer.155 Beside this, folic acid conjugated magnetic nanoparticles have been used 
not only to improve the MRI detectability of various tumors in vivo but also this 
conjugated system helps to destroy cancer cells via hyperthermia treatment (Fig. 
1.3).156-158 Advantages of conjugating small targeting molecule on the surface of 
nanoparticle are to diminish the risk of bond breaking and loss of functionality inside 
the body.  
Theranostic magnetic nanoparticles  
Magnetic nanoparticles (MNPs) possess unique magnetic properties and the 
ability to function at the cellular and molecular level of biological interactions making 
them an attractive platform as contrast agents for magnetic resonance imaging (MRI) 
and as carriers for drug delivery.159 Recent advances in nanotechnology have 
improved the specific delivery of therapeutic agents by attaching a targeting agent 
and fluorophores to MNPs. These multifunctional magnetic nanoparticles are called 
“theranostic agents”. The term “theranostic” signifies the development of specific 
therapies for various diseases with simultaneous diagnostic capabilities. Such 
particles have higher magnetic moments, high surface area-to-volume ratios allowing 
for a large number of therapeutic molecules can be attached to individual 
nanoparticles. Additionally, while utilizing an active targeting strategy for specific 
delivery, the magnetic properties of the nanoparticle may be used to provide imaging 
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modality for monitoring drug delivery through MRI,160 or an alternative source of 
treatment through magnetic fluid hyperthermia (MFH) therapy.161 Also 
multifunctional MNPs functionalized with different biomolecules have loaded with a 
various anticancer agent such as carboplatin, doxorubicin, paclitaxel,162 5-
fluorouracil,163epirubicin,164etc directed towards tumor sites by applying an external 
magnetic field. For these applications, the size, surface chemistry, and charge are 
particularly important to ensure that the nanoparticles can stay for a long time in 
circulation. However  it was reported that MNPs having size between 50-100 nm are 
smaller than the spleen cut off (200 nm)  can easily penetrate into large tumors 
following systemic administration.165 Gong et al. have designed multifunctional 
MNPs nanocarriers for both tumors targeted drug delivery and PET/MR imaging of 
tumors. The anticancer drug DOX conjugated to the PEGylated MNPs nanocarriers 
through pH sensitive bonds.166 Chitosan-DOPA-stabilized-ferrimagnetic iron oxide 
nanocubes have developed by Hyeon et al. to provide an effective heat nanomediator 
for cancer hyperthermia. They facilitate successful suppression of cancer cells 
through caspase-mediated apoptosis These nanocomposites also show excellent 
antitumor efficacy in an animal tumor model without showing severe toxicity.167 
Chen et al. developed a magnetic drug delivery system in which doxorubicin (DOX) 
was chemically bonded to Fe3O4 nanoparticles and successfully deliver to the cancer 
cell.168  
Although magnetic nanoparticle-based drug delivery system is very much 
popular strategy for chemotherapy, hyperthermia and imaging applications, still it has 
some demerits such as less stable in physiological environment and nonspecific 
interaction with blood components that bring the side e ects of opsonization, 
aggregation of red blood cells and platelet activation.169 Therefore more and more 
studies focused on the surface modification of  MNPs with different inorganic 
coatings to prepare a stable inorganic  magnetic composite nanoparticles, such as 
silica, gold, hydroxyapatite, and graphene, which can not only deliver drugs through 
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the adsorption of drugs on the surface of the nanoparticles, but also make the 
nanoparticles stable and biocompatible and thereby useful for hyperthermia.170-173 The 
recent progress on the development of such inorganic coating materials concerning 
their medical application has been briefly reviewed in the following few points.  
Mesoporous nanoparticles (MSN) have been considered as promising 
candidate carriers for drug/gene delivery due to their high surface area, large pore 
volume and ease of surface functionalization. Furthermore, encapsulation of MNPs in 
a mesoporous silica matrix enhances the chemical stability of MNPs and avoids the 
potential toxic effects of MNPs on cells. Qiao and coworkers synthesized 
monodisperse yolk–shell magnetic nanoparticles with a porous hierarchical structure, 
and these magnetic nanoparticles exhibited enhanced drug loading capacity and drug 
release behavior.174 Sanchez and coworkers reported the fabrication of mesoporous 
maghemite-organosilica microspheres by the spray-drying process, and for the first 
time proposed mesoporous magnetic microspheres as multifunctional platforms for 
MR imaging and hyperthermia therapy.175 Vallet-Regí and coworkers reported the 
aerosol assisted synthesis of magnetic microspheres composed of γ-Fe2O3 
nanoparticles embedded in a mesoporous silica matrix, and these magnetic 
microspheres showed the abilities to load and release therapeutic drugs and to 
conduct magnetic hyperthermia upon exposure to a low frequency alternating 
magnetic field.176 Lu et al. synthesized magnetic iron oxide loaded hollow 
mesoporous silica nanocapsules using polymer nanospheres as sacrificial templates, 
and found that these magnetic nanocapsules with a particle size of 100 nm showed 
magnetic field induced heating and remotely triggered drug release capabilities, and 
thereby provide a platform for the combination of hyperthermia and chemotherapy.177 
Amorphous calcium phosphate or hydroxyapatite widely used in biomedical 
applications since it has excellent biocompatibility due to its chemical similarity to 
human hard tissue (bone and teeth). In recent years, calcium phosphate/hydrophilic 
block copolymer based drug delivery systems have attracted considerable attention 
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because they not only possess the properties of inorganic-organic ingredients but also 
the porous structure facilitates the incorporation of a high dosage of drug, which 
significantly enhances bio-performance.178 Fabrication of  MNPs with calcium 
phosphate can be developed as a suitable multifunctional nanodevice for 
nanotherapeutics approaches, and used for magnetic targeting drug delivery and 
Magnetic resonance imaging. Zhou et al. fabricated a magnetic calcium phosphate 
nanoformulation by the bio mineralization of calcium phosphate on the surface of 
magnetic nanoparticles with abundant amino groups, and thus the inorganic layer of 
calcium phosphate can improve the biocompatibility and simultaneously the magnetic 
iron oxide can maintain the magnetic targeting function for the delivery of anticancer 
drug doxorubicin hydrochloride  and  DNA.179 Liu et al. developed a novel remotely 
triggered drug vehicle i.e. HAP-coated liposome decorated with super paramagnetic 
iron oxide nanoparticles that exhibit ultrasound triggered drug release behaviour, 
magnetic resonance imaging contrast and ultrasound-induced MRI contrast change.180  
Very recently carbon coating on the surface of MNPs has been used as the 
biocompatible material. One of the advantages of using carbon is its high capacity of 
adsorption and their chemical as well as mechanical stability. The incorporation of 
materials into their inner hollow space is convenient, whereas the outside wall can be 
chemically modified according to the desired purpose. In 2010, Oh et al. have 
explored magnetic carbon nanoparticles with a mesoporous structure, monodispersity, 
magnetism, and biocompatibility as a drug carrier.181 Schreiber et al. have reported 
that carbon magnetic nanoparticles may support efficient immunization protocols or 
diagnostic assays to target, track, and manipulate dendritic cells.182  
1.6. Cobalt ferrite nanoparticles used as suitable magnetic 
component   
Super paramagnetic Iron oxide nanoparticles (SPION) have been a subject of 
interest in recent years due to their promising technological applications, especially in 
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biomedicine. However, cobalt ferrite nanoparticles can also be explored as a suitable 
candidate in the world of nanomedicine due to its extraordinary physical and 
mechanical properties. One of the most important reasons for using cobalt ferrite 
nanoparticles in the biomedical application is its high magneto crystalline anisotropy 
that originates from the spin–orbit (L–S) coupling at crystal lattices. In addition to 
this, the surface of this  material  is hard  with a high Curie temperature TC (520 °C), 
high coercivity of about 4.3 kOe at room temperature for the 40 nm size single 
domain, moderate saturation magnetization of about 80 emu/g for bulk at room 
temperature, high anisotropy constant (2.65×106 – 5.1×106 erg cm−3) and high 
magnetostrictive (−225×10−6).183 Moreover, the cobalt ferrite nanoparticles show 
excellent chemical stability, mechanical hardness, wear resistance, ease of synthesis, 
and electrical insulation. Hence, due to the above-mentioned properties cobalt ferrite 
nanoparticles would be one of the most promising candidates for medical applications 
including magnetic drug delivery, radio-frequency hyperthermia, magnetic resonance 
imaging (MRI) and medical diagnostics.184-187 Rittich et al.188used cobalt ferrite for 
the isolation of deoxyribonucleic acid (DNA). Lee et al reported the use of cobalt 
ferrite nanoparticles as contrast enhancing agent in magnetic resonance imaging 
(MRI). They investigated the use of cobalt ferrite nanoparticles for hyperthermia 
treatment due to the self-heating characteristics of cobalt ferrite nanoparticles.189 
Christopher et al observed that the heat is generating from aqueous dispersed 
CoFe2O4 nanoparticles and hence they used cobalt ferrite nanoparticles as a heat 
generating agent for magnetically activated drug delivery and hyperthermia.190  
Superparamagnetic nature of magnetic nanoparticles has been determined 
from magnetocrystalline anisotropy. This magnetocrystalline anisotropy nature of 
magnetic particles is originating from the spin- orbital (L-S) coupling at crystal 
lattices. For a cubic spinel structure of a crystal, the relative magnitude of magnetic 
anisotropy can be determined from the significant difference in L-S coupling strength 
between the cations. Among different spinel ferrites, Co-ferrite has the highest value 
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of the S–L coupling and anisotropy constant [K1 (×105) (MnFe2O4) = − 0.25 (erg 
cm−3), K1 (×10
5) (Fe3O4) = −1.2 (erg cm−3 ), and K1(×105 ) (CoFe2O4) = +19, +30 
(erg cm−3)].191 Co2+ cation with 3d7 electronic configuration at a B site in  CoFe2O4 
has a triplet 4T1g ground state. Even though the trigonal field is introduced with the 
T1g ground state further splitting into A2 and E states, the Co
2+ cation with a 
degenerated ground state of E is still considered to have a strong L–S coupling and 
consequently contributes greatly to the magnetic anisotropy of CoFe2O4.
192  
Highly dispersed cobalt ferrite nanoparticles generate efficient and controlled 
heat for hyperthermia application. Furthermore the small size, high magnetic 
crystalline anisotropy and moderate saturation magnetization are also suitable for 
hyperthermia treatment. The amount of heat generating from magnetic nanoparticles 
depends upon the magnetic moment, field, frequency, and particle volume because 
power loss describes the heat generation due to Brownian and Neel relaxation 
mechanisms. The power loss equation can be expressed as [P = μ0 πf x″H2] where P 
is the heat generation of nanoparticles, x″ is the susceptibility, H is the amplitude of 
the magnetic field intensity, and μ0 = 4π×10−7 (T mA)−1.193,194  
It is obvious that the desired heat to achieve the magneto thermally triggered 
drug delivery and hyperthermia can be reached using cobalt ferrite nanoparticles by 
adjusting the magnetic field and frequency.195 Magnetic cobalt ferrite nanoparticles 
were found to resonantly respond to a time-varying magnetic field with advantageous 
results related to the transfer of energy from the exciting field to nanoparticles. 
Besides to this hyperthermia treatment varies with an important parameter i.e., the 
specific absorption rate (SAR).   
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Where, C is the specific heat of the ferrofluid and sample holder taken 
together, ΔT/Δt is the initial slope of the time-dependent temperature curve; m ferrite 
is the total ferrite content in the fluid.196 It is experimentally found that SAR value is 
at the highest level for cobalt ferrite (~396 W/gFe) than MnFe2O4 (136 W/gFe), and 
Fe3O4 (168 W/gFe), making cobalt ferrite more appropriate for hyperthermia. In 
addition to this, cobalt ferrite offers excellent r2 relaxivity (transverse) in MRI. 
Higher the value of saturation magnetization higher r2 relaxivity is observed. The r2/r1 
values for MnFe2O4, Fe3O4 and CoFe2O4 are 12.2, 23.1 and 62.3 respectively.  
1.7. Current state-of-the-art 
The major design concept of current theranostic nanomaterials takes into 
account all three components, i.e., imaging agent, therapeutic agent, and targeting 
moiety. All three components have been under extensive investigation for 
development of tailored theranostic applications. It is now common practice to 
combine two imaging modalities for multimodal imaging. Nanoparticles have been 
particularly developed for optical imaging and MRI. In the field of MRI, several 
superparamagnetic iron oxide based nanoparticles such as Feridex, Resovist, Lumiren 
have been clinically approved. However, there remains ample scope to explore other 
ferrites (MFe2O4) where M = Ni, Zn or Mn for their potential applications in MRI. It 
would be advantageous to explore the contrast enhancing properties of other ferrite 
nanoparticle for magnetic resonance imaging and therapy. Great innovations can be 
introduced in terms therapy and imaging by making hybrid carrier matrices such as 
core-shell, hollow structures with ample guest loading capacity, mesoporous hollow 
structures to integrate more than one probe for imaging. The conjugation of the 
payloads to the nanocarrier requires suitable intermolecular interaction such as π-π 
stacking interaction, hydrogen bonding, and covalent bond formation between the 
carrier and the payload molecules. In particular, the release kinetics of the drug either 
conjugated to the carrier or entrapped in the carrier would be significantly different 
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from those of conventionally administered systemic drugs which might lead to 
significant difference in therapeutic efficacy. In addition to this, protection of 
therapeutic drugs and imaging agents is of paramount importance in order to 
minimise the side effects of premature drug release. Among the nanotheranostics 
developed for various cancer chemotherapeutic drugs, doxorubicin (DOX) is the most 
explored. Research efforts are desirable to accommodate some challenging 
therapeutic moieties in the theranostic nanogent for which there is no other suitable 
delivery system available till now. Another important requirement is that targeting 
theranostic agent to specific site. Robust chemical conjugation strategies must be 
adopted to attach cancer directing agents such as folic acid. Judicious control on 
number of marker molecules and therapeutic as well diagnostic moieties would be 
advantageous to obtain optimum efficacy of the theranostic multifunctional 
nanoparticle. 
The overall goal of this research work is to develop fluorescent magnetic 
nanoparticle for target specific delivery of some potential anticancer drugs, like 
cisplatin, methotrexate, pemetrexed etc., monitoring drug activity in vitro by 
fluorescence imaging and exploring the possibilities of our material in MRI. To 
realize our goal we focus on four important issues. 1) Overall structure, morphology 
and stability of the carrier matrix; 2) Adopting low cost materials to design the 
carrier; 3) Suitable conjugation strategy to attach therapeutic agent and marker 
molecule which ensures long term stability and stimuli responsive controlled release 
of the therapeutic agent; 4) Overall integrity of the theranostic agent with reasonable 
hydrodynamic size and all functional properties intact till it reaches the target site. We 
hypothesize that because of the merits of cobalt ferrite nanoparticle as discussed in 
section 1.6, if it is used instead of iron oxide the transverse relaxivity (r2) of the 
theranostic agent would be improved and hence more negative contrast would be 
generated in MRI. Hollow spheres may be employed as a single carrier to encapsulate 
sparingly water soluble anticancer drugs, hydrophilic anticancer drugs and imaging 
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agents to achieve combinational therapy and imaging simultaneously. A fluorescent 
inorganic matrix can be used as a carrier in the theranostic system to avoid additional 
fluorophore conjugation. In this connection fluorescent carbon may be explored due 
to its inertness, high fluorescence quantum yield and excitation dependent 
luminescence. 
1.8. Objectives  
Our current research is focused on the development of suitable synthetic 
methodology or improvement of existing technologies for large scale production of 
multifunctional magnetic nanoparticles based formulations for some widely 
acceptable anticancer drugs. Our research objective is set as follows:  
 To develop an easy, eco-friendly and cost-effective synthetic technique for 
large scale production of functionalized porous metal ferrites 
  To explore the suitability of cobalt ferrite nanoparticles as a magnetic 
component in multifunctional theranostic nanoparticle 
 To design a robust matrix to carry cargoes such as ferrite nanoparticle and 
cancer drugs and to regulate their stimuli responsive release mechanism while 
keeping their therapeutic activity intact.  
 To explore the luminescence properties of carbon nanostructures in 
theranostic application 
 To investigate the suitability of the developed theranostic nanoparticles as a T2 
contrast agent in MRI  
 To evaluate the performances of the synthesized drug loaded particles in vitro 
in some model cancer cells  
In line with this approach a mesoporous cobalt ferrite based drug carrier has 
been designed for the targeted delivery of leading anticancer drugs doxorubicin as 
well as methotrexate. Magnetic hydroxyl apatite nanoparticles have been developed 
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for the delivery of cisplatin. Mesoporous hollow silica and carbon based theranostic 
agents have been developed for anticancer drugs pemetrexed, cisplatin and 
doxorubicin. The therapeutic and diagnostic performances have been evaluated in 
vitro. The detail of the material design and added advantages of each system have 
been discussed in subsequent chapters. 
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Chapter-2 
One pot synthesis of uniform and spherically assembled 
functionalized MFe2O4 (M= Co, Mn, Ni) nanoparticles 
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2.1. Introduction  
 Monodisperse magnetic nanoparticles and nanoassemblies are currently of 
emerging interest because of their unique physico-chemical properties and wide 
applications in memory storage devices, catalysis, sensors, MRI, magnetically 
controlled drug delivery and hyperthermia treatment of tumour cells.
1-3 
Nano sized 
magnetic particles have physical and chemical properties that are characteristics of 
neither the atom nor the bulk counterparts. The large surface area and quantum size 
effect of magnetic nanoparticles dramatically change some magnetic properties and 
exhibit superparamagnetic phenomena and quantum tunnelling of magnetization. 
Among the materials explored so far, spinel ferrites MFe2O4 (M = Co, Mn, Ni) are 
emerging as promising materials especially for biomedical applications.  
        Compared to iron oxide nanoparticles, spinel ferrites provide ﬂexibility to 
control both crystal structures and magnetic properties by choosing different non-iron 
metals in spinel ferrite backbone and controlling their molar concentrations.
4
 Hence 
the surface of these magnetic nanoparticles could be modified through the creation of 
few atomic layers of organic polymer or inorganic metals (e.g. gold) or oxide surfaces 
(e.g. silica or alumina), suitable for further functionalization by the attachment with 
various bioactive molecules. They are either dispersed through a large volume of a 
polymeric bead or occur as core in colloidal reagent with a biodegradable shell. As 
the magnetic particles accumulates in tumour tissue, they can play an important role 
in detection through MRI or electron microscopic imaging to locate and measure the 
therapeutic effect of anticancer drugs.
 
Therefore, research on development of 
fabrication methods for ferrite nanoparticles with desirable magnetic property, 
acceptable chemical stability and surface chemistry that allow straight forward 
functionalization with different surface active moieties has continued to attract 
interest of several research groups. 
 A number of chemical routes have been utilized for the controlled synthesis of  
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monodispersed ferrite particles and to establish the correlation between magnetic 
properties and synthetic conditions. Techniques such as coprecipitation,
5
 sol-gel,
6 
microemulsion
7
 and microwave,
8 
ultrasound irradiation,
9
 have been employed to 
prepare ferrite nanoparticles. But synthesis of strictly monodisperse particles, precise 
control of their size, shape and surface was still a challenge. Recently thermal 
decomposition technique offered an opportunity to prepare monodispersed magnetic 
nanoparticles. Sun and Zeng
10
 have succeeded in synthesizing metal ferrites using 
Fe(acac)3 as the precursor. Yànez-Vilar et al. adapted the same method to synthesize 
single phase nanosized MFe2O4 (M = Co, Mn and Ni) nanoparticles.
11
 
On the other hand, self-assembly of magnetic nanoparticles based on selective 
control of non-covalent interactions
12-15 
not only acts as a powerful tool for the 
creation of structured systems at a molecular level, but also provides a direct bridge 
between nanoscale objects and the macroscale devices.
16 
Monolayer-functionalized 
nanoparticles can be made with a wide variety of metallic and non-metallic cores, 
providing a versatile building block for such approaches. The integrity of the building 
blocks based on selfassembly might provide a fascinating strategy for designing 
frameworks with for desirable shapes and sizes. To date, a number of methods have 
been developed to fabricate magnetic nanoparticle clusters with uniform size.
17,18 
An 
efﬁcient approach that has gained popularity for well deﬁned clusters is the use of 
self-assembled structures such as polymers or surfactants. Yin et al. reported the 
synthesis of monodisperse magnetite colloidal clusters composed of small primary 
nanocrystals by high temperature solution phase process using poly(acrylic acid).
19
 
Amine functionalized Fe3O4 with high T2 effect have recently reported by Barik et al. 
which ideally suited their use as contrast agent in MRI.
20 
Cheng et al. have developed 
a facile polyol process to synthesize carboxyl-functionalized magnetite nanoclusters 
using urea as homogeneous precipitator and sodium acetate as stabilizer.
21
 Self-
assembly of magnetite and  maghemite nanoparticles into necklace like nanorings is 
reported by Hui et al.
22
 Although momentous progress has been made in studies on  
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iron oxide nanoparticle assemblies, other ferrites are less explored in this direction.In 
the present work we have employed a cost-effective, eco-friendly, one-pot solution 
Phase method to synthesize highly  hydrophilic uniform spherical nanoassemblies of 
ultra-small amine-functionalized MFe2O4 (M=Co, Ni, Mn) nanoparticles. Our 
synthesis method mainly involves heating low cost metal chloride precursors in 
ethylene glycol in presence of weak base sodium acetate and ethanolamine. 
Ethanolamine meets both the purpose of stabilizer as well as surface functionalization 
with –NH2 groups. The effects of the nature of the base, reaction temperature and 
ethanolamine concentration on aggregate size have been thoroughly investigated 
through DLS measurements. 
2.1 . Experimental 
Materials 
All chemicals were of analytical grade and used without further puriﬁcation. 
All metal chlorides were taken from Merck, India. Ethylene glycol and ethanolamine 
have been procured from Sigma–Aldrich. 
Synthesis of amine functionalized MFe2O4 (M= Co, Mn, Ni) nanoparticles  
 Amine functionalized superparamagnetic MFe2O4 nanoparticles were 
prepared by thermal decomposition of MCl2 and FeCl3 in ethylene glycol in the 
presence of sodium acetate and ethanolamine (Fig. 2.1). Brieﬂy, anhydrous FeCl3 (4.2 
mmol) and MCl2·7H2O (2.1mmol) were taken in 30 ml ethylene glycol and 0.5 g of 
sodium acetate was added to it. The above solution was stirred for 30 minutes 
followed by the addition of 15 ml of ethanolamine. Now the entire solution was 
heated at 150 °C for 6 h during which ﬁne black colloidal particles appeared in the 
reaction mixture. 
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Fig. 2.1 Schematic representation for synthesis of amine functionalized MFe2O4 
nanoparticles. 
 After that it was cooled down to room temperature. The particles were 
recovered using a magnetic separator (DynaMag2, Invitrogen)  washed with 
Millipore water (5 × 5 ml) and dried in hot air oven at 80  °C for 2 h. 
2.3. Characterization 
The identiﬁcation of the crystalline phase of the synthesized ferrite particles 
was performed by an Expert Pro Phillips X-ray diffractometer. The morphology and 
microstructure were analysed using scanning electron microscope (HITACHI COM-
S-4200) and high resolution transmission electron microscopy (JEOL 3010, Japan) 
operated at 300 KV. The particle sizes from TEM micrographs were calculated using 
image J software. The hydrodynamic size and dispersion stability of particle 
aggregates were investigated through dynamic light scattering using a Malvern ZS90 
zetasizer. Hydrodynamic size was measured by dispersing 0.1 mg of sample in 1 ml 
phosphate buffered saline. The surface charge was determined through zeta potential 
measurements. The pH was adjusted between 4 and 9 using dilute NaOH/HCl 
solutions for both HD size and zeta potential measurements. The surface chemistry of 
the nanoparticles was studied using FTIR spectroscopy (Perkin Elmer (BX 12)). The 
surface composition of different nanoparticles was investigated through X-ray 
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photoelectron spectroscopy in an ESCA-2000 (VG microtech) apparatus. Magnetic 
measurements were performed in a SQUID magnetometer. 
2.4. Results and discussion 
XRD analysis 
X-ray diffraction analysis (Fig. 2.2) shows that in all metal cases the 
diffraction pattern perfectly matches with the expected cubic spinel structure of Co, 
Mn and Ni ferrites and has been identified as CoFe2O4 (JCPDS no. 03-0864), 
MnFe2O4 (JCPDS no. 10-0319) and NiFe2O4 (JCPDS no. 03-0875) respectively. The 
crystallite sizes were calculated using Scherer’s equation taking into account 
broadening of each diffraction peak and are summarized in Table 1. 
 
 
 
 
 
 
 
 
 
Fig. 2.2 XRD patterns of MFe2O4 (M = Co, Mn, Ni) nanoparticles. The planes corresponding to 
each peak have been indicated at the top of the graphs. 
 
The lattice parameters calculated from reflections of [400] plane is 8.36 Å, 8.4 
Å and 8.32 Å for CoFe2O4, MnFe2O4 and NiFe2O4 respectively. The most important 
and interesting observation is that effective broad peaks in case of all ferrites indicate 
fine nanocrystalline nature of samples. 
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TEM 
Fig. 2.3(a)-(h) shows representative TEM micrographs of synthesized ferrite 
nanoparticles. In all cases spherical particles of size 35–50 nm were produced (Table 
2.1). These spherical nanoassemblies are discrete, well defined and porous in nature. 
In case of MnFe2O4, these spherical particles further assemble to produce necklace 
like structures unlike CoFe2O4. This is possibly due to higher magnetization of 
MnFe2O4 which promotes further aggregation. Fig. 2.3(b) and (g), showing images at 
higher magnification indicate that each spherical particle is an assembly of primary 
cubic nanocrystals of about 4–5 nm and worm-like pores of about 2–3 nm. These 
ultrafine nanocrystals spatially assembled spontaneously to give porous spherical 
superstructures in order to minimize their surface energy. The high resolution TEM 
image of CoFe2O4 (Fig. 2.3c) shows a single aggregate, where the parallel lattice 
fringe is uniformly extended over the primary building blocks, grain boundaries and 
pores. Similar result was also obtained by Cannas et al.
18 
in case of spherical nano-
aggregates of CoFe2O4 nanoparticles synthesized by surfactant assisted route. Thus it 
can be concluded that the nanoparticles are organized into an oriented attached 
structure by sharing identical lattice planes. The lattice plane distance was calculated 
to be 1.69 Å from the image which corresponds to the reflection of [211] plane in the 
cubic CoFe2O4. Similar observations were found in case of MnFe2O4 and NiFe2O4 
particles. From the selected area electron diffraction pattern the corresponding planes 
were calculated using the relation: 
 
 
Where = wave length of electron wave; L = camera length; R = radius of diffraction 
ring. 
d = Interplannar distance between two lattice planes. 
      The d values indexed in SAED pattern for each ferrite samples correlate with 
XRD pattern dXRD is the crystallite size of the grain calculated using Scherrer’s 
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equation; a is the lattice parameter obtained from XRD experiments; dDLS is the 
hydrodynamic size of ferrite nanoparticles observed in PBS (pH 7.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3 TEM images of (a and b) CoFe2O4, (d and e) MnFe2O4, (g) NiFe2O4 at different 
magnifications; (c, f and h) HRTEM images of CoFe2O4, MnFe2O4, and NiFe2O4 respectively. 
The insets are the corresponding SAED patterns. 
 
 
 Chapter 2                                                                                                       Synthesis of MFe2O4 NPs 
50 
 
Table 2.1 
Physical characteristics of different ferrite nanoparticles 
 
 
 
 
 
dXRD is the crystallite size of the grain calculated using Scherrer’s equation; a is the 
lattice parameter obtained from XRD experiments; dDLS is the hydrodynamic size of 
ferrite nanoparticles observed in PBS (pH 7.4) using dynamic light scattering; dTEM is 
the diameter of spherical assemblies observed by TEM; Ms is the saturation 
magnetization at room temperature; dBET is the particle size calculated from specific 
surface area; SBET specific surface area and n is the density of –NH2 groups present on 
the surface. 
Plausible mechanism for the formation of MFe2O4 nanoparticles 
Formation of magnetic particles can be explained according to the well-known 
polyol method of synthesis.
25, 27-28 
In our system ethanolamine acts as a strong 
complexing agent for cobalt and iron ions as observed by instantaneous colour change 
upon addition of ethanolamine to the solution of M(II) and Fe(III) in ethylene glycol. 
With increase in temperature metal ions are slowly released into the solution and 
combined with [OH
−
] to give MFe2O4. The effect of base on aggregate size has been 
investigated (Table 2.2) and it is found that in presence of stronger bases larger 
aggregates are formed. It is possibly due to rapid formation of ferrite mass in 
presence of high concentration of [OH
−
]. The same trend was observed even when 
volume of ethanolamine increases in the reaction medium. At higher concentration of 
ethanolamine size of the ferrite particles was drastically increased (Table 2.3) due to 
higher pH. Using a weak base such as NaOAC at optimum concentration of 
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ethanolamine the mass formation takes place slowly in a controlled manner. In 
addition to this at high temperature ethylene glycol is oxidized to glycolic acid 
aerially and creates an oxygen deficient atmosphere which further protects the ferrite 
nanoparticles from being oxidized to hydroxides as shown in equation 2.1.
28  
 
 
 
The ferrite particle formation proceeds in a controlled manner due to synergic 
effect of ethylene glycol and ethanolamine. In addition to this, ethanolamine acts as a 
nucleation and growth controlling as well as amine functionalizing agent for ferrite 
nanoparticles. From the TEM image it was observed that nanoparticles are organized 
into an isooriented attached structure by sharing identical lattice planes. From this 
observation oriented attachment growth mechanism can be proposed for the 
formation of clusters.
29–31 
The clusters are formed from self-assembly of ultrafine  
particles by sharing common crystallographic orientation. The driving force for such 
spontaneous arrangement is that the elimination of pairs of high energy surfaces 
which will lead to reduction of surface free energy from thermodynamic view point. 
The formation of such nanoassemblies may be dependent on the collective behaviour 
of nanoparticles and intermolecular forces existing between them.
32
 The no. of –NH2 
groups present on each spherical assembly was determined using UV–visible 
spectroscopy according to the previously reported procedure,
33
 and it was found that 
each porous particle of 40 nm size contains approximately 490 amine groups. The 
aqueous dispersion stability of magnetic nanoparticles is an important factor for their 
utilization in drug delivery as well as tumor diagnosis through MRI.
 
 
 
 
CoFe2O4 + 0.25 O2 + 4.5 H2O                    Co(OH)2 + Fe(OH)3   -------- 2.1 
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Table 2.2 
Effect of base on aggregate size 
 
Table 2.3 
Variation of particle size with different amount of ethanolamine 
 
 
 
 
Hydrodynamic size and zeta potential measurement
 
The hydrodynamic size, calculated from the diffusional properties of the 
particle is an indicative of the apparent size of the dynamic hydrated/solvated particle. 
It was observed that the hydrodynamic (HD) size of CoFe2O4 by DLS shows a narrow 
distribution of size from 50 to 60 nm with mean HD size 50.8 nm with polydispersity 
0.2 (Fig. 2.4). When HD size was measured against time, it was found that there was 
absolutely no change in mean HD size up to 3 days. After that it was slightly 
increased to 70.8 nm and was consistent at 70.8 nm even after one week of 
incubation. This exceptional stability in aqueous medium may be attributed to the 
excellent hydrophilicity of the surface, contributed by surface –NH2 groups. 
Measurement of size over pH (4–7.6) shows almost no change in mean HD size. The 
presence of free surface amine groups was further investigated by examining the 
surface charge properties over pH 3–7.4 by zeta potential measurement. It was found 
that at neutral pH the ZP is−5.65 mV i.e. slightly negative which agrees with 
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observations reported by Bae et.al.
30 
With slight increase in pH there is substantial 
increase in ZP value which may be due to protonation of surface amine groups. The 
isoelectric point of synthesized CoFe2O4 was found to be 6.8 which is slightly greater 
than that of co-precipitated ferrite particle. This shifting in isoelectric point may be 
due to surface modification with –NH2 groups. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4(a) Particle size distributions of ferrite nanoparticles. (b) Change in hydrodynamic size 
with time. (c) Variation of zeta potential with pH in case of CoFe2O4 nanoparticles. 
 
FTIR Analysis 
The IR spectra for all synthesized metal ferrites are shown in Fig. 2.5.  The 
strong band at low frequency region (500–800 cm−1) in each sample is ascribed to the 
M–O stretching in the oxide nanoparticles. The appearances of peaks at 890 and 1324 
cm
−1
 correspond to the out of plane bending vibration of –N–H bond in primary 
amine and C–N stretching. This observation indicates the existence of ethanolamine 
molecules on nanoparticle surfaces. Therefore it can be concluded that nanoparticles 
are stabilized by ethanolamine through –OH group-metal complexation, which is 
further supported by ESCA (Electron spectroscopy for chemical analysis) analysis. 
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Fig. 2.5 FTIR spectra of –NH2 spectra of –NH2 functionalized CoFe2O4, MnFe2O4 and NiFe2O4 
nanoparticles. 
 
XPS Analysis 
Fig. 2.6 shows representative XPS spectra of CoFe2O4. A careful observation 
of the peak corresponding to C1s region shows that the curve is well-fitted if it is 
considered as contributions from three peaks centered at 286.8, 289.07 and 290.8 eV. 
The C1s spectra corresponding to reference shows a shift of 2 eV to higher binding 
energy and hence taking the reference shift into consideration all other binding 
energies are to be evaluated. The Fe2p shows two peaks at 710.17 and 723.7 eV 
which is in consistency with Fe2p binding energy for cobalt ferrite nanoparticles.
31 
Co2p spectrum shows peaks at 779 and 784 eV corresponding to Co2p3/2 and Co 2p1/2 
electrons associated with corresponding shake ups at 785 and 801 eV. In addition to 
this the asymmetric nature of the peak is ascribed to Co
2+
 present in 
octahedral/tetrahedral sites.
32
 The broad shoulder of O1s electron at 531.7 eV can be 
deconvoluted into two peaks centred at 531.5 and 533.2 eV corresponding to oxygen 
present in Fe–O and C–O bonds. In N1s region, a symmetric peak centred at 398.7 
appears indicates the presence of only free –NH2 groups on the surface of the  
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nanoparticles. The position of the peak well matches with that of N bonded to sp3 
carbon as reported by Gammon et al.
37 
So from XPS it is concluded that the 
ethanolamine has been chemically bonded on the surface of uniform sized spherical 
aggregates of ferrite nanoparticles through –OH site leaving –NH2 as the pendant 
group which lead to the excellent stability of ferrite particles in aqueous medium (Fig. 
2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6. XPS survey spectrum of CoFe2O4. High resolution scans corresponding to C1s, O1s, 
Fe 2p, N1s and Co2p binding energy. 
Thermal analysis 
 
The chemical bonding of ethanolamine on ferrite nanoparticles is further 
supported by thermal analysis. It was found that the density of amine groups is 
significantly high as compared to other previously reported methods by different 
research groups.
28,34
 There are three weight loss steps in TG curves of ferrite 
nanoparticles (Fig. 2.7). The first mass loss of 1% (between 34 and 130°C) is due to 
removal of moisture from ferrite surface. The second weight loss above 150°C and 
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below 280°C is due to adsorbed water, ethylene glycol and ethanolamine. The loss of 
weight at temperatures higher than 410°C may be ascribed to the decomposition of 
surface bonded ethanolamine molecules which are mainly responsible for the 
excellent stability of the nanoparticles in the aqueous medium. 
 
 
 
 
 
 
 
 
 
 
                           
                                Fig. 2.7 Thermogravimetry curves of ferrite nanoparticles. 
 
Nitrogen adsorption–desorption study 
Nitrogen sorption experiment was conducted to further investigate the porous 
nature of ferrite nanoparticles. Fig. 2.8 represents the nitrogen adsorption–desorption 
isotherms and BJH pore size distribution curves of CoFe2O4 and MnFe2O4 
nanoparticles. The isotherms are identified as type IV, which is characteristic of 
mesopores. It is notable that besides mesopores formed by aggregation of spherical 
particles; the BJH pore size distribution clearly indicates mesopores centred at 3–4 
nm formed among the ultrafine nanoparticles within the aggregate which is in 
accordance with the TEM result. BET surface area of CoFe2O4 and MnFe2O4 powder 
were calculated to be 210 m
2
/g and 209 m
2
/g. To our knowledge surface area values 
for porous magnetic oxides synthesized by various other synthetic methods have not  
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exceeded 150 m
2
/g.
18,28,35
 Hence in the present synthetic route the surface area of 
magnetic oxides can be significantly increased and it would be particularly beneficial 
in bioseparation and drug delivery. 
 
 
 
 
 
 
 
 
Fig. 2.8(A) Nitrogen adsorption–desorption isotherm and (B) Pore size distribution of 
CoFe2O4 and MnFe2O4. 
  
Squid analysis 
Fig. 2.9(a)–(c) shows the temperature dependent zero-field cooling and field-
cooling curves of CoFe2O4, MnFe2O4 and NiFe2O4 nanoparticles. The magnetic 
behaviour shown by each ferrite sample can be interpreted according to TEM results. 
The curves are not superposing even at 300 K indicating the nanoparticles are more 
likely to be present in a ferrimagnetic state.
36 
In case of FC (5 mT), there is slight 
increase in magnetization with decrease in temperature up to 160°C, and a constant 
trend is observed below 160°C. The magnetization measured under zero-field cooling 
condition continuously increases till 300 K with a broad hump around 150–160°C. 
This particular behaviour can be ascribed to the strong nanoparticle interactions 
forming an assembly which can lead to a collective magnetic order state with high 
anisotropy,
37 
and this is also expected in case of iso-oriented ferrite nanoparticles. 
Field dependent magnetization curves of all three ferrite nanoparticles at room 
temperature are illustrated in Fig. 2.9d. The magnetization rose rapidly as the applied  
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field increased up to 1T and reached at a saturation point at 2 T. In all cases the 
saturation magnetizations (Ms) display higher values for synthesized nanoparticle 
assemblies than the corresponding nanodots. Ms values for synthesized CoFe2O4, 
MnFe2O4 and NiFe2O4 particles are found to be 59.4, 56 and 40.88 e.m.u./g, which 
are higher than Ms for corresponding nanodots 35 e.m.u./g, 27 e.m.u./g and 25 
e.m.u./g,
38-40 
but lower than their bulk counter parts 71.2, 80, 51 e.m.u./g 
respectively.
41–43
 This decrease in Ms value could be mainly attributed to small 
particle surface effect (i.e. spin canting) that becomes more dominant as the particles 
are smaller.
44
 The curves show almost no hysteresis opening and are completely 
reversible at room temperature. As observed by XRD and TEM the size of primary 
nanocrystals is 4–5 nm, which is smaller than superparamagnetic critical size of 
MFe2O4. Thus it is logical that synthesized clusters show superparamagnetic 
behaviour even though their size exceeds critical size and at the same time the 
improved coalescence of crystallites in the nanostructures results in increased 
magnetic coupling and higher magnetization. The magnetic on–off switching 
behaviour owing to superparamagnetism is particularly advantageous in 
bioseparation, magnetic resonance imaging as well as magnetically controlled drug 
delivery. 
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Fig. 2.9 Zero-field-cooling (black) and field-cooling (grey) curves of (a) CoFe2O4, (b) MnFe2O4, 
and (c) NiFe2O4nanoassemblies under 5 mT applied  field and (d) their corresponding field-
dependent magnetization at 300 K. Each sample shows almost no hysteresis and zero 
coercivity at room temperature. 
2.5. Conclusion 
The synthesis technique described in this chapter is a versatile process to develop 
mesoporous amine functionalized magnetic ferrite MFe2O4  (M = Co, Mn, Ni). The 
uniform and monodisperse structures are formed due to careful control of the reaction 
parameters. The nanospheres simultaneously show superparamagnetism and high 
saturation magnetisation because of iso-oriented attachment of small particles to give 
an assembled structure. Further, due to high surface area, presence of nanochannels 
and high density of surface amine groups routine bioconjugation as well as 
incorporation of drugs can be facilitated. 
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Chapter-3 
Synthesis and surface functionalization of monodisperse 
mesoporous cobalt ferrite nanoparticles for targeted delivery of 
antitumor drugs 
 
 
 
 
 
 
 
 
 
 
 Chapter 3                                                                      Mesoporous CoFe2O4 NPs for drug delivery 
63 
 
3.1 . Introduction  
From last few years, numerous efforts  have been devoted to  develop a 
suitable  magnetic nanocarriers for tumor diagnostic and therapy.
1,2
 Generally, the 
nanocarrier used for biomedical applications should an inexpensive material, follows  
very simple methods to fabricate, spherical, narrow size distribution, biocompatible, 
good dispersion stability in physiological environment and  have large surface area  
for maximal drug loading. Among the different types of functional nanostructures, 
superparamagnetic iron oxide nanoparticles (SPION)  with appropriate  surface 
chemistry  have been widely used  in several  biomedical  fields such as contrast 
enhancing agent in MRI,  tissue repair, cell separation, hyperthermia treatment and an 
active agent in  drug delivery.
3-5
 Since its first use as a liver contrast agent in 1986,
6,7
 
many researchers have developed novel nanoparticulate systems with improved 
surface functionalization with biocompatibility, targeting ability and 
multifunctionality.
8,9
 However, the use of other ferrites such as spinel ferrites or 
garnets with larger anisotropy may be envisioned for biomedical applications, as it 
could allow a significant improvement in material efficiency.
10-12
 Besides to this, the 
use of spinel ferrites is more  advantageous in therapeutic applications 
because  magnetic property and Curie temperature (Tc) can be tuned by substitution 
with variable nonmagnetic cations.
13  
More importantly, spinel cobalt ferrite forms 
such a magnetic system in which it is easy to control magnetic properties at the 
atomic level through chemical manipulation.
14-16
 Cobalt ferrite has been proposed for 
biomedical applications since it is known to have large anisotropy compared to other 
oxide ferrites.
17
 As the magnetic anisotropy is directly connected to hyperthermic 
efficiency,
18
 the use of cobalt ferrite nanoparticles could introduce several benefits in 
therapeutic applications.
19
 Recently Frachini and co-workers have developed  bovine-
serum albumin-cobalt ferrite based theranostic nanomedicine which would make a 
negative contrast agent in MRI and can be employed as heat mediators allowing 
enhanced hyperthermic effects even with the reduced magnetic field.
20
Scaberry and  
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coworkers have developed biocompatible glucuronic acid coated magnetic spinel 
cobalt ferrite nanoparticle-peptide conjugate to target and extract malignant ovarian 
cancer cells.
21 
Napini and coworkers have also studied several cobalt ferrite based 
magneto liposome for controlled drug release in presence of alternate magnetic 
field.
22-23 
Due to the large anisotropic effect of cobalt ferrite, it can be used instead of  
iron oxide particles with appropriate physical characteristics and allowing the 
assembly of smaller biocompatible devices that are known to promote cellular uptake 
and to better avoid the reticuloendothelial system.
2
 one important strategy to improve 
physicochemical characteristics of nanoparticles is surface coating. Proper surface 
coating such as organic polymers,
24 
small coupling molecules,
25
 or inorganic silica 
materials
26
 allows ferrite nanoparticles to disperse homogeneously into the carrier 
fluid and drugs can be attached through the surface functional groups for therapeutic 
applications. Furthermore, the nanoparticles designed for controlled drug delivery 
should have an efficient mechanism for controlled release of the drug within the 
target cell. An emerging concept to improve the targeting capacity and drug releasing 
efficiency of nanoparticles is active targeting through folate receptor-mediated 
endocytosis.
27-28
 It has been revealed that aggressive or undifferentiated tumors at an 
advanced stage such as ovarian, endometrial, colorectal, breast, lung, renal cell 
carcinomas, brain meta stages derived from epithelial cancers have an increased 
folate receptor density compared to normal tissues.
29-30
 Also it has been reported that 
folic acid conjugated superparamagnetic iron oxide nanoparticles can  efficiently 
show in vitro intracellular uptake by folate receptor overexpressed HeLa and B16 
melanoma cells.
31
 
Alternatively, Methotrexate (MTX) is an analogue of folic acid and inhibits 
the target enzyme, dihydrofolate reductase (DHFR). Methotrexate not only display 
the targeting role of folic acid but also it has the ability to treat many types of cancer 
cells that overexpress folate receptor on their surfaces.
32
 Impairment of drug import  
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into cells and increase in drug export from cells may render cells resistant to MTX. 
MTX, when locally administered in a soluble form, is rapidly absorbed through 
capillaries into the circulatory system, which may also account for therapeutic failure 
in patients. Serious attempts have been made to propose new nanoparticle based 
formulations for retention of MTX within tumor cells for longer duration and alter its 
pharmacokinetic behavior. Methotrexate conjugated iron oxide nanoparticles was 
developed by Kohler et al. which act as contrast enhancing agent in MRI and as a 
drug carrier in controlled drug delivery, targeted at cancer diagnostics and 
therapeutics.
33
 Recently Das et al. have successfully synthesized multifunctional 
nanoplatform, which serve as MRI contrast as well as the delivery of methotrexate.
34
 
They have also shown the controlled release of MTX through pH sensitive cleavage 
of the ester bond. However, a serious disadvantage of such methods is the multistep 
reaction for surface modification leading to the possibility of loss of magnetic 
property and other physical properties of nanoparticles due to the repeated exposure 
to the reaction conditions.  
Keeping in mind the advantages of cobalt ferrite as the magnetic component 
and methotrexate as the therapeutic component we deem to develop a theranostic 
nanoparticle which can deliver methotrexate in its acid form. In additions to this a 
robust stimuli responsive attachment between the drug and the carrier would prevent 
the premature release of the drug before it reaches the target site. For this we 
hypothesize that amide bond would be an appropriate choice to bind MTX on cobalt 
ferrite. In addition to this extreme care must be taken to control the proportion of 
drug, maker molecule and fluorophore. 
In this study, we have developed a facile synthetic route to prepare water 
soluble –NH2 functionalized superparamagnetic CoFe2O4 nanoparticles with high 
surface area in one-pot by taking the advantages of thermal decomposition method. 
The solvents ethylene glycol and ethanolamine served as stabilizer and surface 
functionalizing agent, thus avoiding multistep synthesis for surface 
functionalization. We have loaded these –NH2 functionalized particles with 
 Chapter 3                                                                      Mesoporous CoFe2O4 NPs for drug delivery 
66 
 
anticancer drug methotrexate and a fluorescent marker RITC. The entire MTX 
conjugated CoFe2O4 nanoparticles have been characterized in terms of their 
structure, morphology, size, and magnetic property. The in vitro biocompatibility of 
CoFe2O4-MTX was investigated through MTT assay. The intracellular uptake 
efficiency was thoroughly investigated through fluorescent microscopy and flow 
cytommetry (FACS). The MTX release profile was investigated by mimicking the 
lysosomal conditions in presence of bovine protease. In addition to this, the 
effective loading and pH sensitive release behavior of another anticancer drug 
doxorubicin have also been demonstrated using synthesized CoFe2O4 nanospheres.  
3.2 . Experimental 
Materials 
Ethylene glycol, ethanolamine, sodium acetate, ferric chloride, cobalt chloride 
were procured from Merck, Germany. RITC, folic acid, bovine serum albumin, 
methotrexate (MTX) and doxorubicin (DOX) were purchased from Sigma-Aldrich. 
N-hydroxysuccinamide (NHS), ethyl-(N’,N’-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC), 4-(N, N dimethylamino) pyridine (DMAP) were procured 
from Spectrochem, India. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide), paraformaldehyde, propidium iodide (PI), 
dimethylsulfoxide (DMSO), 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), 
Rodamin B isothiocyanate (RITC) and  RNase A were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Millipore water was used throughout the 
experiment. 
Preparation of CoFe2O4-NH2 nanoparticles 
Amine functionalized superparamagnetic CoFe2O4 nanoparticles were 
prepared by thermal decomposition of CoCl2.6H2O and FeCl3 in ethylene glycol in 
presence of sodium acetate and ethanol amine (Fig.1). Briefly, anhydrous FeCl3 
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(0.683 g, 4.2 mmol) and CoCl2.6H2O (0.576 g, 2.1 mmol) were taken in 30 mL 
ethylene glycol and 0.5 gm of sodium acetate was added to it. The reddish black color 
solution thus obtained was stirred for 30 min at 80°C followed by addition of 15 mL 
of ethanol amine. The entire solution was allowed to reflux for 6h during which fine 
black colloidal particles appeared in the reaction mixture. Then it was cooled down to 
room temperature. The CoFe2O4 were recovered using a magnetic separator 
(DynaMag2, Invitrogen) washed with millipore water (5x5 mL) and dried in hot air 
oven at 80 °C for 2h. 
Synthesis of folate decorated fluorescent magnetic carriers 
The folic acid conjugation with amine functionalized cobalt ferrite NPs is 
shown in Fig. 3.1. 100 mg of amine functionalized CoFe2O4 nanoparticles were 
dispersed in 5mL of water. To a stirred solution of EDC (18 mg, 0.09 mmol) in 5 mL 
of H2O, NHS (41 mg, 0.35 mmol) was added. To the resulting solution, alkaline 
solution of folic acid (13 mg, 0.031 mmol) in 5 mL of H2O was added followed by 
addition of 100 mg amine functionalized CoFe2O4 nanoparticles dispersed in 5 mL 
H2O. The entire solution was stirred in dark for 12h and the particles were separated 
magnetically, washed thoroughly with (3x5mL) millipore H2O and dispersed in 5 mL 
H2O (CoFe2O4-FA). To this dispersion RITC (100μg in 1mL DMSO/H2O) was 
added. The resulting suspension was sonicated for 1h in dark. Particles were 
recovered by magnetic separation and washed thoroughly with millipore water 
(CoFe2O4-FA-RITC).  
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Fig. 3.1 Schematic representation for the synthesis and conjugation of folic acid and 
methotrexate to mesoporous cobalt ferrite nanoparticles. 
Loading and release of MTX 
In a 50 ml round bottom flask, EDC (0.018 g, 0.093 mmol) and NHS (41 mg, 
0.35 mmol) were taken in 5 mL water. To this solution, slightly alkaline solution (pH 
8) of methotrexate (63.6 mg, 0.14 mmol, molar ratio FA:MTX ≈ 1:5) in 5 mL H2O 
was added and agitated for 2h in dark. Then 2 mL of aqueous dispersion of particles 
(0.1 mg/mL) was added and stirred in dark for 10 h at room temperature. Then the 
particles were recovered using magnetic separator, washed thoroughly with millipore 
water (5 x 5 mL) and suspended in phosphate buffer (pH 7.4) and used for in vitro 
studies (CoFe2O4-FA-RITC-MTX). Simultaneously another two sets of samples were 
also prepared, 1) without conjugating RITC (CoFe2O4-FA-MTX), 2) without 
conjugating FA and RITC (CoFe2O4-MTX) using the same procedure. In order to 
study MTX release behavior, 5 mL suspension of CoFe2O4-FA-RITC-MTX particles 
(0.1 mg/mL) was suspended in a solution containing 0.1 mg/ml protease from bovine 
pancreas (sigma) and 5 ml of PBS. The solution pH was adjusted to 3, 5 and 7.4 using 
0.1 M HCl and NaOH. Following incubation for 8, 12, 24, 48 and 72 h the 
 Chapter 3                                                                      Mesoporous CoFe2O4 NPs for drug delivery 
69 
 
nanoparticles suspensions were isolated and the MTX cleaved from nanoparticles was 
then quantified with UV spectroscopy (λmax = 270 nm). 
Loading and release of DOX    
To load DOX, the amine functionalized magnetic nanoparticles were converted to 
acid terminated particles through ring opening reaction with succinic anhydride in the 
presence of DMAP (Fig. 3.2). For this purpose, 10 ml aqueous dispersion (0.1 
mg/mL) of nanoparticles were washed thoroughly with millipore water and then 
dispersed in 5 mL of methanol. In a 100 mL round bottom flask, succinic anhydride 
(0.05g, 0.5 mmol) and DMAP (0.06g, 0.5 mmol) were taken in 15 mL methanol 
followed by addition of CoFe2O4 nanoparticles. The total mixture was refluxed for 24 
h at 80ºC (CoFe2O4-FA-COOH). The particles were recovered, washed thoroughly 
with methanol (5x5mL), dried at 80ºC (5mL of aqueous solution containing NHS 
(41mg, 0.358 mmol) and EDC (18 mg, 0.0938 mmol) was taken in a 50 ml of round 
bottom flask and was kept in dark for 2 h. After that the aqueous solution of DOX (74 
mg in 12 mL water, molar ratio FA:DOX≈1:5) was added to the above solution 
followed by addition of CoFe2O4-FA-COOH. The resulting suspension was stirred at 
room temperature for overnight and the particles (CoFe2O4-FA-DOX) were isolated 
magnetically. In order to study release behavior 5 ml suspension of CoFe2O4-FA-
DOX particles (0.1 mg/ml) was suspended in a solution containing 0.1 mg/ml 
protease from bovine pancreas and 5ml of PBS (0.1 mg/ml). The solution pH was 
adjusted to 3, 5 and 7.4 using 0.1 M HCl and NaOH. Subsequent to incubation for 5, 
10, 20, 25h, at 37 °C, the nanoparticles were isolated magnetically and the recovered 
DOX in the supernatant was quantified spectrophotometrically in UV 
spectrophotometer (λmax= 255 nm). 
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Fig. 3.2 Schematic representation for conjugation of doxorubicin on mesoporous 
cobalt ferrite nanoparticles. 
3.3. Characterization 
Phase purity 
The identification of crystalline phase of cobalt ferrite particles was performed 
by an Expert Pro Phillips X-ray diffractometer. The morphology and microstructure 
were analysed by Scanning electron microscope (HITACHI COM-S-4200) and High 
resolution transmission electron microscopy (JEOL 3010, Japan) operated at 300 kV. 
The particles size from TEM micrographs were analysed using image J software. 
Measurement of particle size, stability and zeta potential. 
Hydrodynamic (HD) size of particle aggregates was measured by laser light 
scattering using a particle size analyzer (Nano ZS 90, Malvern). Measurement was 
performed at 90° angle in 0.01 M phosphate buffer varying pH 5 to 9. For all 
measurements the concentrations of particles were maintained at 66.67µg/ ml. Also 
the hydrodynamic sizes of particles were measured with respect to time at pH 7.4.  
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Surface chemistry 
FTIR spectra of as prepared, MTX and DOX conjugated nanoparticles were 
obtained from a Thermo Nicolet Nexus FTIR model 870 spectrometer. Surface 
composition of MTX conjugated particles was obtained by analyzing XPS data using 
AlKα excitation source in ESCA-2000 Multilab apparatus (VG microtech).  
Cytotoxicity  
Human cervical carcinoma (HeLa), cells were obtained from the National 
Centre for Cell Sciences (Pune, India), cultivated in minimal essential medium 
supplemented with 10% fetal calf serum, 100 units/mL penicillin, and 100 μg/mL 
streptomycin, 4 mM l-glutamine under 5% CO2 and 95% humidified atmosphere at 
37 °C. From 10
5 
cells/ml cell suspension, 180 μl cell suspension was seeded at into 
each well of 96 wells tissue culture plates and incubated for 18 h followed by an 
addition of CoFe2O4 nanoparticle, CoFe2O4-MTX nanoparticle and CoFe2O4-FA-
MTX nanoparticle at concentrations from 1 μg/ml to 20 μg/ml and were incubated for 
72 h at 37°C in a humidified incubator (HERA cell) maintained with 5% CO2. The 
cell proliferation was estimated by MTT assay. 
Intracellular uptake study. 
CoFe2O4-FA-RITC-MTX nanoparticles were incubated for 0, 30, 60, 90 and 
120 min with HeLa cells at a concentration of 5mg /ml. Cells were then fixed with 
4% paraformaldehyde after the incubation period for 15 min and stained with DAPI 
(1mg/mL) for 5 min at 37 °C. Then cells were washed with PBS and examined under 
fluorescence microscopy (Olympus IX 70). 
Cell cycle analysis 
Cell cycle analysis by flow cytometry with PI staining was performed 
according to Maiti et al with minor modifications.
35 
HeLa cells were incubated for 
24h in presence of increasing concentration of CoFe2O4-FA-MTX nanoparticle (1-
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10μg/mL) at 37 °C in CO2 incubator. The cells were then harvested with 
trypsinisation and fixed with chilled 70% ethanol and stored at −20 °C. Then, the 
cells were washed with ice cold PBS (10 mM, pH 7.4) and incubated with 20 μl 
DNAase-free RNase (10 mg/mL) and 20 μl of  DNA intercalating dye PI (1 mg/mL) 
at 37 °C for 1 h in dark. The distribution of cells in the different cell-cycle phases was 
analyzed from the DNA histogram using a Becton–Dickinson FACS Calibur flow 
cytometer and analysed with Flow Jo software. 
DAPI Staining for nuclear morphology study 
To study the nuclear morphology of HeLa cells DAPI staining was performed 
according to reported procedure.
35 
HeLa cells treated PBS or with CoFe2O4-FA-MTX 
nanoparticle in vitro for 24 h. The cells were fixed with 3.7% formaldehyde for 15 
min, permeabilized with 0.1% Triton X-100 and stained with 1 μg /ml DAPI for 5 
min. The cells were then washed with PBS and examined under fluorescence 
microscopy (Olympus IX 70). 
3.4. Results and Discussion 
XRD pattern 
In the XRD pattern of CoFe2O4 (Fig. 3.3), all d values correspond to that of 
inverse spinel CoFe2O4 (03-0864). The broadening of peaks corresponds to 
nanocrystalline nature of the sample. The crystallite size was calculated using Debye-
Scherer’s equation taking broadening of each peak into account and was found to be 
5.2 nm. The lattice parameter was calculated from reflections of [400] plane as 8.36 
Å which is very close to that of inverse spinel CoFe2O4. 
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Fig. 3.3 XRD pattern of mesoporous CoFe2O4 nanoparticles. 
Morphology 
The SEM image (Fig. 3.4a) of CoFe2O4-NH2 indicates that the nanoparticles 
are spherical in nature and are almost monodisperse. Fig. 3.4(c) is the representive 
TEM micrograph of CoFe2O4 in PBS. It is very clear from the image that each 
particle is a spherical assembly of ultrafine ferrite particles. These spherical 
nanoassemblies are of size 35-40 nm and are discrete, well defined and porous in 
nature. Fig. 3.4(c) showing image at higher magnification indicates that each sphere 
is an assembly of primary nanocrystals of 4-5 nm and worm like pores of diameter 2-
3 nm. The high resolution TEM of a single aggregate (Fig. 3.4d) shows lattice planes. 
The inter planner distance d is calculated from the image as 2.97 Å which 
corresponds to reflection of [220] plane. This result is in line with the observations 
reported by Cannas et al. for the synthesis of nanoporous CoFe2O4 by surfactant 
assisted route.
38 
The individual planes identified from the SAED pattern (Fig. 3.4e) 
correlate with XRD pattern. Most important observation is that each spherical 
assembly is well separated from the other which was not observed in earlier methods 
for synthesis of mesoporous magnetic nanoparticles.
39,40 
Here it may be noteworthy 
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that dispersion state of magnetic nanoparticles is the most important factor as far as 
the magnetic property is concentrated. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4 (a) SEM image, (b, c) TEM images, (d) HRTEM (e) SAED pattern of CoFe2O4 
nanoparticles. 
Magnetic measurements 
Field dependent magnetization at room temperature (300K) was measured and 
it was found that the magnetization raised rapidly as the applied field increases upto 
1T and reached at a saturation point 2T, shows no hysteresis representing 
superparamagnetic nature of the nanoparticles (Fig. 3.5). The saturation 
magnetization of cobalt ferrite was found to be 59.4 e.m.u./g corresponding to its bulk 
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counterpart 71.2 e.m.u/g. This decrease in magnetization (Ms) value corresponds to 
decrease in particle size
41 
due to surface protection by ethanol amine. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5 Field dependent magnetization curve of mesoporous CoFe2O4nanoparticles. 
 
Hydrodynamic and zeta potential measurement 
 
An investigation on hydrodynamic size of fluorescent magnetic carrier CoFe2O4-FA-
RITC and drug conjugates CoFe2O4-FA-RITC-MTX and CoFe2O4-FA-DOX was 
carried out through dynamic light scattering (Fig. 3.6) in PBS. Product CoFe2O4-FA-
RITC-MTX shows presence of stable non aggregated particles with hydrodynamic 
size 61 nm, PDI< 0.2 and surface charge -27.3 mV. The stability of MTX-conjugated 
particles investigated by measuring hydrodynamic size against time shows that there 
is almost no change of hydrodynamic size and zetapotential even after several 
months. This observation implies that such stable drug conjugates can be circulated in 
blood stream for a long period minimizing the rapid clearance of particles by 
macrophages.  
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Fig. 3.6 .(a) Change in HD size with drug conjugation, Variation of HD size of CoFe2O4-FA-
MTX conjugate nanoparticles (b) with pH, (c) with time. (d) Change in zeta potential with pH. 
 
Again the Fig. 3.7 shows the surface charge of as synthesized cobalt ferrite 
nanoparticles and after modification with succinic anhydride. After modification with 
succinic anhydride the surface charge becomes -35.2 mV at pH 11 due to 
incorporation of –COOH groups. Similarly the CoFe2O4-FA-DOX also shows stable 
particles with hydrodynamic size 72 nm and also these particles are highly stable in 
aqueous medium, since there is almost all no significant change of hydrodynamic size 
upto three months (Fig. 3.8). 
 
 
 
 
 
 
 
 
Fig. 3.7 Change in zeta potential with respect to pH (a) as synthesized CoFe2O4 
nanoparticles (b) after treated with succinic anhydride. 
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Fig. 3.8 Change in HD size of DOX loaded particles with time. 
FTIR spectra 
The FTIR spectrum of the MTX conjugated particles (CoFe2O4-FA-MTX) 
shows strong absorption at 500-600 cm
-1 
characteristic vibration of M-O in the ferrite 
lattice (Fig. 3.9). In addition to this, the intensification of methylene signature at 2935 
and 2854 cm
-1 
along with C=O stretching at 1630 and 1546 cm
-1
 indicates that MTX 
has been conjugated to –NH2 terminated particles through –NHCO linkage. Similarly 
the successful attachment of DOX was also established using FTIR. 
  
 
 
 
 
 
Fig. 3.9 FTIR spectra of (A)CoFe2O4-NH2, CoFe2O4-NH2-MTX and MTX and (B) CoFe2O4- NH2, 
succinylated CoFe2O4- NH2, succinylated CoFe2O4- NH2-DOX and DOX. 
(A) (B) 
Wavenumber (cm-1) Wavenumber (cm-1) 
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XPS analysis 
X-ray photoelectron spectra were further used to validate the successful 
conjugation of MTX on amine functionalized mesoporous magnetic nanoparticles. 
Fig. 3.10 shows high resolution XPS scan of MTX conjugated amine functionalized 
CoFe2O4 nanoparticles. The C1s peak corresponding to reference shows a shift 2eV 
to higher binding energy and hence taking reference shift to consideration all other 
binding energies are to be evaluated. 
In high resolution scan C1s region shows four peaks centred at 286.9, 288.3, 
289.6 and 291.99 eV corresponding to C-C, C-O, -NHCO- and COOH carbons. The  
O1s peak can be deconvoluted into 3 peaks centred at 532.09, 533.7 and 535.25 eV 
corresponding oxygen atoms present in M-O, C-O, COOH and -NHCO respectively. 
In as prepared CoFe2O4 nanoparticles, the N1s binding energy appeared at 398.7 eV 
which is close to N present in primary amine (Fig. 3.10), whereas in 
 
 
 
 
 
 
 
 
 
Fig. 3.10 XPS spectrum of product CoFe2O4-FA-MTX conjugate nanoparticles. High resolution 
scan of C1s, O1s, N1s and Co2p. 
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CoFe2O4-FA-MTX conjugated particles the N1s binding energy shows two additions 
peaks present at 401.91 and 403.51 eV corresponding to the –NHCO and NH3
+ 
groups.
42 
Also intensity of N1s peak was significantly increased after conjugation 
with MTX. Co2p3/2 and Co2p1/2 electrons show binding energy at 779 and 784 eV 
associated with corresponding shake ups at 785 and 801 eV.
43 
Fe2p region shows two 
peaks at 711.5 and 725 eV which is consistent with Fe2p binding energy for CoFe2O4 
nanoparticles. 
Nitrogen adsorption-desorption study 
Nitrogen sorption experiment was conducted to further investigate the porous 
nature of ferrite nanoparticles. Fig. 3.11 represents the nitrogen adsorption-desorption 
isotherms and BJH pore size distribution curves (inset) of CoFe2O4. The isotherms 
are identified as type IV, which is characteristic of mesopores. It is notable that 
besides mesopores formed by aggregations spherical particles, the BJH pore size 
distribution clearly indicates mesopores centred at 4-5 nm formed among the ultrafine 
nanoparticles within the aggregate which is in accordance with the TEM result.  
 
 
 
 
 
 
 
Fig. 3.11 Nitrogen adsorption-desorption isotherm and the corresponding pore size 
distribution of as synthesized CoFe2O4nanoparticles. 
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The BET surface area of the CoFe2O4 powder was calculated to be 210 m
2
/g. 
To our knowledge, surface area values for porous magnetic oxide synthesized by 
various other synthetic methods
39,40  
have not exceeded 150 m
2
/g. Hence in the 
present solvochemical route the surface of magnetic oxides can be significantly 
increased and it would be particularly beneficial in magnetic separation and drug 
delivery. 
Formation mechanism and compositions of magnetic nanocarriers 
Formation of magnetic particles can be explained according to well-known 
polyol method of synthesis.
44 
The formation of such nanoassemblies may be 
dependent on the collective behavior of nanoparticles and intermolecular forces 
existing between them.
40 
The number of –NH2, FA, MTX, RITC and DOX present on 
each spherical assembly was determined using UV-visible spectroscopy following the 
procedures reported elsewhere,
45,46 
and it was found that each porous particle of 40 
nm size contains approximately 490 –NH2 groups and particle CoFe2O4-FA-RITC-
MTX contains 280 MTX molecules. 
pH dependent drug-release  
In vitro drug release experiments were carried out with MTX and DOX 
conjugated nanoparticles in two separate batches. To simulate lysosomal condition, 
the nanoparticles were incubated with bovine protease in pH (3, 5, 7.4). It was well 
established that protease found in the lysosomal compartment is capable of 
hydrolyzing amide bond releasing drug molecule to the cytoplasm. Both MTX and 
DOX showed typical release profiles. MTX showed rapid release rates from the 
beginning followed by a sustained release pattern (Fig. 3.12). This release behavior is 
consistent with previously reported literature.
33,34,50 
 But in case of DOX slow release 
rates were observed from the beginning. The overall release rates were higher in 
lower pH (3, 5) and very less release was observed in physiological pH. This is 
because the drugs have been covalently grafted through an amide bonds.  
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Fig. 3.12 pH dependent drug-release behaviours of (a) CoFe2O4-FA- MTX and (b) CoFe2O4-FA- 
DOX. The highest absorbance was observed at pH 3 in both cases, where almost no release 
was observed at physiological pH. 
The cleavage of amide bond is controlled by pH and the concentration of 
active protease. This pH sensitive release behavior is attributed to the sensitivity of 
amide bond cleavage to pH and effect of pH on activity of protease.
50
 
This observation suggests that the functionalized magnetic carriers containing 
substantial amount of antitumor drugs will release more drugs in acidic tumor sites 
rather than normal tissues. Furthermore, when these particles will be internalized 
through folate receptor-mediated endocytosis the release behavior will be further 
accelerated in acidic lysosome of cancer cells. 
Calculation of drug loading capacity 
The drug loading capacity was calculated as per the following method. First, 
NH2/-COOH functionalized particles were conjugated with MTX/DOX as described 
in the experimental section and then separated from the aqueous suspension medium 
using magnetic separator (Invitrogen). The obtained drug-loaded CoFe2O4 
nanoparticles were incubated at 60 °C invacuum overnight and were weighted. Drug 
concentration in supernatant was analyzed by the ultraviolet absorption (λMTX = 270 
nm, λDOX = 255 nm), with reference to a calibration curve on a UV-Vis-NIR 
spectrophotometer. The measurements were performed in triplicate. Drug-loading 
content and encapsulation efficiency were obtained by eqs 1 and 2, respectively. 
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Doxorubicin 
Drug loading content (%) = 
Weight  of the drug in nanoparticles
Weight of the nanoparticles
× 100  
                                                              =   
0.00944
0.0697
 × 100 
                                                              = 13.54% --------------- (1) 
Encapsulation efficiency (%) =   
Weight  of the drug in nanoparticles
Weight of the feeding drug
×100 
                                                                 =   
0.00944
 0.0118
 × 100 
                                                                 = 80% ---------------------- (2) 
Methotrexate 
Similarly in case of methotrexate drug loading content (%) = 13.8 % 
Encapsulation efficiency = 80 % 
Cytotoxicity  
HeLa cells are reported to express folate receptor and are studied as model in vitro 
systems for folate mediated targeting.
47
 Here we investigated the effect of CoFe2O4 
nanoparticles, CoFe2O4-MTX nanoparticles (Particle without FA) and CoFe2O4-
MTX-FA nanoparticle on the proliferation of HeLa cells in vitro.  
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Fig. 3.13 Cytotoxicity assay of nanoparticles on (a) Hela and (b) NIH/3T3 cells. Cells were 
treated with different concentration of nanoparticles for 72 h and cell viability measured by 
MTT assay.  
It was observed that CoFe2O4 nanoparticle did not induce any significant 
change in the proliferation in both HeLa and 3T3 cells with concentration up to 20 
ug/mL with respect to the control (Fig. 3.13), suggesting an absence of toxicity of the 
CoFe2O4 nanoparticle. Subsequently the proliferation of HeLa cells reduced 
significantly in presence of CoFe2O4-MTX nanoparticles and at a dose of 10 μg/ml, 
the cell proliferation was uninhibited by 50% (IC50 value). This is possibly 
attributable to the affinity of MTX towards folate receptor owing to its structural 
similarity with folic acid, which results in higher intake of CoFe2O4-MTX particles as 
compared to CoFe2O4 nanoparticle. Whereas in case of 3T3 cells, there was only 20% 
reduction in cell proliferation which may be due to less availability of folate receptors 
on cell surface. However, the proliferation of HeLa cells reduced drastically in a dose 
dependent manner in presence of 5 ug/ml CoFe2O4-MTX-FA nanoparticles and its 
IC50 was 5 ug/mL. In contrast, there was no such change between CoFe2O4-MTX and 
CoFe2O4-MTX-FA was observed in 3T3 cells. This observation is attributed to the 
active uptake of nanoparticles in a folate receptor mediated endocytosis that 
interfered with the cell proliferation, which ultimately results in the target specific 
delivery of MTX to HeLa cells (Fig. 3.13). 
Uptake study 
We further investigated whether the resulting reduction of proliferation is due 
to the uptake of CoFe2O4-MTX-FA nanoparticles. In previous study we observed the 
folate receptor mediated uptake of iron oxide nanoparticles to HeLa cells.
25
Hence we 
performed fluorescence microscopy with CoFe2O4-FA-RITC-MTX nanoparticles to 
study its uptake by HeLa cells in a time dependent manner and DAPI was used as a 
nuclear contrast dye to appreciate the localization. HeLa cells were incubated with 
5μg/ml of CoFe2O4-FA-RITC-MTX nanoparticles for 0, 30, 60, 90 and 120 min. The 
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uptake of CoFe2O4-FA-RITC-MTX nanoparticles was evident by 30 min and the 
internalization increased with time (Fig. 3.14). The RITC signal from the CoFe2O4-
FA-RITC-MTX nanoparticle progressively increased in the cytoplasm surrounding 
the nuclear region. It suggests that nanoparticles are selectively targeted to the cells 
through the folate receptor mediated endocytosis and localized into the cytoplasm. 
Here the uniform distribution of the CoFe2O4-FA-RITC-MTX nanoparticles in the 
HeLa cells is because of their stable dispersion in the culture media. To confirm the 
receptor specificity of the CoFe2O4-FA-RITC-MTX nanoparticles the uptake as well 
as cell viability data of HeLa cells were also compared with folate receptor-negative 
NIH/3T3 cells.  
In the case of HeLa cells nanoparticles uptake as well anti-proliferation effect 
was much greater in comparison to NIH/3T3 cells. Here the uniform distribution of 
CoFe2O4-FA-RITC-MTX nanoparticle in the HeLa cells is because of its stable 
dispersion in the culture media. 
 
 
 
  
 
 
 
 
Fig. 3.14 Uptake study of nanoparticle in HeLa cells and using ﬂorescence microscopy. Cells 
were incubated with CoFe2O4-FA-RITC-MTX nanoparticles for different time intervals and 
observed under ﬂorescence microscope (200X) 
50 µm 
50 µm 50 µm 50 µm 
50 µm 
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Flowcytometric analysis 
A quantitative evaluation of CoFe2O4-MTX-FA nanoparticle-mediated cell 
death was carried out through cell cycle analysis using the standard propidium iodide 
(PI) staining flow cytometry. Fig. 3.15 shows decrease in cells in the G0/G1 phase 
with increase in cell concomitants in the S phase indicating an arrest of the cell cycle 
in the S phase. The S phase distribution of cells increased up to 56% at 5μg/ml as 
compared 17% in the control cells whereas the G0/G1 phase decreased from 62% in 
control to 30% in the 5μg/ml treated cells. This result comes in hand with the known 
property of MTX to arrest cell cycle in the early S phase.
48 
Additionally, MTX is also 
known to induce apoptosis in cancer cells.
49
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.15 Flowcytometric analysis of cell cycle phase distribution in HeLa cells. HeLa cells 
treated with (A) PBS, (B) 1 µg ml-1, (C) 5 µg ml-1, and (D) 10 µg ml-1 of CoFe2O4-FA- MTX 
nanoparticles for 24 h and the percentage of DNA content was determined by FACS calibour 
(BD) using Flow Jo software after the cells were labeled with PI preceding RNAase 
treatment. 
 
Therefore we intended to study whether the targeted delivery of MTX in a 
folate receptor mediated method could result in the similar cell fate. Hence we 
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investigated the nuclear fragmentation which is a hallmark of apoptosis with the cells 
treated with MTX loaded particles. With increasing dose of the CoFe2O4-MTX-FA 
nanoparticles an increase in the formation of fragmented nuclei containing condensed 
nuclear material was observed in fluorescence microscopy after nuclear staining with 
DAPI. 
 
 
 
 
 
 
 
Fig. 3.16 DAPI Fluorescence (200X) images of HeLa cells incubated with(A) PBS, (B) 1, (C) 5, 
and (D) 10 µg ml-1 of CoFe2O4-FA-MTX for 24 h.The arrows represent nuclei with hallmark 
apoptotic features such as nuclear condensation, fragmentation, and formation of apoptotic 
bodies. 
3.5. Conclusion 
This work demonstrates a simple method to produce bio-functionalized, highly water-
soluble, monodisperse, mesoporous, CoFe2O4 nanoassemblies with diameter 35-40 
nm. The synthesis method is cost-effective, easy to scale up and reproducible. The 
presence of high density of surface amine groups and large surface area of the 
particles facilitate incorporation of substantial amount of anticancer drugs within its 
porous network. The nanoparticle modified with folic acid was effectively targeted to 
cancer cells thereby causing the optimal delivery of methotrexate and resulted in the 
cell death following the induction of apoptosis. In a nutshell, a nanotheranostic 
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reagent has been developed which combines superparamagnetic, receptor-targeting 
capacity, optical imaging and pH sensitive drug release behavior into one system.  
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4.1. Introduction 
Research in nanotechnology has advanced to such an extent that it is possible 
to develop nanoparticles with specific functional properties that address the 
shortcomings of traditional disease diagnosis and therapy.
1–3
 The imaging and 
delivery facilities have been significantly combined into unique NP construction 
through smart combinations of nanoscale materials, enabling simultaneous in vivo 
diagnostic imaging and drug delivery for real-time treatment tracking.
4,5
 The 
successful development of the targeted drug delivery vesicles depend on a number of 
factors, such as biocompatibility of the material, suitable surface conjugation 
chemistry, favorable pharmacokinetic properties, possible cell uptake and ease of 
clinical translation.
6
 With respect to this, calcium phosphate is considered as an 
excellent biocompatible inorganic material and its nanostructure can be hybridized 
with natural or synthetic polymers to form nanocomposites. Calcium phosphate has 
excellent biocompatibility due to its chemical similarity to human hard tissue (bone 
and teeth). In nanoparticulate dispersed form, it can be used as a carrier in biological 
systems, e.g. to transfer nucleic acids or drugs. Another important properties of  
calcium phosphate is that it can be easily functionalized with biomolecules and  
fluorescing dyes which is essential for imaging and photodynamic therapy.
7,8
 In 
recent years, calcium phosphate/hydrophilic block copolymer based drug delivery 
systems have attracted considerable attention because they not only possess the 
properties of inorganic, organic ingredients but also the porous structure facilitates the 
incorporation of a high dosage of drug, which significantly enhances bio-
performance.
9
  
Magnetic ferrite nanoparticles have been recently exploited as a suitable 
alternative to superparamagnetic iron oxide nanoparticles (SPION) in biomedical 
applications including magnetic resonance imaging for clinical diagnosis, magnetic 
drug targeting and hyperthermia anticancer strategy.
10–12
 Especially, spinel cobalt 
ferrite has been proposed for biomedical applications since it is known to have a large 
 Chapter 4                                                                                Ca3(PO4)2 NPs for delivery of cisplatin   
93 
 
anisotropy compared to other oxide ferrites, which could introduce several benefits in 
therapeutic applications for cancer therapy. The biocompatibility of cobalt ferrite 
nanoparticles has recently been demonstrated with therapeutic application in our 
previous chapter.
15
 However, attempts to design a stealth magnetic calcium phosphate 
based nanosystem for multifunctional applications has rarely been reported.  
On the other hand, platinum complexes such as cisplatin, carboplatin and 
oxaliplatin are widely used drugs in the treatment of solid tumors such as testicular, 
ovarian, breast, bladder, lung, head and neck carcinomas.
14
 These drugs contain Pt–
N/Pt–Cl, Pt–N/Pt–O coordination bonds with two Pt–N bonds in the cis- position. 
The Pt–Cl and Pt–O bonds in these complexes are chemically much weaker than the 
Pt–N bonds and are subject to facile hydrolysis under low Cl- and/or low pH 
conditions giving charged [Pt(NH3)2(H2O)2]
2+
 complexes. These are highly reactive 
for DNA binding, through the N7 atom, of either an adenine or guanine base. This 
binding interrupts the double helix structure and interrupts the cell’s transcription as 
well as repair mechanism.
15
 In spite of such a critical role, platin drugs do not have 
pervasive applications because of their systemic toxicity owing to their random 
distribution in the body. Selective inorganic nanoparticles based formulations have 
been developed for the target specific delivery of platinum drugs.
16–19
 Although these 
nanoparticulate systems can serve as potential carriers for platinum drugs, their large 
dimension and the costly chemicals involved in the synthesis process may make them 
inappropriate for practical implementation. Therefore, the specific targeting of 
platinum drugs, by integrating a targeting functionality to the drug or delivery 
systems, is a current challenge in this area of research.  
In the present work, we have fabricated porous amorphous calcium 
phosphate/CoFe2O4 integrated composite nanoparticles with high surface area. The 
surface of the particles was modified with N-phosphonomethyl iminodiacetic acid 
(PMIDA) in order to produce an iminodiacetic acid group on the surface. The 
platinum  
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pharmacophore cis-monochlorodiammineplatinum(II) (CMDP), folic acid (FA) and 
rhodamine B isothiocyanate (RITC) were loaded on to the amorphous calcium 
phosphate particles (ACP) through iminodiacetate groups forming a magnetic 
nanoparticles conjugate CoFe2O4/ACP-FA-CMDP-RITC. The intracellular uptake 
efficiency of the drug conjugated nanoparticles in HeLa cells was thoroughly 
investigated through fluorescence microscopy and flow cytometry (FACS). The pH 
sensitive drug release behavior has also been studied. 
4.2. Experimental 
Materials 
Calcium nitrate, ferric nitrate and cobalt nitrate were obtained from Merck, 
Germany. Silver nitrate and diammonium hydrogen phosphate were procured from 
Rankem, RFCL limited, India. Poly(ethylene glycol)-block-poly(propylene glycol)-
block-poly-(ethylene glycol), cisplatin, rhodamin B isothiocyanate (RITC), 2,2′-
(ethylene dioxy)-bis-(ethyl amine) (EDBE), Folic acid (FA), di-tert-butyl-dicarbonate 
anhydrate (BoC2O) and N-(phosphonomethyl) imino-diacetic acid were purchased 
from Sigma Aldrich. Dicyclohexylcarbodimide (DCC), N-hydroxysuccinamide 
(NHS) and 1-[3(dimethylamino) propyl]-3-ethyl carbodimide hydrochloride (EDC) 
were obtained from Spectrochem, India. Millipore water was used throughout the 
experiment. 
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Preparation of water dispersible CoFe2O4 nanoparticles  
Cobalt ferrite nanoparticles were synthesized via an improved co-precipitation 
method. A stoichiometric amount of ferric nitrate (2 mmol, 0.808 g) and cobalt nitrate 
(1 mmol, 0.291 g) were taken in 100 ml of water and 5 ml of ethylene glycol in a 250 
ml beaker. The pH was maintained at 10–12 by dropwise adding 1 M NaOH. A 
brown color precipitate appeared, and the mixture was heated at 80 °C for 2 h. 
Finally, black colloidal CoFe2O4 particles were obtained in the solution. The particles 
were recovered using a magnetic separator (DynaMag-2, Invitrogen), washed with 
millipore water (5 × 5 ml) and dried in a hot air oven at 80 °C for 2 h. 
Synthesis of CoFe2O4/ACP/P123 composite nanoparticles 
Synthesis of CoFe2O4/ACP/P123 composite nanoparticles is presented in Fig. 
4.1. As prepared cobalt ferrite nanoparticles were dispersed in 40 ml of water 
followed by the addition of 5 ml of 0.5 M CaCl2. Then the total mixture was added to 
the aqueous solution of block copolymer pluronic i.e.Poly(ethylene glycol)-
Poly(propelene glycol)-Poly(ethylene glycol)/ (P-123) for 1 h at room temperature. 5 
ml of 0.5 M diammonium hydrogen phosphate was added to the above solution at pH 
10.  
 
 
 
 
 
 
 
Fig. 4.1 Schematic representation for synthesis of porous CoFe2O4@ACP composites. 
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The particles were separated using a magnetic separator (DynaMag-2, 
Invitrogen). 
Preparation of CoFe2O4-ACP-CDDP-FA 
30 mg of CDDP was taken in 10 ml of water and 33 mg of AgNO3 was added 
to it. The solution was stirred at room temperature for 48 h in the dark. The white 
precipitate of AgCl was removed by centrifugation and didechlorinated CDDP 
[cisdiaquadiamino platinum(II)] was obtained in supernatant. To get –COOH 
functionalized particles, 0.1 g of CoFe2O4@ACP particles were sonicated in 30 ml of 
water for 20 min. PMIDA (0.073 g) was added to the above solution and it was 
sonicated for another 5 min. Then, it was stirred for another 30 min at room 
temperature and finally particles were magnetically separated. The particles were 
washed thoroughly with water and methanol to free them from unreacted PMIDA. 
The acid functionalized CoFe2O4@ACP (120 mg) was dispersed with 
[cisdiaquadiamino platinum(II)] and sonicated to give a suspension. This was stirred 
for another 48 h at 45 °C in the dark and the pH was adjusted to slightly basic (9–10) 
with 0.1 M NaOH. After the completion of this reaction, particles were washed with 
PBS and recovered by using a magnetic separator.  
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Fig. 4.2 Schematic representation for conjugation of cisplatin, folic acid and RITC onto 
porous –COOH functionalized CoFe2O4@ACP. 
Folic acid and RITC functionalized with –NH2 groups (FA–NH2 and RITC– NH2) 
were conjugated in stoichiometric amounts through the remaining –COOH groups on 
the surface, following our previously reported protocol.
20
 So, the CoFe2O4-ACP-
CDDP-FA was prepared using the following scheme (Fig. 4.2). 
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4.3. Characterization 
The synthesized materials were well characterized by using standard 
techniques as described in chapter-3. Again the cytotoxicity and intracellular uptake 
experiments were performed following the protocol already described in chapter 3.  
4.4. Results and discussion 
It has been well demonstrated that magnetic nanoparticles with suitable 
surface coating show enhanced performance in biomedical applications rather than 
bare magnetic nanoparticles.
22
 One important approach to modify its surface by 
coating inert inorganic materials like silica and Au.
23-25
 We deemed to synthesize 
amorphous calcium phosphate due to extensive application of Ca3(PO4)2 in biology 
and medicine. We prepared Ca3(PO4)2 coated CoFe2O4 nanoparticles by seed-
mediated deposition.
26,27  
It is well established by Matsuda et. al. that the negative 
groups on the substrate could promote the growth of apatite much more strongly than 
positive groups.
28
 The ethylene glycol coated CoFe2O4 particles (Scheme 4.1) act as a 
suitable substrate for the growth of amorphous calcium phosphate nanoparticles at 
alkaline pH. Magnetic nature of these particles makes their separation possible by 
using external magnet. Pluronic (P123) was used to prepare a highly porous 
CoFe2O4/ACP composite. We have prepared acid functionalized surface by reacting 
phosphonomethyl iminodiacetic acid (PMEDA). Based on the ability of phosphonic 
acid to exchange with the phosphate ions,
29,30
 on HAp crystals, PMEDA has been 
chosen as a robust anchor to functionalize the porous magnetic substrate with –
COOH groups (Fig. 4.2) to link up platinum moiety. In order to load cisplatin, first 
the platinum pharmacophore cis-diaminediaqua platinum(II) dinitrate was prepared 
by reacting 2 equivalents of AgNO3 with cisplatin and subsequently loaded on porous 
magnetic support through –COOH groups by ligand exchange reaction. 
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XRD  
Fig. 4.3a and 4.3b shows XRD patterns of CoFe2O4 and CoFe2O4@ACP, 
respectively. In the case of Fig. 4.3a, six diffraction peaks at 2θ = 30.2°, 35.4°, 43.1°, 
57.0° and 62.6° assigned to inverse spinel CoFe2O4 (JCPDS no 22-1086). Fig. 4.3b 
did not show any characteristic peaks indicating amorphous calcium phosphate (ACP) 
phase. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3 XRD patterns of (a) CoFe2O4, (b) CoFe2O4@ACP, and (c)CoFe2O4@ACP after heating 
at 600 °C. * indicate peaks due to hydroxyapatite. 
When the sample was further heated at 600 °C, peaks at 2θ = 13.7, 16.9, 20.9, 
25.8, 27.9, 32.8, 39.9, 46.7, 49.4, 53.4, 60.11 and 74.23 corresponding to hexagonal 
hydroxyapatite (JCPDS 84-1998) [Ca5(PO4)3OH] became more prominent. The XRD 
pattern indicates the successful deposition of amorphous calcium phosphate (ACP) on 
crystalline CoFe2O4 nanoparticles. 
SEM-EDX 
The SEM image (Fig. 4.4) shows spherical clusters of CoFe2O4@ACP core-
shell nanoparticles with a size of 50 nm and which is in well aggregate with TEM 
image. Due to spherical structure of nanoparticles it shows high surface area. SEM-
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EDX data shows the presence of Co, Fe, Ca and Pt with an atomic ratio of 2.44: 4.79: 
6.83: 5.4.  
 
 
 
 
 
 
 
Fig. 4.4 (a) SEM image of CoFe2O4@ACP-CDDP-FA-RITC nanoparticles and (b) EDX spectrum 
of CoFe2O4@ACP-CDDP-FA-RITC nanoparticles. 
Hydrodynamic size and zeta potential measurement 
The measurement of the hydrodynamic size of CoFe2O4@ACP after each step 
of conjugation in phosphate buffer saline (PBS) by dynamic light scattering shows 
stable nanoaggregate particles with PDI < 0.3. The mean HD size of as synthesized 
CoFe2O4@ACP particles was found to be 42 nm (Fig. 4.5). However, the mean HD 
size was further increased to 62 nm after conjugation with folic acid and the platinum 
complex. The HD size, PDI and intensity of each particle remained unaffected over a 
long period indicating the colloidal stability of synthesized particles in PBS. The 
surface charge of drug conjugated particles (CoFe2O4@ACP-CDDP-FA) measured 
with different pH and it was found that zeta potential increases in negative direction 
with increase in pH and the surface charge remain unaltered after a long time, which 
it indicates the conjugated particles are highly stable in physiological environment.  
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Fig. 4.5 (A) Change in hydrodynamic size of CoFe2O4@ACP-CDDP-FA with respect to time, (B) 
Variation of hydrodynamic size after each step of modification, (C) Zeta potential variation 
of CoFe2O4@ACP-CDDP-FA with  respect to respect to pH. 
TEM 
The microstructures of particles at various stages of synthesis were examined 
by transmission electron microscopy. Fig. 4.6a represents the micrograph of CoFe2O4 
nanoparticles precipitated in the presence of ethylene glycol. In spite of magnetic 
interaction the particles show good dispersion due to surface protection by ethylene 
glycol. Particles show narrow distribution between 8–12 nm with a mean diameter of 
10 ± 0.5 nm. From the high resolution TEM the interplanar distance d is calculated as 
4.8 Å, which corresponds to the reﬂection of the [111] plane. The individual planes 
identiﬁed from the SAED pattern correlate with the XRD pattern. Fig. 4.6b shows 
micrographs of CoFe2O4@ACP–P123 composite nanoparticles. It appears that the 
CoFe2O4@ACP–P123 composites have irregular shape and porous morphology.  
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Fig. 4.6 (a) TEM image and SAED pattern (inset) of ethylene glycol coated CoFe2O4, (b) 
polymer coated CoFe2O4@ACP, and (c) CoFe2O4@ACP after washing. (d) CoFe2O4@ACP at 
high resolution showing core-shell structures. 
However, after removal of the copolymer (Fig. 4.6c) porous spherical 
structures of CoFe2O4@ACP were observed, which is in line with the SEM image. 
The image at high magniﬁcation (Fig. 4.6d) shows that each porous sphere consists of 
CoFe2O4@ACP core-shell nanoparticles with a spherical cobalt ferrite core and a 
uniform calcium phosphate shell.  
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 Formation mechanism of CoFe2O4 @ ACP nanocomposites 
The formation mechanism for the core-shell nanoparticles can be proposed 
according to Fig. 4.2. Ethylene glycol strongly adsorbs on the surface of ferrite 
nanoparticles and forms a negatively charged attracts positively charged Ca
2+
 ions by 
coulombic force of attraction and latter attracts PO4
3- 
which triggers the nucleation of 
calcium phosphate on the surface of cobalt ferrite. With time these ﬁne core shell 
particles agglomerate to form clusters, possibly due to the surface energy being 
minimized. However, the block copolymers impart porous nature to the cluster. The 
micelle of the P123 can act as a soft template for the formation of a porous hybrid 
nanocomposite. 
FTIR 
The FTIR spectrum of as prepared CoFe2O4 (Fig. 4.7) shows strong 
absorption at 597 cm
-1 
corresponding to the M–O stretching vibration. Additionally, 
the faint impression of the methylene signature is also visible at 2906 and 2850 cm 
which indicates chemical adsorption of ethylene glycol on the CoFe2O4 surface. In 
the case of CoFe2O4@ACP nanoparticles prepared in the presence of block polymer 
P123, peaks at 1104, 1038, 600 and 558 cm
-1
 represent characteristic stretching and 
bending modes of PO4
3-
. It indicates the deposition of amorphous calcium phosphate 
on the surface of CoFe2O4 nanoparticles. More intensiﬁcation of the methylene 
signature may be attributed to the presence of the block copolymer on CoFe2O4 
@ACP core-shell nanoparticles even after leaching. It is probably due to inter particle 
hydrogen bonding after surface modiﬁcation with PMIDA. In CoFe2O4@ACP-
PMIDA–CDDP particles there is a slight shifting of carboxylate stretching towards 
lower frequency indicating the coordination of carboxylates to Pt. CoFe2O4@ACP–
PMIDA–CDDP–FA shows bands in the range of 1642 to 1466 cm-1. The appearance 
of two prominent characteristic bands at 1603 (amide I) and 1510 (amide II) cm
-1
 
indicate that folic acid has been conjugated to CoFe2O4@ACP–PMIDA nanoparticles 
through amide linkages according to Fig. 4.7c. X-Ray photoelectron spectra and 
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SEM-EDX were further used to validate the successful complexation of platinum on 
the synthesized magnetic calcium phosphate matrix. 
 
                    
 
 
 
 
 
 
 
 
 
Fig. 4.7 FTIR at various stages of synthesis: (a) CoFe2O4, (b) CoFe2O4@ACP, (c) 
CoFe2O4@ACP-PMIDA, (d) CoFe2O4@ACP-PMIDA-CDDP and (e) CoFe2O4@ACP-PMIDA-CDDP-
FA nanoparticles.  
XPS 
 In the XPS spectra of CDDP loaded particles (Fig. 4.8) the C1s peak 
corresponding to the reference shows a shift of 3 eV towards the higher side and 
hence, taking the reference shift into consideration, all other binding energies are 
calculated. The Gaussian ﬁt to the high resolution scan of C1s shows four peaks 
centred at 288.36, 289.9, 291.3 and 293.8 eV corresponding to C–C/C–H, C–N/C–O, 
NHCO and -COOH, respectively. The O1s peak is observed at 534 eV and the three 
peaks a534.1, 534.7, 536.3 eV can be ﬁtted to double bonded oxygen (C=O and/or 
P=O), single bonded oxygen (C–O–P and/or P–O–P)31 and chemisorbed oxygen 
and/or water. The N1s binding energy appears at 402.5, 402.9, 403.6, which may be 
attributed to NH3 in cisplatin,
32
 NHCO and/or C=N (N bonded to two sp
2
 carbons) 
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and tertiary nitrogen (nitrogen bonded to three sp
3
 carbons), respectively. The 
unidentiﬁed peak at higher binding energy with low intensity may be due to presence 
of traces of protonated amines. The P2p peak in the range of 130.9 to 139.5 
corresponds to pentavalent tetra coordinated phosphorus
31
 associated with low 
intensity shake ups. The high resolution scan of the Pt4f region shows two peaks 
centred at 76.72 and 79.72 eV for Pt4f7/2 and Pt4f5/2, respectively. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 (a) XPS survey spectrum of CoFe2O4@ACP-CDDP-FA. High resolution scans of (b) C1s, 
(c) O1s, (d) N1s, (e) Ca2p, (f) Pt4f 
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Nitrogen adsorption–desorption study 
The porous nature of the nanocomposite was further investigated using 
nitrogen adsorption and desorption experiment (Fig. 4.9). The BET surface area of 
CoFe2O4@ACP nanosphere was found to be 296 m
2
g
-1
. The corresponding BJH pore 
size distribution was signiﬁcantly narrow and centered at 7 nm. The large surface area 
with a narrow pore size of 7 nm is favourable for higher adsorption, which would be 
particularly beneﬁcial in drug delivery applications. 
           
 
 
 
 
Fig. 4.9 Nitrogen adsorption-desorption isotherm and the corresponding pore size 
distribution (inset) of as synthesized CoFe2O4 nanoparticles. 
Room temperature magnetic moment study 
The magnetic properties of the products, CoFe2O4 and CoFe2O4@ACP–
PMIDA–CDDP–FA particles, were examined by vibration sample magnetometry. 
Fig. 4.10 shows the magnetic hysteresis opening with saturation magnetization of 46 
e.m.u. g
-1
 and 25 e.m.u. g
-1
, respectively. The Ms value of  CoFe2O4@ACP–PMIDA–
CDDP–FA decreased evidently after coating with ACP, because the diamagnetic 
contribution of the thick ACP shell resulted in a low mass fraction of magnetic 
CoFe2O4. The Ms value of the synthesized CoFe2O4 is less than that of bulk CoFe2O4 
(71.2 e.m.u. g
-1
). This decrease in saturation magnetization is due to surface spin 
canting, owing to small particle sizes.
33
 Unlike the superparamagnetic CoFe2O4 
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nanoparticles synthesized by thermal decomposition method, as reported in our 
previous work, here both the samples show coercivity (Hc) and remanent 
magnetization (Mr). The Hc values for CoFe2O4 and CoFe2O4@ACP–PMIDA–
CDDP–FA were found to be 0.64 kOe and 0.9 kOe. The coercivity may be attributed 
to magnetic anisotropy, strain, and disorder of the surface spins of CoFe2O4 
nanoparticles, as reported by Limaye et al. for the case of oleic acid coated CoFe2O4 
nanoparticles.
34
 The higher Hc in the case of CoFe2O4@ACP may be due to the 
higher amorphicity and smaller magnetic core of ACP coated cobalt ferrite 
nanoparticles. 
 
 
 
         
 
 
 
 
Fig. 4.10 Field-dependent magnetization of as prepared CoFe2O4 and CoFe2O4@ACP 
nanoparticles. 
pH dependant drug release 
The drug release proﬁles are plotted as cumulative release against time (Fig. 
4.11). It is observed that in all pH conditions the CDDP showed a rapid release 
pattern from the beginning followed by a sustained release pattern. Additionally, at 
pH 4.3, ~45% of the drug was released from CoFe2O4@ACP–PMIDA–CDDP–FA 
particles after 10 h, while at pH 5.4 the amount of platin released was reduced to 
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28%. At pH 7.4 the release was further reduced to 10%. Undoubtedly, the lower pH 
condition accelerates the release of platin drug from the drug conjugated 
nanoparticles. In lysosome, the pH is ~5, so platin release will be accelerated once the 
conjugate is taken inside the endosome. 
 
                           
 
 
 
 
 
 
 
 
 
 
 Fig. 4.11 Drug release profile over time at different pH. 
                  
MTT assay 
The antitumor potential of CoFe2O4@ACP–PMIDA–CDDP–FA was veriﬁed 
against HeLa cells by MTT assay (Fig. 4.12). It shows that our drug carrier 
CoFe2O4@ACP–PMIDA–FA barely exhibits cytotoxicity against HeLa cells. In 
contrast, the CDDP conjugated carrier demonstrates a remarkable inhibition towards 
the growth of HeLa cells. The IC50 of   CoFe2O4@ACP–PMIDA–CDDP–FA and 
cisplatin towards HeLa cells in terms of Pt concentration is 0.6 and 2.2 µM; and those 
towards L929 cells is 3.1 and 4.4 µM (Table 4.1). It indicates that the antitumor 
activity of cisplatin is enhanced after being adsorbed on functionalized ACP surface. 
The cytotoxicity of synthesized CoFe2O4@ACP and CoFe2O4@ACP–PMEDA was  
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also veriﬁed in normal cell line i.e.  L929 cells. The results conﬁrm that these 
nanoparticles do not have cytotoxicity and hence are safe for biomedical applications. 
 
 
 
 
 
Fig. 4.12 Cytotoxicity assay of nanoparticles on (a) HeLa and (b) L929 cells. Cells were 
treated with different concentrations of nanoparticles for 72 h and cell viability was 
measured by MTT assay 
 
Table 4.1 Comparison of IC50 values for HeLa and L929 cells as measured by MTT assay. 
 
 
 
 
 
Uptake with HeLa and L929 
In vitro cellular uptake experiments were performed taking human cervical 
cancer cell (FR +ve) and L929 (FR -ve) as control and DAPI was used as a nuclear 
contrast dye to appreciate localization. The uptake of CoFe2O4@ACP–PMIDA–
CDDP–FA particles was evident after 30 min (Fig. 4.13). The ﬂuorescence signal 
from RITC increased in the cytoplasm surrounding the nucleus in HeLa cells. In 
IC50 (μM) CoFe2O4@ACP 
-PMEDA 
CoFe2O4@ACP 
-PMEDA-CDDP-FA 
Cisplatin 
Hela ----- 0.6 2.2 
L929 ----- 3.1 4.2 
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contrast, no such increase in RITC signals were seen in the case of L929 cells. This 
suggested that CDDP-conjugated particles are selectively targeted to HeLa cells 
through FR mediated endocytosis and localized in the cytoplasm.  
 
                            
  
 
 
 
 
 
Fig. 4.13 Uptake of CoFe2O4@ACP–PMIDA–FA–CDDP-RITC nanoparticles in L929 and HeLa 
cell using ﬂuorescence microscopy. 
To verify the nuclear morphology and cell death the cell nuclei were further 
stained with 4'-6-diamidino-2-phenylindole (DAPI), a nuclear staining dye known to 
exhibit strong blue ﬂuorescence when bound to DNA. As predicted from cytotoxicity 
experiments, the ﬂuorescent images of HeLa cells incubated with drug unloaded 
particles (control) show the nuclear structures are almost preserved with 
abnormalities, whereas cells treated with CoFe2O4@ACP–PMIDA–CDDP–FA 
displayed typical apoptotic morphology such as nuclear fragmentation, condensation 
and formation of apoptotic bodies (Fig. 4.14). 
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Fig. 4.14 DAPI fluorescence (200X) images of HeLa incubated with (A) PBS, (B) 5, (C) 30, (D) 
60 µg ml-1 of CoFe2O4@ACP-CDDP-FA for 24 h. 
Flow cytometry analysis 
A quantitative evaluation of the CoFe2O4@ACP–PMIDA–CDDP–FA 
nanoparticles mediated cell death was carried out using cell cycle analysis, using 
propidium iodide (PI) ﬂow cytometry .Signiﬁcant DNA fragmentation was observed 
for CoFe2O4@ACP–PMIDA–CDDP–FA with respect to the control under similar 
conditions, evidenced by a sub-G1 peak in the DNA ﬂuorescence histogram (Fig. 
4.15). A decrease in cells in G0/G1 phase with an increase in cell concomitant in S 
and G2/M phase indicates that the arrest of cell cycle in S and G2/M phase. The S and 
G2/M phase distribution increased from 9.36% and 13.16% (in control) to 31.73% 
and 26.64% with 90 µg ml
-1
 treated cells. Consistent with the mode of action of 
platinum complexes, the cell cycle was arrested in both S and G2 phase.
35,36
 This 
arrest is accountable for appreciable morphological changes in cell, as visualized by 
ﬂuorescence microscopy, and ultimately resulted in cell death. In vitro drug release 
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experiments were carried out at 37 °C in aqueous HEPES buffer and monitored for 
180 h.  
 
      
 
 
 
 
            
 
 
 
               
Fig. 4.15 Flow cytometric analysis of the cell cycle phase distribution in HeLa cells. HeLa cells 
treated with (A) PBS (control), (B) 30 µg ml-1, (C) 60 µg ml-1, and (D) 90 µg ml-1 of 
CoFe2O4@ACP–CDDP–FA nanoparticles for 48 h and the percentage of DNA content was 
determined by FACS calibour (BD) using Flow Jo software. 
4.1 Conclusion 
Highly water soluble magnetic mesoporous CoFe2O4@ACP composite nanoparticles 
with a diameter of 41 nm have been prepared using block copolymer P123. The 
surfaces of the amorphous calcium phosphate have been modiﬁed with 
phosphonomethyl iminodiacetic acid to produce a highly –COOH functionalized 
surface. Development a nanoparticles based formulation for the controlled as well as 
targeted delivery of cisplatin has been satisﬁed by conjugating folic acid, cisplatin 
and RITC on the surface following simple chemistry. The nano drug carrier is 
effectively targeted to cancer cells, causing the optimal delivery of cisplatin and 
resulting in cell death following the induction of apoptosis. The advantages of this 
drug delivery system include simple and scalable synthesis method, 
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multifunctionality of particles, high drug loading capacity and pH sensitive release 
behaviour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4                                                                                Ca3(PO4)2 NPs for delivery of cisplatin   
114 
 
4.6. References 
1. M. Ferrari, Nat. Rev. Cancer, 2005, 5, 5161. 
2. N. Sanvicens and M. P. Marco, Trends Biotechnol., 2008, 26, 425. 
3. O. C. Farokhzad and R. Langer, Adv. Drug Delivery Rev., 2006, 58, 1456. 
4. V. P. Torchilin, Adv. Drug Delivery Rev., 2006, 58, 1532. 
5. C. Sun, J. S. H. Lee and M. Q. Zhang, Adv. Drug Delivery Rev., 2008, 60, 
1252. 
6. O. C. Farokhzad and R. Langer, ACS Nano, 2009, 3, 16. 
7. M. Epple, K. Ganesan, R. Heumann, J. Klesing, A. Kovtun, S. Neumann and 
V. Sokolova, J. Mater. Chem., 2010, 20, 18. 
8. Q. Tang, Y. J. Zhu, Y. R. Duan, Q. Wang, K. W. Wang, S. W. Cao, F. Chen 
and J. Wu, Dalton Trans., 2010, 39, 4435. 
9. M. C. Chang, C. C. Ko and W. H. Douglas, Biomaterials, 2003, 24, 2853. 
10. L. D. Tung, V. L. Kolesnichenko, D. Caruntu, N. H. Chou, C. J. O’Connor 
and L. Spinu, J. Appl. Phys., 2003, 93, 7486. 
11. R. E. Rosenweig, J. Magn. Magn. Mater., 2002, 252, 370. 
12. J. P. Fortin, C. Wilhelm, J. Servais, C. Menager, J. C. Bacri and F. Gazeau, J. 
Am. Chem. Soc., 2007, 129, 2628. 
13. S. Mohapatra, S. R. Rout, S. Maiti, T. K. Maiti and A. B. Panda, J. Mater. 
Chem., 2011, 21, 9185–993. 
14. B. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading Anticancer 
Drug, Wiley-VCH, 1999. 
15. L. Kelland, Nat. Rev. Cancer, 2007, 7, 573. 
16. R. Xing, X. Wang, C. Zhang, J. Wang, Y. Zhang, Y. Song and Z. Guo, J. 
Mater. Chem., 2011, 21, 11142. 
17. C. Xu, B. Wang and S. Sun, J. Am. Chem. Soc., 2009, 131, 4216. 
18. S. Likhitkar and A. K. Bajpai, Carbohydr. Polym., 2012, 87, 300. 
19. A. Taylor, Y. Krupskaya, K. Krämer, S. Füssel, R. Klingeler, B. Büchner and 
M. P. Wirth, Carbon, 2010, 48, 2327. 
 Chapter 4                                                                                Ca3(PO4)2 NPs for delivery of cisplatin   
115 
 
20. S. Mohapatra, S. K. Mallick, T. K. Maiti, S. K. Ghosh and P. Pramanik, 
Nanotechnology, 2007, 18, 385102. 
21. S. Maiti, S. K. Bhutia, S. K. Mallick, A. Kumar, N. Khargi and T. K. Maiti, 
Environ. Toxicol. Pharmacol., 2008, 26, 187. 
22. A. K. Gupta and M. Gupta, Biomaterials., 2005, 26, 3992. 
23. J. L. Lyon, D. A. Fleming, M. B. Stone, P. Schiffer and M. E. Williams, Nano 
Lett., 2004, 4, 719. 
24. J. Lim, A. Eggeman, F. Lanni, R. D. Tilton and S. A. Majetich, Adv. Mater., 
2008, 20, 1721. 
25. H. Y. Park, M. J. Schadt, L. Wang, I. I. S. Lim, P. N. Njoki, S. H. Kim, M. Y. 
Jang, J. Luo and C. J. Zhong, Langmuir, 2007, 23, 9050. 
26. D. Rautaray, S. Mandal and M. Sastry, Langmuir, 2005, 21, 5185. 
27. I. Ming-Tang, N. Krishnamra, N. Charoenphandhu, R. Hoonsawat and W. 
Pon-On, Nanoscale Res. Lett., 2011, 6, 19. 
28. M. Tanahashi and T. Matsuda, J. Biomed. Mater. Res., 1997, 34, 305. 
29. Y. E. Greish and P. W. Brown, Biomaterials, 2001, 22, 807. 
30. N. Pramanik, S. Mohapatra, P. Bhargava and P. Pramanik, Mater. Sci. Eng., 
C, 2009, 29, 228. 
31. A. M. Puziy, O. I. Poddubnaya and A. M. Ziatdinov, Appl. Surf. Sci., 2006, 
252, 8036. 
32. J. Y. Han, T. T. Y. Tan and J. S. C. Loo, J. Nanopart. Res., 2011, 13, 3441. 
33. B. Martínez, X. Obradors, L. I. Balcells, A. Rouanet and C. Monty, Phys. Rev. 
Lett., 1998, 80, 181. 
34. M. V. Limaye, S. B. Singh, S. K. Date, D. Kothari, V. R. Reddy, A. Gupta, V. 
Sathe, R. J. Choudhary and S. K. Kulkarni, J. Phys. Chem., 2009, 113, 9070. 
35. G. Zhu and S. J. Lippard, Biochemistry, 2009, 48, 4916. 
36. X. Pan, M. Wilson, L. Mirbahai, C. McConville, T. N. Arvanitis, J. L. Griffin, 
R. A. Kauppinen and A. C. Peet, J. Proteome Res., 2011, 10, 3493. 
  
 
                  
         
 
 
 
 
Chapter-5 
Multifunctional cobalt ferrite encapsulated mesoporous 
hollow silica nanocapsules for targeted co-delivery of 
cisplatin-premetrexed and MR imaging 
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5.1. Introduction 
Multifunctional nanomaterials with combined features of diagnostic and 
therapeutic applications have been one of the key issues in nanomedicinal research.
1–4
 
The main approach for the design of multifunctional theranostic nanoparticles is the 
simultaneous incorporation of a diagnostic element and therapeutic agents into a 
single particle. Among the matrix materials used for theranostic applications, 
mesoporous silica is a promising platform for the delivery of drug molecules and 
imaging agents due to its well documented biocompatibility.
5–14
 Importantly, by 
adding diverse functional inorganic nanostructures (such as Fe3O4 magnetic 
nanoparticles,
15
 Au nanocrystals,
16
 and quantum dots
17
) or by chemically grafting 
functional groups (tumor-targeting moieties,
18
 fluorescent molecules,
19
 PEG,
20
 etc.) 
onto the mesoporous silica surface, multifunctional nanostructured materials can be 
produced that are potential platforms for biomedical imaging and simultaneous 
therapy for lesion sites such as cancers.
21
 Compared to conventional mesoporous 
materials, hollow mesoporous spheres are expected to show increasing therapeutic 
efficiency because of their large surface area, high pore volume, and tunable pore 
sizes which facilitate incorporation of ample therapeutic agents.
22–26
 In addition, the 
large fraction of voids in their inner space can seal drugs, thus protecting 
biomedicines from degradation or interaction with the biological environment before 
they reach the target site. Several research groups have made extensive reports on the 
synthesis of hollow mesoporous silica or heteroatom incorporated mesoporous silica 
for the delivery of a number of hydrophobic as well as hydrophilic anticancer 
drugs.
27–30 
On the other hand, combination therapy or simultaneous administration of 
multiple drugs has become a widely adopted strategy in clinical cancer therapy.
31
 
Clinical and preclinical studies have shown that cocktail therapy of cancer with dual 
drug combinations may lead to better tumor regression than either drug alone.
32
 For 
instance, cisplatin has been the mainstay chemotherapy drug for the treatment of  
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mesothelioma and non-small cell cancers. However, it has been verified that a 
relatively new drug, pemetrexed (Alimta, Eli Lily), when given with cisplatin, can 
reduce tumor size up to 40% and thus increase the longevity of the patient.
33
 
Pemetrexed is a new generation antifolate antimetabolite that exhibits its anticancer 
activity by potentially inhibiting the action of multiple enzymes such as dihydrofolate 
reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), and 
thymidyl synthetase which are involved in de novo purine synthesis.
34
 However, the 
prominent molecular action of pemetrexed is essentially governed by its efficient 
cellular internalization and retention. In the form of free acid, pemetrexed is poorly 
water-soluble and sensitive to light, heat, and moisture, and also has a strong 
tendency for degradation.
35
 Also, the administration of pemetrexed in the form of a 
disodium salt fails to provide a high aqueous solubility and more stable storage.
36 
Thus the administration of the drug at a high dose and frequent dosage program 
results in systemic toxicity.
37
 To the best of our knowledge, there are very few reports 
on the development of stealth drug delivery systems for the successful administration 
of pemetrexed in its acid form.
38,39 
The necessity of enhancing the therapeutic efficiency of pemetrexed by active 
targeting and the success in combining pemetrexed with platinum anticancer drugs 
inspired us to synthesize a highly water soluble multifunctional biocompatible 
mesoporous drug delivery vehicle not only to safeguard both the drugs but also to 
enable the real time monitoring of the treatment by magnetic resonance imaging or 
fluorescence imaging. In the present work, we have developed hollow mesoporous 
silica nanoparticles with high surface area which are capable of delivering both the 
therapeutic cargoes. The hollow interior space can encapsulate the hydrophobic drug 
pemetrexed and the magnetic oxide based T2 contrast agent where the hydroxyl 
groups on the exterior surface can be chemically modified to conjugate platinum 
anticancer drugs, folic acid and the fluorescent molecule RITC. The structure and 
physical properties of the multifunctional nanoparticles were established through a 
series of  
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physical characterization like X-ray diffraction analysis (XRD), superconducting 
quantum interference devices (SQUID), scanning electron microscopy (SEM), 
transmission electron microscopy (TEM), Fourier transform infrared spectroscopy 
(FTIR) and X-ray photoelectron spectroscopy (XPS) studies. The dynamic light 
scattering (DLS) and zeta potential studies confirm the excellent stability of our 
system over time. We have demonstrated that such a dual drug loaded nanoparticle 
would be more effective than a single drug by the cytotoxicity assay and cell 
apoptosis studies.
 
5.2. Experimental 
Materials 
Calcium nitrate and di-ammonium hydrogen phosphate were obtained from 
Merck, Germany. Silver nitrate and diammonium hydrogen phosphate, and ethylene 
glycol were procured from Rankem, RFCL Limited. Benzyl ether, 
cetyltrimethylammonium bromide (CTAB), Fe(acac)3, Co(acac)2, 3-
aminopropyltrimethoxy silane (APTS), oleic acid, oleylamine, tetraethyl orthosilicate 
(TEOS), folic acid (FA), cisplatin, pemetrexed disodium, rhodamine B isothiocyanate 
(RITC), 2,2′- (ethylene dioxy)-bis-(ethyl amine) (EDBE), di-tert-butyl-dicarbonate 
anhydrate (BoC2O) and dimercaptosuccinic acid (DMSA) were purchased from 
Sigma Aldrich. Dicyclohexylcarbodiimide (DCC), N-hydroxysuccinamide (NHS) and 
1-[3dimethylamino) propyl]-3-ethyl carbodiimide hydrochloride (EDC) were 
obtained from spectrochem, India. Commercially available toluene was purified by 
distillation over sodium metal with benzophenone. Prior to use, dimethylsulfoxide 
(DMSO) was vacuum distilled. All other reagents and solvents were used without 
further purification. Millipore water (18.2 MΩ cm) was used throughout the 
experiment. 
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Synthesis of monodisperse hydrophobic CoFe2O4 nanoparticles 
CoFe2O4 nanoparticles were prepared by the solvothermal method (Figure. 
5.1). Briefly, Fe(acac)3 (706 mg, 2 mmol), Co(acac)2 (257 mg, 1 mmol), 1,2 
dodecanediol (2.023 g, 10 mmol), oleic acid (1.9 ml, 6 mmol), oleylamine (1.97 ml, 6 
mmol) and benzyl ether (30 ml) were mixed and stirred for 15 minutes at room 
temperature. Then the total mixture was transferred to a teflon lined stainless steel 
autoclave and heated for 10 h at 190 °C. Then the as synthesized mixture was allowed 
to cool to room temperature and CoFe2O4 nanoparticles were precipitated by adding 
ethanol. The precipitate was collected by centrifugation at a speed of 1600 rpm for 10 
minutes and dried under vacuum for 48 h. 
Transferring hydrophobic CoFe2O4 nanoparticles to water through ligand 
exchange  
Hydrophobic CoFe2O4 nanoparticles synthesized above were oil   soluble and 
not suitable for biological application. To make this sample water soluble, a ligand 
exchange reaction was carried out with dimercapto succinic acid (DMSA). 200 mg of 
the dried sample was dispersed in 80 ml of hexane and 100 mg DMSA was dispersed 
in 100 ml acetone as well as 0.1 ml of TEA were added to a 250 ml flask one after 
another. The total mixture was stirred and refluxed for 4 h, and a black precipitate 
appeared at the bottom, signifying that the DMSA molecules have been conjugated 
on the surface of CoFe2O4 NPs. A homogeneous colloid was obtained by dissolving it 
with deionized water. 
Synthesis of CoFe2O4/HAP/SiO2 composite nanoparticles 
The DMSA coated CoFe2O4 nanoparticles were dispersed in 40 ml water 
followed by addition of an aqueous solution of calcium nitrate. Then the total mixture 
was stirred for 30 minutes at pH 10. After that 10 ml diammonium hydrogen 
phosphate was added dropwise to the above solution at pH 10. The particles were 
separated using a magnetic separator (Dynamag2, Invitrogen). 200 mg of the 
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CoFe2O4/HAP composite nanoparticles were dispersed ultrasonically into a mixture 
of 140 ml of water and 180 ml of ethanol for 10 minutes and then stirred for 10 
minutes in a beaker. Then 0.5 g of CTAB was added to the above suspension; after 
that, 3 ml of ammonia was added and stirred for 30 minutes and then 2 ml of TEOS 
was added dropwise into the reaction mixture slowly for 10 minutes to reach the pH 
value of 11. Now the above suspension was stirred for 4 h at room temperature, and 
then the particles were washed with a mixture of water and ethanol and dried under 
vacuum. 
 
 
 
 
 
Fig. 5.1 Schematic presentation of the synthesis of CoFe2O4 encapsulated mesoporous 
hollow silica particles. 
 
Synthesis of exterior aminopropyl grafted CoFe2O4@m-SiO2 hollow nanoparticles 
The selective grafting of the exterior surface of CoFe2O4@m-SiO2 hollow 
particles was done by following the procedure reported by Lin et al.
40
 CoFe2O4@-
HAP@m-SiO2 sphere nanocomposites (200 mg) were added to 30 ml dry toluene 
with 0.5 ml of aminopropyltrimethoxy silane (APTS) under refluxing under an N2 
atmosphere for 24 h (Fig. 5.2). The amine modified CoFe2O4@HAP@m-SiO2 
particles were washed with acidic ethanol to remove CTAB. The hydroxyapatite core 
was removed by immersing the composite nanoparticles in dilute acetic acid 
(HAC/H2O = 1: 15) for 6 h. Finally the sample was dried in an oven at 65 °C. The 
sample is named CoFe2O4@m-SiO2 hollow nanocapsules. 
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Iminodiacetic acid modified CoFe2O4@m-SiO2 hollow mesoporous sphere 
nanoparticles. 
The amine-modified CoFe2O4@m-SiO2 hollow spheres were treated with a 
mixture of 30 ml ethanol and 20 ml triethylamine that contained excess amount of 
sodium chloroacetate at 80 °C for 48 h. The molar ratio of sodium chloroacetate and 
amine modified particles was 5:1. Then the final product was washed with water and 
ethanol, and then dried at 80 °C under vacuum. 
Preparation of CoFe2O4@m-SiO2–CDDP–FA 
30 mg of cisplatin was taken in 10 ml of water, and 33 mg of AgNO3 was 
added to it (Fig. 5.2). The solution was stirred at room temperature for 48 h in the 
dark. The white precipitate of AgCl was removed by centrifugation and 
didechlorinated CDDP [cis-diaquadiamino platinum(II)] was obtained in the 
supernatant. 120 mg of iminodiacetic acid functionalized CoFe2O4@m-SiO2 
nanoparticles were dispersed in the solution of CDDP and sonicated to give a 
suspension, which was stirred at 200 rpm for 48 h at 45 °C in dark after the pH was 
adjusted to 9 with NaOH (2 M). The obtained product was purified with a magnetic 
separator and washed with water for at least five times to remove the reductant 
CDDP. The marker molecule folic acid and RITC functionalized with –NH2 groups 
(FA-NH2 and RITC-NH2) were conjugated in stoichiometric amounts through the 
remaining –COOH groups on the surface following our previously reported 
protocol.
41
 Now the obtained magnetic hollow sphere, grafted with folic acid, RITC 
and the platinum pharmacophore CDDP on its exterior surface, still has enough free 
interior space which can be further utilized to load hydrophobic drugs. 
Conversion of hydrophilic pemetrexed into hydrophobic form 
Pemetrexed disodium salt (50 mg) was dissolved with 5 ml of water with 
stirring; one drop of conc. HCl was added and continuously stirred for 10 h. During 
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the reaction time a white precipitate came; after completion the white precipitate was 
filtered and dried. 
Preparation of pemetrexed loaded into the hollow cavity of CoFe2O4@m-
SiO2@CDDP@-FA@RITC. 
The nano-precipitation method was used to load the hydrophobic drugs into 
the hollow cavity of CoFe2O4@m-SiO2@CDDP@-FA@RITC nanoparticles (Fig. 
5.2). 50 mg of CoFe2O4@m-SiO2@CDDP@-FA@RITC nanoparticles and 10 mg of 
hydrophobic pemetrexed were mixed with 5 ml of methanol solution and stirred for 2 
h. 6 ml of water was then added dropwise into the suspension with stirring. The 
suspension was stirred under vacuum for 5 h until the methanol evaporated. The drug 
loaded particles pemetrexed@CoFe2O4@m-SiO2@CDDP@-FA@RITC were 
collected by magnetic separation and washed with methanol repeatedly to remove the 
free drug. Finally, the drug loaded particles were dispersed in PBS buffer (pH 7.4). 
The drug concentration and loading capacity were calculated by measuring the visible 
absorbance at 274 nm for pemetrexed after the drugs were extracted from the hollow 
sphere by a mixture of ethyl acetate and water. 
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Fig. 5.2 The selective functionalization of the exterior surface of silica nanoparticles with 
iminodiacetic acid to conjugate platinum drugs, folic acid and RITC. 
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5.3. Characterization 
The synthesized materials were well characterized by using standard 
techniques as described in chapter-3. The cytotoxicity and intracellular uptake 
experiments were performed following the protocol already described in chapter 3. 
MR imaging 
MRI contrast agents are a group of materials which are used to increase the 
visibility of the internal body structure in MRI. MRI contrast agents can alter the 
relaxation times of the atoms present in tissues where they are present. T2 contrast 
agents are a class of contrast agents which can reduce the transverse relaxation time 
which can introduce negative contrast into the image. Superparamagnetic iron oxide 
nanoparticles were widely used as a T2 contrast enhancing agent. The relaxation time 
(T2) and transverse relaxivity (r2) of the nanoparticles were measured with varying 
iron concentration (0.015–0.075 mM) using a clinical MRI scanner (MAGNETOM 
Symphony, SIEMENS) at a magnetic field of 1.5 T. T2-weighted images were 
obtained with a spin echo multisection pulse sequence having a fixed repetition time 
(TR) of 4000 ms with various echo times (TE) ranging from 105 to 291 (105, 116, 
128, 139, 151, 163, 174, 186, 198, 291). The spatial resolution parameters were as 
follows: field of view FOV = 300 × 300 mm2, matrix = 358 × 358, slice thickness = 
4.0 mm. The MRI signal intensity (SI) was measured using in-built software. T2 
values were obtained by plotting the SI of each sample over a range of TE values. T2 
relaxation times were then calculated by fitting a first-order exponential decay curve 
to the plot. The fitting equation can be expressed as: 
𝑆𝐼 = 𝑆0𝑒
−𝑇𝐸
𝑇2
⁄ + 𝐵  
Where SI is the signal intensity, TE is the echo time, S0 is the amplitude, and B is the 
offset. The relaxivity value r2 is determined from the slope of the linear plots of the 
relaxation rate R2 (1/T2, s
−1
) against Fe concentrations (mM). Here, R2
0
 is regression 
coefficient of the plot. 
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𝑅2 =  𝑅2
0 +  𝑟2 [𝐹𝑒] 
5.4. Results and discussion 
The synthetic strategy for hollow mesoporous silica spheres having magnetic 
CoFe2O4 inner particles has been shown in Fig. 5.1. Di-mercapto succinic acid 
(DMSA) coated CoFe2O4 nanoparticles were prepared from hydrophobic oleic acid 
capped CoFe2O4 nanoparticles by a simple phase transfer method.
43
 Later this DMSA 
coated CoFe2O4 acts as a seed for the growth of hydroxyapatite. Crystal growth is 
promoted by a monolayer of DMSA bound to the surface of the CoFe2O4 
nanoparticles; the carboxylate ions in DMSA are excellent binging sites for Ca
2+
 ions. 
Subsequently, the formation of m-SiO2. on the surface of the CoFe2O4@HAP was 
performed by sol-gel method using CTAB template (Fig. 5.2). The as synthesized 
CTAB containing CoFe2O4@HAP@mSiO2 was functionalized with –NH2 by grafting 
by grafting an organoalkoxysilane, aminopropyltrimethoxysilane (APTMS), onto the 
exterior surfaces of these particles by refluxing in toluene. The resulting –NH2 
functionalized CoFe2O4@HAP@mSiO2 particles were washed with water and 
recovered. Then CTAB and HAP were removed according to the procedure described 
in experimental section. HAP serves as a sacrificial template for the formation of 
hollow capsule which was utilised in accommodating another hydrophobic anticancer 
drug pemetrexed. The hollow CoFe2O4@mSiO2 nanocapsules were further 
functionalized with iminodiacetic acid not only to hold platinum pharmacophore 
Pt[OH2](NH3)2 but also to be used as a functional site for the attachment of marker 
molecule folic acid and fluorescent dye RITC. 
XRD 
In the wide angle XRD pattern of CoFe2O4/HAP (Fig. 5.3A), in addition to the 
reflection planes corresponding to the inverse spinel CoFe2O4 (JCPDS no. 22-1086), 
the lines corresponding to the reflection of the planes [002], [211], [130], [213], and 
[004] of hexagonal hydroxyapatite (JCPDS no. 72-1243) are prominent. In the case of 
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CoFe2O4/HAP@m-SiO2, a broad peak in the range 2θ = 20°–30° was observed in 
addition to all the characteristic peaks of the CoFe2O4 and HAP. The absence of any 
HAP peak in the XRD pattern of CoFe2O4@m-SiO2 and the retention of CoFe2O4 
indicates that the HAP template has been completely removed after etching whereas 
magnetic CoFe2O4 nanoparticles still exist in the hollow sphere. 
 
 
 
 
 
 
Fig. 5.3 (a) Wide angle diffraction pattern of CoFe2O4@m-SiO2 hollow sphere at different 
stages of synthesis, (b) is the low angle XRD pattern of CoFe2O4@m-SiO2 hollow spheres. 
The mesoporous structure is indicated by low angle XRD. The low angle 
XRD pattern of the CoFe2O4@m-SiO2 hollow spheres (Fig. 5.3B) shows well 
resolved peaks between 0.5 and 4° representing long range ordering. The peaks have 
d-spacing ratios corresponding to ordered 2D hexagonal mesostructure (p6mm).
44
  
SEM and TEM 
The SEM image presents well dispersed spherical hollow particles (Fig. 5.4a). 
TEM image of CoFe2O4@HAP@m-SiO2 clearly shows the formation of spherical 
particles of size 120–150 nm with the interior cavity crowded with CoFe2O4 and HAP 
nanoparticles. After etching with acidic ethanol, the interior HAP particles were 
completely removed, leading to a hollow sphere (Fig. 5.4b) with the shell thickness of 
30 nm. The hollow capsule with ample inner space and a robust as well as chemically 
stable Si–O–Si structured shell opens up the possibility for a wide range of 
applications. The magnified image of one capsule shows inclusion of an uneven 
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number of CoFe2O4 nanoparticles in its interior cavity. However, still a profitable 
space is left for the accommodation of therapeutic cargoes. The high resolution image 
clearly shows the lattice fringes of [220] and [111] crystalline planes of the inverse 
spinel CoFe2O4. EDX analysis shows that the atomic ratio of Si:Ca of 20:10 as found 
in precursor CoFe2O4@HAP@m-SiO2 nanoparticles appreciably decreases to 50 : 1 
indicating complete erosion of the HAP template. 
 
 
 
 
 
 
 
 
Fig. 5.4  (a) SEM image of CoFe2O4@m-SiO2, (b) TEM image of CoFe2O4@m-SiO2, (c) image at 
high magnification, (d) Image showing a single hollow capsule having inner CoFe2O4 
particles.. 
Nitrogen adsorption-desorption study 
A comparison of N2 adsorption–desorption isotherms of CoFe2O4@HAP@m-
SiO2 and CoFe2O4@m-SiO2 has been presented in Fig. 5.5A. Both the samples reveal 
type IV isotherms. In the case of CoFe2O4@m-SiO2 hollow spheres, a very large 
hysteresis loop exists at P/P0 of 0.3 to 0.4 which is indicative of the mesoporosity 
produced by the ion exchange process.
45
 The BET surface area of the as synthesized 
CoFe2O4@HAP@m-SiO2 nanospheres is found to be 297 m
2
 g
−1
 which appreciably 
increases to 542 m
2
 g
−1
 after removal of the HAP template. The pore size of the 
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hollow capsule has been calculated using BJH and is found to be 7.2 nm (Fig. 5.5B). 
The unique structures of the hydrophilic nanospheres with their mesostructured pore 
walls and the hollow cavities are ideal for small molecules delivery. 
 
 
 
 
 
 
 
Fig. 5.5 (A) N2 adsorption isotherm and (B) Pore size distribution of CoFe2O4@m-SiO2 and 
CoFe2O4@HAP@m-SiO2. 
FTIR 
The comparison of FTIR (Fig. 5.6) spectra at different stages of synthesis 
clearly establishes the functionalization of the hollow sphere with pemetrexed and 
CDDP. The strong absorption bands near 500–600 cm−1 are due to the M–O 
stretching in the ferrite nanoparticles. The peak centered at 1080 and 794 cm
−1
 
corresponds to asymmetric and symmetric stretching vibrations of the Si–O–Si bond 
respectively. A broad prominent peak at 3400 cm
−1 
clearly shows the presence of 
hydroxyl groups or physically adsorbed water on the surface of CoFe2O4@m-SiO2 
hollow particles. After APTS modification on the surface of CoFe2O4@m-SiO2, the 
peaks at 1640 cm cm
−1
 and 1480 cm cm
−1
 correspond to N–H bending and C–N 
stretching of amine functionalized CoFe2O4@m-SiO2. In addition to N–H bond 
vibration there are two other peaks centered at 2923 cm
−1
 and 2857 cm
−1 
corresponding to asymmetric and symmetric stretching vibrations of methylene 
protons. In the case of iminodiacetic acid modified particles the appearance of a 
strong asymmetric stretching band near 1635 cm
−1
 and a weaker symmetrical 
stretching band near 1400 cm
−1
 corresponds to the C–O bond of the carboxylate ion. 
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After the conjugation of folic acid through carbodiimide, bands in the range of 1680 
to 1410 cm
−1
 appeared. The appearance of two prominent characteristic bands at 1680 
(amide I) and 1514 (amide II) cm
−1
 indicates that folic acid has been conjugated to 
CoFe2O4@m-SiO2 nanoparticles through amide linkage. The high resolution XPS 
scan shows two peaks centered at 76.75 and 79.7 eV for Pt4f7/2 and Pt4f5/2 
respectively. 
 
                        
 
 
 
 
 
 
Fig. 5.6  (A) FTIR at various stages of synthesis: (a) CoFe2O4@m-SiO2 hollow spheres, (b) 
CoFe2O4@m-SiO2@APTS, (c) CoFe2O4@m-SiO2@IDA, (d) CoFe2O4@m-SiO2@IDA-FA, (e) 
CDDP, (f) pemetrexed in acid form, (g) pemetrexed encapsulated CoFe2O4@m-SiO2@IDA-FA, 
(h) pemetrexed@CoFe2O4@m-SiO2@IDA-FA@CDDP dual drug nanoparticles , (B) High 
resolution XPS scan of pemetrexed@CoFe2O4@m-SiO2@IDA-FA@CDDP showing Pt peaks. 
Magnetic measurement 
Field dependent magnetization curves of both precursors CoFe2O4@HAP@m-
SiO2 and CoFe2O4@m-SiO2 nanocapsules show no coercivity and hence is 
superparamagnetic at room temperature (Fig. 5.7). The saturation magnetization 
values are found to be 20 and 59 e.m.u. g
−1
 respectively at high magnetic field (2 T). 
The substantial increase in saturation magnetization is attributed to the removal of 
nonmagnetic HAP in the etching process. The HAP coating screens and decreases the 
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magnetic coupling interaction between neighboring CoFe2O4 nanoparticles. However, 
the high saturation magnetization along with superparamagnetism is highly desirable 
for application of the synthesized hollow spheres in magnetically guidable drug 
delivery and as a contrast enhancing agent in MRI.  
 
 
 
 
 
 
 
 
 
Fig. 5.7 Comparison of magnetisation curves of CoFe2O4@mSiO2 and CoFe2O4@HAP@mSiO2 
at room temperature. 
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Magnetic Resonance Imaging (MRI) 
To verify the potential imaging applications of the synthesized magnetic 
mesoporous hollow spheres we further carried out relaxometric measurements with a 
MRI scanner (1.5 T). The relaxivity coefficient was determined from the slope of the 
1/T2 vs. metal ion plot and found to be 421 mM
−1
 s
−1
 (Fig. 5.8a). With increasing 
concentration of CoFe2O4@m-SiO2 in the phantom solution the signal intensity 
decreased, showing that the particles have generated magnetic resonance contrast 
(Fig. 5.8b).  The transverse relaxivity coefficient is higher than that for the 
commercially available iron oxide based contrast agents such as ferumoxytol (91 
mM
−1
 s
−1
) and feridex (120 mM
−1
 s
−1
). However, the relaxivity value is consistent 
with the r2 values for CoFe2O4 as reported by other groups.
46–49
 The higher value of r2 
is attributed to the high saturation magnetization of CoFe2O4 nanoparticles. All these 
results point out that due to higher transverse relaxivity this dual drug loaded hollow 
capsules will have a better negative contrast effect than commercially available iron 
oxide based MRI contrast agents. 
 
 
 
 
 
 
 
 
Fig. 5.8 (a) Relaxivity (r2) measurement and (b) MR phantom images of 
pemetrexed@CoFe2O4@mSiO2-FA-CDDP in water. 
Hydrodynamic size and zeta potential measurement  
The surface modification processes were further verified by investigating 
surface charge properties. The iminodiacetic acid modified particles showed a zeta 
potential of −30 mV at neutral pH which increases to −45.4 mV with an increase in 
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pH, indicating the transformation of the carboxylic acid group of the iminodiacetic 
acid into a carboxylate anion. The hydrodynamic size of the functionalized 
nanoparticles after each step of the synthesis has been presented in Fig. 5.9. The HD 
size increases after each step of modification indicating addition of one molecular 
layer. The size of the final dual drug loaded particles is 85 nm with polydispersity 
index PDI < 0.5. The HD size increases to 40% after 4 weeks. However, PDI and zeta 
potential remain almost unchanged over a long period demonstrating the suitability of 
this dual drug capsule in practical applications. 
 
 
 
 
 
 
 
 
 
Fig. 5.9 (a) HD sizes at different stage of modification (b) Stability of particles with 
Pemetrexed@CoFe2O4@mSiO2@IDA-FA@CDDP after several weeks. (c) Zeta potential of 
Pemetrexed@CoFe2O4@mSiO2@IDA-FA@CDDP over different pH. 
Loading capacity and pH dependent drug release  
To demonstrate the material’s potential use as a drug delivery system, the 
drug loading capacity of the capsules was investigated by stirring it with respective 
drug solutions (1.0 mg ml
−1
). The percentages of CDDP and pemetrexed adsorbed on 
(a) (b) 
(c) 
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the CoFe2O4@m-SiO2 hollow capsules are 76% and 64% respectively (Fig. 5.10 a). 
The cumulative releases of both CDDP and pemetrexed were found to increase with a 
decrease in environmental pH. In all pHs CDDP showed a burst release followed by a 
sustained release pattern (Fig. 5.10 b). Particularly at pH 4.5, a burst release of 45% 
of CDDP was observed from the hollow capsules in the first 20 h which was reduced 
to 10% as the pH was increased to 7.4. CDDP is bonded to the nanoparticles surface 
through covalent coordinate bonds by the interaction of –COOH groups of the 
iminodiacetic acid on the nanoparticles surface with Pt (II). The bonding of –COOH 
to Pt is well established in the literature and supported by a decrease in carbonyl 
stretching frequency in the IR spectra. This type of bonding is acid sensitive and is 
cleavable at low pH. In our case a distinctly prolonged and pH-responsive release of 
therapeutic platin is observed which is very similar to the release profile of platin 
from dumb bell-like Au–Fe3O4 nanoparticles, where the platin complex was anchored 
on the Au-side by reacting Au–S-CH2CH2N(CH2COOH)2 with cisplatin,
54
 in the case 
of high density surface carboxylic groups grafted on mesoporous silica,
55
 and also in 
our previously designed mesoporous calcium phosphate for the delivery of cisplatin 
where the CDDP was adsorbed on the calcium phosphate surface through surface 
iminodiacetate groups.
51
 This indicates that the presence of pemetrexed did not 
significantly affect the release of CDDP in the dual delivery system.  
In the case of the hydrophobic drug pemetrexed, the release from the 
functionalized multidrug capsule is triggered when the environmental pH value was 
decreased similarly to the release behavior of pemetrexed from mesoporous silica 
particles. The significant pH-dependent release observed for pemetrexed may be 
mainly due to the change in the ionization state of the molecule and the subsequent 
interaction with the silica surface. Pemetrexed is a polyelectrolyte carrying two 
carboxyl groups, with pKa of 3.46 (α-carboxyl) and 4.77 (γ-carboxyl), and the 
guanidinic N-1 on the pterine ring (pKa 5.27).
56 
At physiological pH, pemetrexed 
exists in a predominantly
 
negatively charged form due to the deprotonation of the two
 
carboxyl groups. When the pH decreased from 7.4 to 5.5, there
 
is negligible change in 
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the ionization of carboxyl groups (i.e.,
 
from 99% to 97%), but a marked increase in 
the calculated
 
ionization of nitrogen groups (i.e., from 0% to 30%) in water.
 
It is 
possible that at acidic pH (4.5–5.5) the enhanced positive potential of the inner silica 
surface weakens the
 
electrostatic interaction between the positively charged 
pemetrexed
 
leading to a faster release. Thus, both the releases can occur across the 
range of pH found in intracellular lysosomes (4–5) or the local environment of some 
cancerous tissues, thereby enabling targeted therapeutic capacity by passive release at 
the pathologically relevant sites in addition to active targeting through the folate 
receptor.  
  
 
 
 
 
 
 
Fig. 5.10 (a) Percentage of drug loading with time, drug release profile over time at different 
pH: (b) Cisplatin, (b) Pemetrexed. 
 
Calculation of drug loading content and encapsulation efficiency 
 
For cisplatin  
 Drug loading content (%) = 
𝑊𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 ×100 
                                                              =       
0.024
0.140
  × 100 
                                                               =    17.14%  
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Encapsulation efficiency (%) =
𝑊𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑑𝑟𝑢𝑔
 × 100 
                                                                 =   
0.024
 0.030
  × 100 
                                                                  = 80% 
 
 
For Pemetrexed 
Drug loading content (%) =  
𝑊𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
  ×100 
                                                                =     
0.008
0.140
  × 100 
                                                                  = 5.71% 
Encapsulation efficiency (%) = 
Weight  of the drug in nanoparticles
Weight of the feeding drug
 ×100  
                                                                        =   
0.008
 0.013
 = 61.53% 
Both cis-Platin and Pemetrexed 
Drug loading content (%) = 
𝑊𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
  × 100 
=     
0.032
0.140
  × 100                                                                                
= 22.85% 
Encapsulation efficiency (%) = 
 𝑊𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑑𝑟𝑢𝑔
×100 
                                                                       =   
0.032
 0.038
  × 100 = 84.21%                                                                       
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Cytotoxicity 
The biocompatibility of the carrier is a key factor in evaluating the potential of 
the drug delivery systems. It has been already reported that mesoporous silica based 
nanocapsules do not show any cytotoxicity or show very low cytotoxicity.
50
 Our 
synthesized CoFe2O4@m-SiO2 hollow capsules showed more than 85% cell viability 
against HeLa cells, HaCat and mouse fibroblast 3T3 cells. In contrast, 
pemetrexed@CoFe2O4@m-SiO2–FA–CDDP particles showed remarkably high 
cytotoxicity (Fig. 5.11). Also the cytotoxic effect of folate modified dual drug loaded 
particles was compared with the free drugs cisplatin, pemetrexed and the dual drug 
loaded nanocapsule. The results indicate that the cytotoxicity of the dual cargo loaded 
capsule is significantly enhanced compared to individual free drugs. In addition to 
this, the toxic effect was further increased when the capsule was modified with 
marker molecules such as folic acid as observed in our previously reported cases.
51–53 
 
 
 
 
 
 
Fig. 5.11 MTT assay of the dual drug loaded hollow capsule with HeLa cells and HaCaT cells. 
In the legends, P – pemetrexed, C – cisplatin, NP – as prepared CoFe2O4@m-SiO2 hollow 
spheres, FA – folic acid. 
Cellular uptake 
In vitro cellular uptake of pemetrexed@CoFe2O4@m-SiO2– FA–CDDP 
nanocapsules by the folate receptor overexpressed HeLa (FR+ve) cells was 
investigated using fluorescence microscopy. Cells incubated with 
pemetrexed@CoFe2O4@m-SiO2–FA–CDDP–RITC nanocapsules for 60 min 
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endocyted the capsules as evidenced by the intense red fluorescence signal coming 
from RITC. With the increase of time the red luminescence in the cytoplasm was 
increased leaving a clear nuclear zone (Fig. 5.12). In contrast, no such increase in 
RITC signal was observed in the case of pemetrexed@CoFe2O4@m-SiO2–CDDP–
RITC nanoparticles. Additionally, when pemetrexed@Co-Fe2O4@m-SiO2–FA–
CDDP–RITC was incubated with FR(−ve) HaCat cells no such time dependent 
increase in the RITC signal was observed. This clearly indicates that the dual drug 
loaded nanocapsules are selectively targeted to the folate receptor overexpressed 
HeLa cells.  
 
 
 
 
 
   
 
Fig. 5.12 Fluorescence images showing intracellular uptake of (a) to (d) 
pemetrexed@CoFe2O4@m-SiO2–FA–CDDP–RITC nanospheres by HeLa cells, (e) and (f) HaCat 
cells and (g) and (h) Fluorescence image of pemetrexed@CoFe2O4@m-SiO2–CDDP–RITC in 
HeLa cells. 
Cell apoptosis 
The internalization of drug capsules results in cell death or apoptosis. The cell 
breaks apart into several vesicles called apoptotic bodies. To verify the rampant 
chromatin condensation and apoptotic body formation, the cell nuclei were further 
stained with 4′-6-diamidino-2-phenylindole (DAPI), a nuclear staining dye, known to 
0 min 120 min 
(a) (b) (c) (d) 
(e) (f) (g) (h) 
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exhibit strong blue fluorescence when bound to DNA. It was observed that the 
capsules loaded with both pemetrexed and cisplatin show better apoptotic features 
than capsules loaded with individual drugs (Fig. 5.13).  
 
          
 
 
 
 
 
 
 
Fig. 5.13 DAPI fluorescence (200×) images of HeLa cells incubated with (A) PBS, (B) 1.5, (C) 
3.0, (D) 6.0 μg mL−1 pemetrexed@CoFe2O4@m-SiO2–FA–CDDP nanospheres 
A quantitative evaluation of dual drug loaded capsule mediated apoptosis was 
investigated by fluorescence activated cell sorting (FACS) or fluorescence flow 
cytometry. It is a laser based, biophysical technology employed in cell counting and 
cell sorting by suspending cells in a stream of fluid and passing them through an 
electronic detection apparatus. It allows fluorescence analysis of up to thousands of 
particles per second based upon the specific light scattering and fluorescence 
characteristics of each cell. It is observed that both cisplatin and pemetrexed cause 
apoptosis in HeLa cells to a similar extent (M1). However, cisplatin arrests the cell 
cycle at the S phase (or synthesis phase when replication of DNA starts) as reported 
in the case of cisplatin,
57,58
 and promotes cells towards apoptosis whereas pemetrexed 
does not allow cells to go to the S phase and promotes the cells towards apoptosis by 
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arresting them at the G1 phase (it is the first of the four phases of the cell cycle that 
takes place in eukaryotic cell division, after G1 phase comes to S phase) in 
accordance with the earlier reported results with pemetrexed conjugated 
nanoparticles.
59
 However with dual drug loaded nanocapsules 
(pemetrexed@CoFe2O4@m-SiO2–FA–CDDP) apoptotic population increases in a 
dose dependent manner. According to the flow cytometry data, it may be inferred 
that, at lower concentration of our multidrug loaded nanocapsules, the cells are 
arrested at the S-phase and then apoptosis starts whereas, at higher concentration, 
cells go to apoptosis from the G1 phase without entering the S-phase. The arrest is 
responsible for appreciable morphological changes as monitored by fluorescence 
microscopy that eventually resulted in cell death. 
 
 
 
 
 
 
 
 
          
   Fig. 5.14 Flow cytometric analysis of the cell cycle phase distribution in HeLa cells. 
5.5. Conclusion 
We report the synthesis of mesoporous hollow spherical silica nanoparticles 
with a size of 130 nm using the calcium phosphate template. The internal space of 
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hollow spheres was utilized to cluth the hydrophobic anticancer drug pemetrexed and 
superparamagnetic CoFe2O4 nanoparticles while the external surface was chemically 
modified to grasp the platinum pharmacophore CDDP [ cis-diaquadiamino platinum 
(II)],  the marker molecule folic acid and the fluorescent dye RITC.The combined 
advantages of enhanced therapeutic efficacy due to drug synergism, site specific 
targeting through folate receptor mediated endocytosis, fluorescence properties and 
T2 contrast enhancement in MRI make these multifunctional nanoparticles a suitable 
platform for cancer treatment and further exploration in pharmaceutical industries. 
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Synthesis of luminescent magnetic mesoporous carbon 
nanosphere for the delivery of doxorubicin and MR imaging 
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6.1. Introduction 
Development of drug encapsulated nanoparticles that effectively detect and 
treat malignancy is an emerging area in the field of nanobiotechnology.1 In this 
regard, increasing attention has been paid to mesoporous nanoparticles due to their 
open-framework structure, large surface area and well-defined mesoporosity, which 
make them greatly interesting and potentially useful as a drug carrier and control 
release system.2-7 Especially mesoporous silica nanoparticles are widely used as drug 
carriers due to their large pore volume,8  high surface area,9 ease of 
functionalization,10 biodegradability11 and generally low cytotoxicity.12 MSNs with a 
diameter below 200 nm can be eﬀectively internalized into cells by intracellular 
endocytosis and thus have been successfully investigated by several groups as anti-
cancer drugs,13 protein14 and gene delivery  vehicles.15 Although silica based drug 
delivery system has been explored more in the field of biomedical applications still 
there remain some difficulties for large scale fabrication and industrial/clinical 
translations.16 Apart from this, construction of a smart mesoporous nanoplatform 
which can simultaneously perform as a diagnostic imaging and stimuli-responsive 
anticancer drug-release is still in its infancy. As compared to mesoporous silica, 
mesoporous carbon nanoparticles (mCN) are less toxic and biocompatible.17  
Furthermore, the mCN have also high surface area and large pore diameter. In 
contrast mCN have been less exploited as a drug delivery carrier in the field of 
biomedical applications as probably due to the hydrophobic nature of the matrix. 
However, a few reports have been published on ordered mesoporous carbons (OMC) 
as an effective drug delivery carrier due to the following facts. First, OMC fabricated 
by conventional methods usually have irregular particle shape with a large average 
size (>1 mm).18 These randomly aggregated particles with large size cannot be 
eﬀectively taken up by most types of cells. Second, those OMCs could hardly be 
dispersed in aqueous solution due to their inherent hydrophobicity, which in turn 
makes the intravenous administration of drugs and their circulation in blood almost 
impossible. So, it is still a great challenge to prepare mCN with a uniform size below 
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200 nm and hydrophilicity for good water dispersibility. Recently, Sun and Li19 have 
reported one hydrothermal synthesis route for fabricating monodisperse carbon 
microspheres with a hydrophilic surface and good stability in aqueous systems. 
Unfortunately, due to nonporous structure and large particle size of the resultant 
material, it cannot be used as anti-cancer drug carriers. Recently, Zhu et al. 
synthesized mesoporous carbon nanospheres (mCNs) with small diameters of ~90 nm 
that can effectively regulate the release of anticancer drugs in response to a pH 
change.20 
On the other hand, luminescent magnetic carbon spheres are newcomers to the 
world of nanomedicines and have shown great impact in the field of magnetic drug 
targeting and imaging applications. Huang et al have reported the synthesis of 
graphitic carbon@silica nanospheres with dual ordered mesopores for cancer targeted 
doxorubicin delivery and photothermal therapy.21 Recently, our research group has 
published fabrication of luminescent magnetic mesoporous silica nanoparticles 
decorated with carbon dots which have been successfully used in multifunctional 
applications such as a T2 contrast agent in MRI, fluorophore in luminescence imaging 
and for targeted delivery of anticancer drug camptothecin.22 Instances have also been 
reported to enhance the luminescence property of carbon shells by doing nitrogen or 
other heteroatoms.23  
 Doxorubicin (DOX) is one of the commonly used chemotherapeutic agents 
(the pKa of its amino group is 7.6) and highly toxic to humans and result in severe 
suppression of hematopoiesis, and gastrointestinal and cardiac toxicity.24, 25 Hence, 
the development of an appropriate delivery vehicle for DOX and simultaneous 
monitoring of the therapeutic response through MRI and/or fluorescence imaging 
would provide important feed back towards the disease treatment. Taking the 
advantage of significant π-π stacking interaction of aromatic ring of DOX at different 
pH values based on its nonionized and ionized states with mesoporous carbon 
materials,20 we design highly hydrophilic magnetic mesoporous carbon nanoparticles 
which may exhibit significant interaction with anticancer drug doxorubicin.  
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In the present study, we have focused on the development of highly 
luminescent magnetic nanoparticles by employing superparamagnetic CoFe2O4 as 
magnetic component and mesoporous carbon as luminescent component. Mesoporous 
carbon was synthesized by carbonization of resorcinol-formaldehyde polymer (RF) 
on CoFe2O4@mSiO2 nanospheres which were prepared by employing an in situ 
polymerization of resorcinol and formaldehyde on CoFe2O4@mSiO2 seeds in aqueous 
solutions. We choose RF as a polymer shell because it provides large number of 
aromatic π- electrons after carbonization for π-π stacking with small aromatic 
anticancer agent doxorubicin. The hydrophilicity of as synthesized CoFe2O4@mCs 
was increased by simple thermal activation in oxygen atmosphere at 300ºC without 
using any harsh chemical for oxidation. The silica template was removed to form 
mesoporous magnetic carbon nanospheres (CoFe2O4@mC). The DLS and zeta 
potential studies overtime ensure excellent stability of the nanoparticles in 
physiological medium. The in vitro cytotoxicity of the drug carrier as well as 
intracellular uptake and cell apoptosis were evaluated in HeLa cells through confocal 
microscopy. The pH dependent drug release has been investigated by using UV 
spectrophotometer. The possible application of the developed multifunctional 
particles was also evaluated through MR imaging.  
6.2. Experimental 
Materials 
Fe(acac)3, Co(acac)2, oleic acid, oleylamine, Doxorubicin hydrochloride 
(DOX.HCl) were obtained from Sigma Aldrich. Tetraethyl orthosilicate (TEOS), 
cetyltrimethylammonium bromide (CTAB), resorcinol, formaldehyde solution, 
ammonium nitrate were purchased from spectrochem India. All other reagents and 
solvents were used without further purification. Millipore water (18.2 M Ω cm) was 
used throughout the experiment. 
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Synthesis of monodisperse hydrophobic CoFe2O4 nanoparticles 
CoFe2O4 nanoparticles were prepared by solvothermal method. Briefly 
Fe(acac)3 (706 mg, 2 mmol), Co(acac)2 (257 mg, 1 mmol) , 1,2 dodecanediol (2.023 
g, 10 mmol), oleic acid (1.9 ml, 6 mmol) oleylamine (1.97 ml, 6 mmol) and benzyl 
ether (30ml) were mixed and stirred for 15 minutes at room temperature and then the 
total mixture was transferred to a teflon lined stainless steel autoclave for 10h at 
1900C. Then as synthesized mixture was allowed to cool to room temperature and 
CoFe2O4 nanoparticles were precipitated by adding ethanol. The precipitate was 
collected by magnetic separator and dried in vacuum for 48h. 
Synthesis of cobalt ferrite nanoparticles embedded in mesoporous silica spheres 
(CoFe2O4@m-SiO2) 
20 mg of oleic acid stabilized monodisperse CoFe2O4 nanoparticles dispersed 
in 1.5 mL of chloroform was added to a 20 mL of aqueous solution containing 0.4 g 
of CTAB (1.096 mmol). After vigorous stirring, a homogeneous oil-in-water micro 
emulsion was obtained. The resulting mixture was heated at 60 ºC for 10 min induced 
evaporation of the chloroform of the solution, which generated aqueous phase 
dispersed nanoparticles. Then 20 mL of the resulting aqueous solution was diluted 
with 200 ml of water. After that 1.5 ml of NH4OH solution, 0.15 ml of tetraethyl 
orthosilicate, were successively added drop wise to the diluted aqueous solution 
containing the CoFe2O4 nanoparticles. The resulting mixture was heated at room 
temperature for 3 h to ensue complete polymerization of silica. Then the particles 
were washed three times with ethanol to remove the unreacted species and dispersed 
in 20 mL of ethanol separated by using a magnetic separator (DynaMag-2, 
Invitrogen). CTAB was removed from the matrix by dispersing the as-synthesized 
nanoparticles in a solution of 160 mg of ammonium nitrate and 60 mL of 95% 
ethanol and heating the mixture at 60 °C for 15 min.26 Nanoparticles were then 
washed with ethanol and separated using the magnetic separator. 
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Synthesis of CoFe2O4@mSiO2@RF and CoFe2O4@mC 
For polymer coating, 0.08 g of as obtained CoFe2O4@mSiO2 was 
homogeneously dispersed in deionized water (10 mL). 0.035 g of resorcinol, 2.82 ml 
of ethanol and 0.01 mL of ammonia were stirred at 35 °C for 30 min to form a 
uniform dispersion. Then, 0.05 ml of formalin was added to the above solution. After 
6 h, the total mixture was heated at 100 ºC for another 24 h. Then the entire mixture 
was cooled to room temperature overnight without stirring. CoFe2O4@mSiO2@RF 
was collected by centrifugation and then repeatedly washed with water and ethanol. 
The obtained CoFe2O4@mSiO2@RF was heated at 5°C min
-1 from room temperature 
to 150 °C and kept at this temperature for 1 h under a nitrogen flow. The temperature 
was again raised at 5°C min-1 to 600 °C and maintained at this temperature for 2 h. 
CoFe2O4@mSiO2@mC nanoparticles were obtained after the product was cooled to 
room temperature. After that mesoporous magnetic carbon nanospheres 
(CoFe2O4@mC) were formed by etching silicon dioxide with 2M sodium hydroxide 
solution.27 The surface of CoFe2O4@mC was oxidized to -COOH by oxidation of 
CoFe2O4@mC in air at 300 ºC for 1 h.
28 After thermal treatment, particles were 
dispersed in aqueous medium, which is necessary for bio applications. 
 
                     
 
 
 
 
 
 
 
   
 
 Fig. 6.1 Schematic representation of synthesis of CoFe2O4@MC. 
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Calculation of fluorescence quantum yield 
The quantum yield (Φ) of the CoFe2O4@mC was calculated using quinine 
sulfate as reference. For calculation of quantum yield, five concentrations of each 
compound were made, all of which had absorbance less than 0.1 nm at 360 nm. 
Quinine sulfate (literature Φ = 0.54) was dissolved in 0.1 M H2SO4 (refractive index 
(η) of 1.33) while the nanoparticles were taken in water (η = 1.33). Their fluorescence 
spectra was recorded at same excitation of 360 nm. Then by comparing the integrated 
photoluminescence intensities (excited at 360 nm) and the absorbance values (at 360 
nm) of the sample with the references quinine sulfate, quantum yield was determined.  
The quantum yield was calculated using the following equation    
Φx = ΦST  (mx / mST) (η2x /η2ST )   
Where Φ is the quantum yield, m is slope, η is the refractive index of the solvent, ST 
is the standard and X is the sample. The quantum yield for CoFe2O4@mC is found to 
be 9.5. 
Magnetic resonance imaging 
The relaxation time (T2) and transverse relaxivity (r2) of the nanoparticle were 
measured with varying iron concentration (0.015-0.075 mM) using a clinical MRI 
scanner (MAGNETOM Symphony, SIEMENS) at a magnetic field of 1.5 T. T2-
weighted images were obtained with a spin echo multisection pulse sequence having 
fixed repetition time (TR) of 4000 ms with various echo times (TE) ranging from 105 
to 291 (105, 116, 128, 139, 151, 163, 174, 186, 198, 291). The spatial resolution 
parameters were as follows: field of view (FOV) = 300×300 mm2, matrix = 358×358, 
slice thickness = 4.0 mm. The MRI signal intensity (SI) was measured using in-built 
software. T2 values were obtained by plotting the SI of each sample over a range of 
TE values. T2 relaxation times were then calculated by fitting a first-order exponential 
decay curve to the plot. The fitting equation can be expressed as: 
𝑆𝐼 = 𝑆0𝑒
−𝑇𝐸
𝑇2
⁄ + 𝐵 
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Where SI is the signal intensity, TE is the echo time, S0 is the amplitude, and 
B is the offset. The relaxivity value r2 is determined  from  the  slope  of  the  linear  
plots  of  relaxation  rate  R2  (1/T2 , s
−1) against Fe concentrations (mM). 
𝑅2 =  𝑅2
0 +  𝑟2[𝐹𝑒] 
Loading and release of DOX 
CoFe2O4@mCNs (20 mg) and DOX (10 mg) were added to 15 ml of water. 
The mixture was stirred at room temperature for 48 h. The drug loading capacity was 
measured by UV/Vis spectrophotometry with different time intervals. To verify drug 
release, CoFe2O4@mCNs were dispersed in buffers with different pH values and 
shaken at 100 rpm at 37 ºC. The supernatant after magnetic separation was collected 
for quantitative analysis by UV/Vis spectrophotometry. 
In vitro applications  
The cytotoxicity and intracellular uptake experiments were performed 
following the protocol already described in chapter 3.  
6.3. Characterization  
The synthesized materials were well characterized by using standard 
techniques as described in chapter-3. Additionally the Raman spectrum of as 
synthesized sample was recorded at ambient temperature on Renishaw in via Raman 
(UK make). Fluorescence microscopy images were captured using Axiovert 40 
Carlzeiss India fluorescence microscope. Fluorescence spectroscopy was performed 
with a Horiba Fluoromax 4 spectrophotometer at different excitation energies ranging 
from 320 to 450 nm. Live-cell and plane particles imaging was done under Olympus 
FV-1000 confocal microscope with laser excitations of 405, 488 nm and 561 nm.    
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6.4. Results and discussion 
Fig.1 illustrates the synthetic strategy for CoFe2O4@mCN nanospheres. The 
mesoporous silica coated CoFe2O4 nanoparticles were synthesized using CTAB as a 
surfactant where it plays dual role such as (1) for the transfer of hydrophobic 
CoFe2O4 to aqueous phase, (2) organic soft template for the formation of mesoporous 
silica spheres. The pores of the mesoporous silica can be filled up with resorcinol and 
formaldehyde by capillary force and in situ polymerization takes place in presence of 
ammonia.29 The CoFe2O4@mSiO2@RF nanocomposite spheres were further 
carbonized in a nitrogen flow to obtain CoFe2O4@mSiO2@C. Removal of silica on 
washing with 5M NaOH gives highly luminescent magnetic CoFe2O4@MCN 
nanospheres which are sparingly dispersible in water. These hydrophobic 
CoFe2O4@MCN nanospheres were purified by thermal treatment in order to remove 
disordered carbon and also to oxidize their surface with –COOH groups as reported 
by Gabriel et al in case of carbon nanotubes.28 
Investigation of phase by XRD and Raman spectroscopy 
The phase purity of CoFe2O4, CoFe2O4@mSiO2, CoFe2O4@mSiO2@RF and 
CoFe2O4@mCNs were investigated through powder X-ray diffraction analysis (Fig. 
6.2). In case of free cobalt ferrite nanoparticles five diffraction peaks were indexed  at 
30°, 35.40°, 43.16°, 57.01° and 62.63°, which correspond to reflection of plane of 
(220), (311), (400), (511), (440) indicating the inverse spinel structure of  CoFe2O4 
(JCPDS no 22-1086). The crystallite size was also calculated by using Debye Scherer 
equation and it was found to be 9.2 nm. CoFe2O4@mSiO2 did not show any 
characteristics peaks within 2θ = 15º-35º indicating amorphous silicon dioxide phase 
coated on the surface of magnetic nanoparticles.35 After polymer modification, broad 
peak in the range 2θ=12º-25º degree originated from amorphous phase of RF 
component which overlaps with the amorphous mesoporous silica range.30 After 
carbonization the peaks corresponding to cobalt ferrite nanoparticles are intensify and 
shows decomposition of organic polymer.  
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Fig. 6.2 (A) Wide angle diffraction pattern of CoFe2O4@mC nanoparticles at different stages 
of synthesis, *marks indicate the peaks from graphitic carbon (a) CoFe2O4 (Oleic acid), (b) 
CoFe2O4 (calcined), (c)CoFe2O4@mSiO2, (d)CoFe2O4@mSiO2@RF, (e)CoFe2O4@SiO2@RF@C, 
(f) CoFe2O4@mC and:  (B) Low angle diffraction pattern of (a) CoFe2O4@mC and (b) 
CoFe2O4@mSiO2. 
 
The absence of amorphous range and appearance of new plane at (110)* for 
graphitic carbon (JCPDS no 82-0505) indicates that silicon dioxide template has been 
completely removed after etching. The low-angle X-ray diffraction pattern of mC 
nanospheres exhibited two resolved diffraction peaks at 2θ values of 0.78º and 1.3º, 
respectively (Figure 6.2B), which can be indexed as the typical (110) and (210) 
reflections of a highly ordered body-centered cubic Im3m mesostructure.21 The N2 
adsorption-desorption isotherm and corresponding pore diameter distribution curve 
well agree with it, having pore diameter 4 nm.  
The bonding, order, and crystallinity of the materials are studied by Raman 
spectroscopy (Figure 6.3). Figure 6.3 reveals disordered graphitic materials, as 
suggested by the two Raman modes. The peak at 1594 cm-1 (G-band) corresponds to 
an E2g mode of hexagonal graphite and is related to the vibration of sp
2 hybridized 
carbon atoms in a graphite layer. This means that the magnetic mesoporous carbon 
spheres are composed of graphitic carbon, and is related to sp2 hybridized carbon 
atom in a graphite layer, which is consistent with the XRD results. The D-band at 
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about 1360 cm-1 is associated with the vibration of carbon atoms with dangling bonds 
in the plane termination of disordered graphite.31 Due to this graphite with defects 
aromatic molecules can strongly interact with the basal plane of graphite via π-π 
stacking. The peak at 2702 cm-1 corresponds to the 2D band of the Raman spectrum, 
which shows signature of graphitic sp2 materials. The Raman bands at 2950 cm-1 
corresponds to the combination mode of the D-band and G-band. 
 
 
 
 
 
 
 
                                   
Fig. 6.3 Raman spectra of CoFe2O4@mC 
SEM and TEM 
SEM images indicate that size of CoFe2O4mSiO2 is 55-60 nm and are 
spherical in nature (Figure 6.4a). FESEM image of CoFe2O4@mC shows that the 
magnetic carbon nanoparticles are spherical in nature and size varies from 100-130 
nm. TEM image of CoFe2O4@mCNs is found to be 100-140 nm and the particles are 
porous in nature (Figure 6.4c). 
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Fig. 6.4 (a) SEM image ofCoFe2O4@mSiO2 (b) FESEM image of CoFe2O4@mCNs (c) TEM 
image of CoFe2O4@mC 
Hydrodynamic size and zeta potential 
An investigation on hydrodynamic size after each step of modification of 
magnetic nanocomposites and stability of drug adsorbed DOX@CoFe2O4@mC was 
carried out using dynamic light scattering (Figure 6.5) in PBS. CoFe2O4@mSiO2 
shows the presence of stable non aggregated particles with hydrodynamic size 52 nm, 
PDI<0.2. After polymer modification the particle size was found to be 70 nm, 
PDI<0.3. The size of final product, magnetic mesoporous carbon nanoparticles after 
surface modification with acid group (CoFe2O4@mC-COOH) and DOX adsorbed 
CoFe2O4@mC@DOX was found to be 71 nm and 95 nm with a narrow size 
distribution. Again, the stability of DOX@CoFe2O4@mC were studied by measuring 
hydrodynamic size against time shows that there is almost no significant change of 
hydrodynamic size even after several weeks. This observation implies that such stable 
drug adsorbed particles can be circulated in blood stream for a long period. 
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Fig. 6.5 (A) Particle size distribution at each step of modification (B) Stability of 
DOX@CoFe2O4@mC after several weeks. 
In case of CoFe2O4-mCNs the surface charge varied from 40 mV at lower pH 
(2) to -11.2 mV at pH (11.2). After thermal activation the surface charge increases 
significantly in negative direction, with increase in pH indicating the presence of –
COOH groups on the surface (Figure 6.6). 
 
 
 
 
 
 
 
Fig. 6.6 Change in zeta potential of (a) CoFe2O4@mC-COOH and (b) CoFe2O4 @ mC 
nanoparticles with time. 
N2 adsorption – desorption study 
Nitrogen sorption experiments were conducted to investigate further the 
porous nature of the CoFe2O4@mSiO2 nanoparticles and CoFe2O4@mC. A 
comparison of N2 adsorption-desorption isotherms of CoFe2O4@mSiO2 and 
CoFe2O4@mC has been represented in Figure 6.7. All the samples reveal type IV 
isotherms which is a characteristic feature of mesoporous samples. The BET surface 
area of the as synthesized CoFe2O4@mSiO2 and CoFe2O4@mC was found to be 925 
m2/g and 542 m2/g. In case of CoFe2O4@mSiO2 nanoparticles, the mesopores were 
formed due to the removal of soft template CTAB and aggregation of spherical 
particles. After polymer coating, the surface area of CoFe2O4@mSiO2 nanoparticles 
decreases to 236 m2/g, due to blocking of the pores.  
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Fig. 6.7 (A) Nitrogen adsorption-desorption isotherm and (B) pore size distribution of 
CoFe2O4@mSiO2 and CoFe2O4@mC nanoparticles. 
In case of CoFe2O4@mC, the surface area appreciably increases due to the 
removal of hard template silicon dioxide in the etching process, which indicates the 
opening of pores. BJH shows a narrow pore size distribution and is found to be 10 nm 
for CoFe2O4@mSiO2 and 8 nm for CoFe2O4@mC. Such type of unique structures 
having large surface area and pore size are advantageous for maximum adsorption of 
small drug molecules. 
FTIR 
Figure 6.8 shows FTIR spectra at various stages of synthesis of DOX loaded 
CoFe2O4@mC. The broad band located at 3450 cm
−1 is the stretching absorption peak 
of −OH and the broad peak appears in the lower region (500-600 cm-1) is due to 
metal-oxygen stretching vibrations. The sharp peaks appeared at 1080 and 797 cm-1 
corresponds to asymmetric and symmetric stretching vibration of the Si-O-Si bond 
respectively. The peak showed at 2910 cm-1 is due to the methylene proton of CTAB 
for CoFe2O4@SiO2/CTAB, which was disappeared in case CoFe2O4@mSiO2 after 
washing with ammonium nitrate solutions. In case of figure 6.8(d-g) the bands at 
1600, 1400 and 879 corresponds to the characteristic absorption bands of the benzene 
rings. After thermal activation of CoFe2O4@mCNs, a peak corresponds to the 
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carbonyl group of acids appears at 1710 cm-1 indicates the presence of surface –
COOH groups.  
 
 
 
 
 
 
 
Fig. 6.8 FTIR spectra of (a) CoFe2O4, (b) CoFe2O4@mSiO2, (c) CoFe2O4@SiO2/CTAB, (d) 
CoFe2O4@mC, (e) CoFe2O4@mC/COOH, (f) DOX and  (g)  CoFe2O4@mC@DOX. 
XPS 
X-ray photoelectron spectra were further used to confirm the surface 
composition of CoFe2O4@mC. The different binding energy of C1s, O1s, Co2p and 
Fe2p electrons are shown in Figure 6.9. The spectrum of C1s can be deconvoluted 
into four single peaks which correspond to C-C (284.98 eV), C-O (285.97), C=C (284 
eV) and C=O (289.2 eV) functional groups, which have a good consistence with the 
results of FTIR.32 The spectrum of O1s further confirms the four characteristic 
oxygen states as shown in FTIR, such as C-C=O(530.4), C-C-O(531.4), O-H(532 
eV), C=O/COOH(533.3 eV). The peak appearing at 284 eV indicates the presence of 
aromatic unsaturated carbon containing π electrons which is responsible for the 
adsorption of anticancer drug doxorubicin by π- π stacking. The peak at 533.3 eV of 
O1s and 289.2 eV of C1s validate the generation of carboxylic group on the surface 
of magnetic mesoporous carbon nanoparticles after thermal activation in oxygen 
atmosphere. Also Co2p3/2 and Co2p1/2 electrons show binding energy at 779 and 
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795.3 eV associated with corresponding shake ups at 785 and 801 eV.33 In addition to 
this the asymmetric nature of the peak is ascribed to Co2+ present in 
Octahedral/tetrahedral sites.34 Fe2p region shows two peaks at 713.5 and 727.6 eV 
which is consistent with Fe2p binding energy for CoFe2O4 nanoparticles. 
 
 
 
 
 
 
 
 
 
Fig. 6.9 High resolution scan corresponding to (a) C1s (b) O1s (c) Co2P (d) Fe2P binding 
energy. 
Luminescence and magnetic properties 
The aqueous solution of –COOH functionalized CoFe2O4@mCNs was yellow 
and transparent in day light but changes to intense green under UV excitation. The 
absorption in UV region is attributed to the presence of aromatic π orbitals. At a fixed 
excitation of λex=360 nm, CoFe2O4@mC shows an emission peak at 500 nm. 
Furthermore, the unique property of excitation dependent PL was observed in case of 
CoFe2O4@mC in consistence with carbon quantum dots already reported by 
Mohapatra et al. and other researchers.35,36 Luminescence of the as-prepared magnetic 
mesoporous carbon nanoparticles was studied at different excitation wavelengths, 
ranging from 300 to 500 nm (Fig 6.10). Similar to carbon dots the excitation 
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dependent PL may be ascribed to the presence of surface states. As evident from 
FTIR and XPS there are several functional groups like C=O, -COOH etc. present on 
the surface which creates a series of emissive traps between π and π* orbital of 
mesoporous carbon. PL intensity of the synthesized sample remains unchanged over 
pH 4.5 to 8 (Figure 6.11a). The measurement of fluorescence intensity with time 
shows mesoporous carbon does not show photo bleaching for hours (Fig. 6.11b). The 
PL quantum yield was found to be 9.5% which is significantly high compared to 
other magnetic carbon samples (Fig. 6.12). Laser confocal microscopy images show 
that these CoFe2O4@mC are excellent imaging agents. The excitation dependent 
luminescence gives rise several visible advantages in imaging. When the laser 
excitation was changed to 405, 488 and 561 nm, blue, green and red colors were 
observed respectively. In addition to this there was no reduction in luminescent 
intensity even after prolonged exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.10 (a) UV absorbance and PL emission spectra (λex= 360 nm), inset optical images 
under daylight (left) and UV light (right), (b) emission spectra of CoFe2O4@mCN recorded for 
Ex/Em 
 Chapter 6                                                                     Mesoporous magnetic carbon nanospheres 
161 
 
progressively longer excitation wave length of 20 nm , confocal images of particles (c) 405 
nm, (d) 488 nm, and (e) 521 nm. 
 
 
 
The magnetization curves at room temperature for both samples  
 
 
Fig. 6.11(a) Effect of time on fluorescence intensity of magnetic mesoporous carbon 
in DI water, (b) Effect of pH on the fluorescence intensity of magnetic mesoporous 
carbon. 
 
 
 
 
 
 
 
Fig. 6.12 Fluorescence intensity ~ UV absorbance of CoFe2O4@mC particles, QS: 
Quinine sulfate 
CoFe2O4@mSiO2@RF and CoFe2O4@mC show no hysteresis opening and hence are 
superparamagnetic at room temperature (Figure 6.13). The saturation magnetization 
values were found to be 20 and 51 e.m.u/g at high magnetic field (2T). The low Ms 
Value of CoFe2O4@mSiO2@RF is attributed due to the presence of thick inert 
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material silicon dioxide and a polymer which is coated on the surface of cobalt ferrite 
nanoparticles. The substantial increase in saturation magnetization of CoFe2O4@mC 
has been attained after removal of nonmagnetic SiO2 in the etching process. High 
saturation magnetization of CoFe2O4@mC along with superparamagnetism is highly 
desirable for application in magnetically guidable drug delivery and as a contrast-
enhancing agent in MRI. Hence, CoFe2O4@mC would be a suitable material for the 
above applications.  
 
 
 
 
 
 
 
 
Fig. 6.13 Field dependent magnetization curve of (a) CoFe2O4@mSiO2@RF and (b)   
CoFe2O4@mC. 
Relaxometric measurements 
 
As an initial investigation towards potential imaging functionality during 
chemotherapy, the visibility of DOX@CoFe2O4@mCNs was tested in water, PBS 
and minimal essential medium (MEM) by MRI scanner (1.5 T). As shown in Figure 
6.14 with an increase in concentration of particles in the phantom solution, the signal 
intensity decreased, indicating that the magnetic mesoporous carbon spheres have 
generated magnetic resonance contrast on the transverse (T2) proton relaxation time 
weighted sequences due to the dipolar interaction of magnetic moments between the 
nanoparticles and proton in the water.22 The T2 relaxation time was inversely 
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proportional to the particle concentration, as expected. The transverse relaxivity (r2) 
of the drug DOX adsorbed particles is found to be 380 mM-1 S-1, resulting  in better 
negative contrast effect than commercially available dextran coated cobalt ferrite such 
as feridex (120 mM-1 S-1), combidex (65 mM-1 S-1) and CLIO-tat ( 62 mM-1 S-1). 
 
 
 
 
 
 
 
 
 
Fig. 6.14 Relaxivity (r2) measurement of CoFe2O4@mCNs particles in water and MR phantom 
images of CoFe2O4@mCNs in three different medium. 
DOX loading and pH dependent release 
 
To further examine the doxorubicin (DOX) loading and delivery in the matrix 
CoFe2O4@mC, doxorubicin, a widely used anticancer drug, loaded into this matrix to 
form the product DOX@CoFe2O4@mC. The loading efficiency of DOX was 
measured to be as high as 86.1% due to the high BET surface area and pore volume 
of the prepared CoFe2O4@mC particles. Before drug loading to the matrix, free DOX 
exhibited high ﬂuorescence intensity, while the ﬂuorescence of extracted supernatant 
decreased signiﬁcantly after DOX was bound to magnetic mC (Figure 6.15a). This 
high degree of ﬂuorescence quenching is evidence of π-stacked DOX with magnetic 
mesoporous carbon. 
 The driving force acting here is π-π stacking between graphitic defects of 
aromatic carboneous framework and aromatic DOX molecules which contributes to 
the high loading capacity. Figure 6.15(b) shows the DOX release profile of the 
DOX@CoFe2O4@mC with three different pH in PBS at 37ºC, which shows initial 
burst release up 40% in first 10h which slowly increases up 70% with 100h at pH 4. 
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In vitro drug release experiments were carried out within buﬀer solutions with 
diﬀerent pH ( pH 7.4, 6.0 and 4.6). The acidic release medium was used to mimic the 
essential tumor acidic microenvironment. The amount of DOX released form the 
matrix over 10h at neutral pH condition was only 5.5%.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.15 (a) 86 % of total drug loaded on the CoFe2O4@mCNs@DOX and (b) pH-dependent 
drug-release behavior of DOX@CoFe2O4@mCNs. The highest percentage of DOX released 
was observed at pH 4. 
 
However, 10% and 40% release percentages could be achieved within 10 h in 
pH 5.5 and pH 4 buffer solutions, respectively. Such a pH-responsive drug release 
behavior was based on the unique supramolecular π-π stacking between the 
carbonaceous framework and aromatic DOX molecules, which could be interfered 
with and broken in a mild acidic environment. Importantly, such a special non-
covalent π-π stacking could also be broken by ionized state of doxorubicin. The 
above observation indicates that DOX is easier to load in basic solutions in its 
nonionized form, where as it is easier to release in acid solution 
The doxorubicin loaded on the mesoporous magnetic carbon nanoparticles 
was also supported by decrease of fluorescence intensity of free DOX (Fig. 6.16). 
Here the concentration of free drug showing very high concentration and it was 
decreased after adsorption on the mesoporous carbon matrix by aromatic π-π 
stacking. 
 
 Chapter 6                                                                     Mesoporous magnetic carbon nanospheres 
165 
 
 
 
  
 
 
 
 
 
 
Fig. 6.16 (a) Fluorescence spectra intensity of free DOX and (b) supernatant after loading 
 
Calculation of drug loading content and encapsulation efficiency 
 
Drug loading content (%) = 
Weight  of the drug in nanoparticles
Weight of the nanoparticles
× 100 
                                                              =   
6.023
20
 × 100 
                                                              = 30.115%  
Encapsulation efficiency (%) =  
Weight  of the drug in nanoparticles
Weight of the feeding drug
×100 
                                                                 =   
6.023
 10
 × 100 
                                                                   = 60% 
The drug loading content and encapsulation efficiency of DOX was found to be 
30.115% and 60% respectively. 
Cytotoxicity 
Here we investigate the cytotoxic effect of the CoFe2O4@mC, DOX and 
CoFe2O4@mC@DOX against HeLa cells to verify wheather the released DOX was 
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pharmacologically active. From Figure 6.17, it was observed that CoFe2O4@mC did 
not induce any significant change in the proliferation with a concentration up to 20 
µg/ml with respect to the control, suggesting the absence of toxicity of the 
CoFe2O4@mC. The DOX loaded particles (CoFe2O4@mC@DOX) exhibit 
significantly higher cytotoxicity than free DOX, especially at relatively low DOX 
concentrations. This may be attributed to the easier uptake of the 
CoFe2O4@mC@DOX via endocytosis by HeLa cells as compared to the passive 
diffusion of free drug molecules which is believed to be highly important in 
minimizing the toxic side eﬀect of free drugs to normal tissues/cells. The IC50 values 
of plain DOX and CoFe2O4@mC@DOX were found to be 10 µg/ml and 5 µg/ml. 
 
 
 
 
 
 
 
 
 
Fig. 6.17 Cytotoxicity assay of nanoparticles on HeLa cells. 
Intracellular uptake and imaging 
The satisfactory biocompatibility of CoFe2O4@mC nanospheres along with 
excellent luminescent properties makes it a reliable bioimaging agent. Figure 6.18 
shows the fluorescence images of HeLa cells incubated with DOX loaded 
CoFe2O4@mC particles revealing that the CoFe2O4@mC particles can be easily 
internalized within and label the Hela cells. Further demonstrate that the mC 
nnosphers are accumulated and distributed uniformly in the whole region of the 
cytosol, which indicates that the CoFe2O4@mC can be well endocytosized by living 
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Hela cells, favoring the fluorescence imaging of the whole cells and drug delivery 
into the cytoplasm. To further investigate the bioimaging application under varied 
excitations, we varied the excitation wavelengths. For fluorescence excitation set at 
360 nm, intense blue colour was observed. 
When excitation light vary to 360 and 480 nm green and light blue colour 
were observed. In addition to his there was no significant loss in fluorescence 
intensity even after excitation for a prolonged time. All the precluded indicate that our 
designed CoFe2O4@mC nanospheres can be used to as a potential substitute to 
organic dyes in fluorescence imaging. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.18 (a) Fluorescence image of HeLa cells incubated with CoFe2O4@mC@DOX 
nanospheres for 2h in MEM, (b) image excited under λex = 360 nm and detected using UV 
filter, (c)  excited under λex = 450 nm and detected using blue filter, (d) under λex = 470 nm 
(e) 
(j) (i) 
(h) (g) (f) 
(l) (k) 
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and detected using blue filter, (e) to (h) images taken after 1 h, (i) to (l) images  taken after 
3h at respective excitation wavelengths. 
 
6.5. Conclusion 
Simple and inexpensive magnetic mesoporous carbon-based multimodal 
theranostic nanoagents best owed with magnetic targeting, magnetic resonance, 
fluorescence imaging, high loading and controlled release of the anticancer drug 
doxorubicin have been developed. Due to surface modification with carboxylic acid 
groups the nanoparticles are highly stable in aqueous buffer. Our surface engineered 
design promotes a reliable strategy for the administration of doxorubicin. The dual 
optical and magnetic properties of the mesoporous spheres may be utilize in advanced 
imaging technologies to track the curative responses. This approach opens a 
possibility for application of magnetic carbonaceous nanocomposites for cancer 
treatment and may be of particular interest in pharmaceutical industries.  
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7.1. Summary  
The development of nanoparticle based drug formulations for the 
administration of water insoluble anticancer drugs along with real-time monitoring of 
the treatment is under continuous investigation. In this regard, the work undertaken in 
this doctoral thesis addressed on the development of some smart multifunctional 
nanoagents which can be used for the administration of widely accepted anticancer 
drugs like doxorubicin, methotrexate, cisplatin, pemetrexed. Most importantly in all 
our developed formulations, the overall dimension of each multifunctional 
nanoparticle does not exceed 150 nm which is perfect for medical applications as 
discussed in section 1.3. The fluorescence as well as magnetic properties of these 
nanoparticles opens the possibility for monitoring the therapeutic response through 
fluorescence and/or magnetic resonance imaging. The major advantages of our 
developed multifunctional systems are summarized as follows. 
Highly hydrophilic amine functionalized mesoporous MFe2O4 (Co, Mn, Ni) 
nanoparticles have been synthesized by a one-step solvochemical approach. Due to 
high surface area, presence of nanochannels, high dispersion stability in aqueous 
medium and high density of surface amine groups bioconjugation as well as 
incorporation of drugs has become facile. Compared to other synthesis process 
reported so far, our technology is easy, gives uniform mesoporous nanospheres and 
can be adopted to synthesize a number of magnetic ferrites. CoFe2O4 synthesized in 
chapter 1 has been utilized to develop multifunctional nanoparticle for the targeted 
delivery of anticancer drug methotrexate. This theranostic nanoagent offers combined 
advantages of superparamagnetism which is beneficial in MRI, receptor targeting 
capacity, optical imaging and pH-sensitive control release of anticancer drug 
methotrexate which has been first time reported. Due to specific targeting at the 
tumor site the therapeutic potential of the nanoparticle is enhanced. Magnetic 
amorphous calcium phosphate nanoparticle has been developed for folate receptor 
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targeted delivery of challenging anticancer drug cisplatin. Although few number of 
polymer and silica based nanoformulations for the delivery of cisplatin have been 
reported, none of them emphasize on the monitoring of the therapeutic response. In 
this context, choosing calcium phosphate as the carrier matrix along with our surface 
engineering technology has manifold benefits. First, calcium phosphate surface 
rigidly binds with phosphonic acid which ultimately holds cisplatin. Second, calcium 
phosphate becomes disintegrated at acidic surface resulting pH-sensitive drug release. 
For the first time we have developed theranostic formulations that can be used for 
monitoring therapeutic response of cisplatin using fluorescence and/or MR imaging. 
Novel mesoporous hollow spherical silica particles with a size of 130 nm having 
CoFe2O4 in its hollow cavity have been synthesized and explored for site specific co-
delivery of pemetrexed and cisplatin. Due to incorporation of nanosized cobalt ferrite 
this nanoprobe has transverse relaxivity (r2) 421mM
-1 which is much better than 
commercially available iron oxide based contrast agents such as ferumoxytol (91 
mM-1s-1) and feridex (120 mM-1s-1). Though in last couple of years few research 
groups have demonstrated the utility of luminescent carbon nanospheres as carriers 
for anticancer drugs, the integration of magnetic cobalt ferrite and luminescence has 
been rarely explored. Apart from this due to presence of surface carboxylic group the 
particle is water dispersible and stable for a prolong time. Such a uniquely designed 
nanosystem can open possibility for administration of other hydrophobic anticancer 
drugs.  
7.2. Future scope 
Although there are many exciting potential biomedical applications of 
multifunctional magnetic nanoparticles, considerable challenges and issues remain to 
be resolved. For instance, it is hard to accurately control the number of therapeutic 
entities present in the composite nanoparticle. Better synthetic strategies may be 
developed to fabricate multifunctional nanoparticles with precise composition, 
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reproducible surface functionalization and uniform surface modification. The scaling-
up of the fabrication techniques is the most important for their pharmaceutical 
applications. Another challenge in the development of coatings involving active 
biomolecules for nanoparticles is to limit the overall size of particles to below 100 
nm, since nanoparticles larger than 100 nm are rapidly cleared by the liver and spleen. 
Once their diagnostic and therapeutic purposes are achieved, these NPs should be 
eliminated by biological systems without any other detrimental effects. The long-term 
effects of these NPs and their conjugates on biological systems should be thoroughly 
studied in vivo. Toxicity of MNPs is multifactorial and depends upon their 
composition, physicochemical properties such as size and surface characteristics, 
route of administration, and dose. Also the benefit-to-risk ratio has to be balanced 
according to the intended medical or pharmaceutical application. Thus, from a 
regulatory standpoint, NPs safety has to be evaluated case-by-case.  
The promise of hyperthermia as a minimal invasive treatment of malignant 
tumors has been well demonstrated.  Magnetic hyperthermia has also been used in 
combination with chemotherapy for obtaining a still more efficient antitumor 
response. In all our cases CoFe2O4 has been successfully used as the magnetic 
component of the multifunctional system with low toxicity. Hence the developed 
systems may be evaluated as heat mediators in presence of an alternative magnetic 
field.  
Similar to silica, carbon nanoparticles are nontoxic, biocompatible, and 
nonimmunogenic. Hence they may be extensively used for intracellular delivery of 
anticancer drugs. The excellent luminescence property of mesoporous carbon may be 
explored to fabricate fluorescence nanosensors for biologically important 
cations/anions/molecules.  
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